<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions to reduce Staphylococcus aureus in the management of eczema - George, SMC - 2019 | Cochrane Library</title> <meta content="Interventions to reduce Staphylococcus aureus in the management of eczema - George, SMC - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions to reduce Staphylococcus aureus in the management of eczema - George, SMC - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003871.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Interventions to reduce Staphylococcus aureus in the management of eczema" name="citation_title"/> <meta content="Susannah MC George" name="citation_author"/> <meta content="Brighton and Sussex University Hospitals NHS Trust, Brighton General Hospital" name="citation_author_institution"/> <meta content="susannah@susannahgeorge.net" name="citation_author_email"/> <meta content="Sanja Karanovic" name="citation_author"/> <meta content="Queen Elizabeth Hospital Birmingham" name="citation_author_institution"/> <meta content="David A Harrison" name="citation_author"/> <meta content="Intensive Care National Audit &amp; Research Centre" name="citation_author_institution"/> <meta content="Anjna Rani" name="citation_author"/> <meta content="Centre of Evidence Based Dermatology" name="citation_author_institution"/> <meta content="Andrew J Birnie" name="citation_author"/> <meta content="East Kent Hospitals University Foundation NHS Trust" name="citation_author_institution"/> <meta content="Fiona J Bath‐Hextall" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Jane C Ravenscroft" name="citation_author"/> <meta content="Nottingham University Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Hywel C Williams" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003871.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003871.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Drug Resistance, Bacterial; Anti‐Bacterial Agents [adverse effects, *therapeutic use]; Dermatologic Agents [therapeutic use]; Eczema [drug therapy, *microbiology]; Randomized Controlled Trials as Topic; Staphylococcal Infections [*drug therapy]; Staphylococcus aureus" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003871.pub3&amp;doi=10.1002/14651858.CD003871.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003871\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003871\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa","fr","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003871.pub3",title:"Interventions to reduce Staphylococcus aureus in the management of eczema",firstPublishedDate:"Oct 29, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003871.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003871.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003871.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003871.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003871.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003871.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003871.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003871.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003871.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003871.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8725 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003871.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0309"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0069"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-sec-0302"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/appendices#CD003871-sec-0314"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/table_n/CD003871StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/table_n/CD003871StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions to reduce Staphylococcus aureus in the management of eczema</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Susannah MC George</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0003">Sanja Karanovic</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0004">David A Harrison</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0005">Anjna Rani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0006">Andrew J Birnie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0007">Fiona J Bath‐Hextall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0008">Jane C Ravenscroft</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information#CD003871-cr-0009">Hywel C Williams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information/en#CD003871-sec-0323">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003871.pub3">https://doi.org/10.1002/14651858.CD003871.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003871-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003871-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003871-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003871-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003871-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003871-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003871-abs-0001" lang="en"> <section id="CD003871-sec-0001"> <h3 class="title" id="CD003871-sec-0001">Background</h3> <p><i>Staphylococcus aureus</i> (<i>S. aureus</i> ) can cause secondary infection in eczema, and may promote inflammation in eczema that does not look infected. There is no standard intervention to reduce <i>S. aureus</i> burden in eczema. It is unclear whether antimicrobial treatments help eczema or promote bacterial resistance. This is an update of a 2008 Cochrane Review. </p> </section> <section id="CD003871-sec-0002"> <h3 class="title" id="CD003871-sec-0002">Objectives</h3> <p>To assess the effects of interventions to reduce <i>S. aureus</i> for treating eczema. </p> </section> <section id="CD003871-sec-0003"> <h3 class="title" id="CD003871-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to October 2018: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We searched five trials registers and three sets of conference proceedings. We checked references of trials and reviews for further relevant studies. We contacted pharmaceutical companies regarding ongoing and unpublished trials. </p> </section> <section id="CD003871-sec-0004"> <h3 class="title" id="CD003871-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of products intended to reduce <i>S. aureus</i> on the skin in people diagnosed with atopic eczema by a medical practitioner. Eligible comparators were a similar treatment regimen without the anti‐staphylococcal agent. </p> </section> <section id="CD003871-sec-0005"> <h3 class="title" id="CD003871-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Our key outcomes were participant‐ or assessor‐rated global improvement in symptoms/signs, quality of life (QOL), severe adverse events requiring withdrawal, minor adverse events, and emergence of antibiotic‐resistant micro‐organisms. </p> </section> <section id="CD003871-sec-0006"> <h3 class="title" id="CD003871-sec-0006">Main results</h3> <p>We included 41 studies (1753 analysed participants) covering 10 treatment categories. Studies were conducted mainly in secondary care in Western Europe; North America; the Far East; and elsewhere. Twelve studies recruited children; four, adults; 19, both; and six, unclear. Fifty‐nine per cent of the studies reported the mean age of participants (range: 1.1 to 34.6 years). Eczema severity ranged from mild to severe. Many studies did not report our primary outcomes. Treatment durations ranged from 10 minutes to 3 months; total study durations ranged from 15 weeks to 27 months. We considered 33 studies at high risk of bias in at least one domain. </p> <p>We present results for three key comparisons. All time point measurements were taken from baseline. We classed outcomes as short‐term when treatment duration was less than four weeks, and long‐term when treatment was given for more than four weeks. </p> <p>Fourteen studies evaluated topical steroid/antibiotic combinations compared to topical steroids alone (infective status: infected (two studies), not infected (four studies), unspecified (eight studies)). Topical steroid/antibiotic combinations may lead to slightly greater global improvement in good or excellent signs/symptoms than topical steroid alone at 6 to 28 days follow‐up (risk ratio (RR) 1.10, 95% confidence interval (CI) 1.00 to 1.21; 224 participants; 3 studies, low‐quality evidence). There is probably little or no difference between groups for QOL in children, at 14 days follow‐up (mean difference (MD) ‐0.18, 95% CI ‐0.40 to 0.04; 42 participants; 1 study, moderate‐quality evidence). The subsequent results for this comparison were based on very low‐quality evidence, meaning we are uncertain of their validity: severe adverse events were rare (follow‐up: between 6 to 28 days): both groups reported flare of dermatitis, worsening of the condition, and folliculitis (325 participants; 4 studies). There were fewer minor adverse events (e.g. flare, stinging, itch, folliculitis) in the combination group at 14 days follow‐up (218 participants; 2 studies). One study reported antibiotic resistance in children at three months follow‐up, with similar results between the groups (65 participants; 1 study). </p> <p>Four studies evaluated oral antibiotics compared to placebo (infective status: infected eczema (two studies), uninfected (one study), one study’s participants had colonisation but no clinical infection). Oral antibiotics may make no difference in terms of good or excellent global improvement in infants and children at 14 to 28 days follow‐up compared to placebo (RR 0.80; 95% CI 0.18 to 3.50; 75 participants; 2 studies, low‐quality evidence)<i>.</i> There is probably little or no difference between groups for QOL (in infants and children) at 14 days follow‐up (MD 0.11, 95% CI ‐0.10 to 0.32, 45 participants, 1 study, moderate‐quality evidence). The subsequent results for this comparison were based on very low‐quality evidence, meaning we are uncertain of their validity: adverse events requiring treatment withdrawal between 14 to 28 days follow‐up were very rare, but included eczema worsening (both groups), loose stools (antibiotic group), and Henoch‐Schönlein purpura (placebo group) (4 studies, 199 participants). Minor adverse events, including nausea, vomiting, diarrhoea, and stomach and joint pains, at 28 days follow‐up were also rare and generally low in both groups (1 study, 68 infants and children). Antibiotic resistance at 14 days was reported as similar in both groups (2 studies, 98 infants and children). </p> <p>Of five studies evaluating bleach baths compared to placebo (water) or bath emollient (infective status: uninfected (two studies), unspecified (three studies)), one reported global improvement and showed that bleach baths may make no difference when compared with placebo at one month follow‐up (RR 0.78, 95% CI 0.37 to 1.63; 36 participants; low‐quality evidence). One study showed there is probably little or no difference in QOL at 28 days follow‐up when comparing bleach baths to placebo (MD 0.90, 95% CI ‐1.32 to 3.12) (80 infants and children; moderate‐quality evidence). We are uncertain if the groups differ in the likelihood of treatment withdrawals due to adverse events at two months follow‐up (only one dropout reported due to worsening itch (placebo group)) as the quality of evidence was very low (1 study, 42 participants). One study reported that five participants in each group experienced burning/stinging or dry skin at two months follow‐up, so there may be no difference in minor adverse events between groups (RR 1.00, 95% CI 0.35 to 2.87, 36 participants, low‐quality evidence)<i>.</i> Very low‐quality evidence means we are also uncertain if antibiotic resistance at four weeks follow‐up is different between groups (1 study, 80 participants ≤ 18 years). </p> </section> <section id="CD003871-sec-0007"> <h3 class="title" id="CD003871-sec-0007">Authors' conclusions</h3> <p>We found insufficient evidence on the effects of anti‐staphylococcal treatments for treating people with infected or uninfected eczema. Low‐quality evidence, due to risk of bias, imprecise effect estimates and heterogeneity, made pooling of results difficult. Topical steroid/antibiotic combinations may be associated with possible small improvements in good or excellent signs/symptoms compared with topical steroid alone. High‐quality trials evaluating efficacy, QOL, and antibiotic resistance are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003871-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003871-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003871-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003871-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003871-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003871-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003871-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003871-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003871-abs-0005" lang="en"> <h3>Treatments to reduce infection with the bacteria Staphylococcus aureus in eczema</h3> <p><b>Background</b> </p> <p>The skin of people with eczema (atopic dermatitis) often contains high numbers of a type of bacteria called <i>Staphylococcus aureus</i> (<i>S. aureus</i>), which can cause skin infections. </p> <p>Eczema treatments intended to reduce <i>S. aureus</i> on the skin include antibiotics, treatments put on the skin, and antibacterial soaps/baths. It is unclear which treatments are helpful. </p> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of treatments aimed at reducing <i>S. aureus</i> on the skin in people with atopic eczema. Eligible comparisons were similar treatments without anti‐<i>S. aureus</i> actions. We included 41 studies involving 1753 participants (evidence is current to October 2018). </p> <p><b>Study characteristics</b> </p> <p>Included studies assessed a range of treatments, which they compared with placebos (an identical but inactive treatment), no treatment, other treatment, vehicle (inactive ingredient(s) which help deliver an active treatment), or textile without the anti‐<i>S.aureus</i> component. </p> <p>Studies were conducted worldwide, and included males and females. Twelve studies recruited children; four, adults; 19, both; and six were unclear; where reported, the average participant age ranged from 1.1 to 34.6 years. Eczema severity varied from mild to severe. Treatment durations ranged from 10 minutes to 3 months; total study durations, from 15 weeks to 27 months. </p> <p><b>Key results</b> </p> <p>Outcomes were measured from treatment start. We classed outcomes as short‐term when treatment duration was less than four weeks, and long‐term when treatment was given for more than four weeks. </p> <p>People may be more likely to experience slightly increased short‐term improvement with topical steroid/antibiotic combinations than with steroid only (low‐quality evidence, one study of infected eczema and two studies with unspecified infection). There is probably little or no difference between the combination group and the steroid only groups in short‐term impact on quality of life (QoL) (moderate‐quality evidence, one study of infected children). Antibiotic resistance was similar between groups in the long term, but we are uncertain of this result due to very low‐quality evidence (one study of infected children). </p> <p>When compared to placebo, oral antibiotics may make no difference to short‐term improvement (low‐quality evidence, two studies: one in uninfected infants and children; the other in mainly infected infants and children). For short‐term QoL, there is probably little or no difference between the groups (moderate‐quality evidence, one study of infected infants and children). Short‐term antibiotic resistance was similar in both groups, but we are uncertain if there is a true difference as the quality of evidence was very low (two studies of infants and children, infected in one study and uninfected in the other). </p> <p>Bleach baths may make no difference to short‐term improvement when compared to placebo (low‐quality evidence, one study of uninfected participants). There is also probably little or no difference in short‐term QoL in children of unspecified infective status (one study; moderate‐quality evidence); based on the same study, we are uncertain if short‐term antibiotic resistance was different between groups (very low‐quality evidence). </p> <p>Side effects bad enough to stop treatment were rare in all studies; however, evidence was very low quality in all three comparisons, so we are uncertain whether there is a difference between groups. Assessment ranged from six days to two months, participants included children and adults with mixed infective status, and causes of withdrawal included worsening of eczema or itch and loose stools. </p> <p>Participants in the topical steroid/antibiotic combination group experienced fewer minor side effects than those given steroids alone. Comparing oral antibiotics to placebo, participants experienced equally low numbers of minor side effects. However, we are uncertain if their are true differences between groups due to very low‐quality evidence. Based on short‐term assessment of mixed participants (children and adults, with mixed infective status), reported side effects included sickness, diarrhoea, stomach/joint pains, and itching. For bleach baths versus placebo, some long‐term minor side effects (burning/stinging, dry skin) were reported in both groups, so there may be no difference between treatment groups (low‐quality evidence, uninfected participants (2 to 30 years)). </p> <p><b>Quality of evidence</b> </p> <p>Evidence quality for improvement in symptoms or signs was low; for improvement in QoL, moderate; for antibiotic resistance, very low; and for side effects, it was almost consistently very low. The studies were small, diverse, and at risk of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003871-sec-0309" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003871-sec-0309"></div> <h3 class="title" id="CD003871-sec-0310">Implications for practice</h3> <section id="CD003871-sec-0310"> <p>The quality of the evidence included in this review was insufficient to address the overall set of objectives and provide definitive guidance for clinical practice. Only a limited number of studies were available to pool in meta‐analyses. </p> <p>We found low‐quality evidence that using a topical antibiotic/steroid combination compared with topical steroid alone may be associated with slight improvement in short‐term good or excellent improvement in symptoms or signs, or both, but there is probably little or no difference between groups in change from baseline in quality of life. </p> <p>Similarly, there is probably little or no difference between oral antibiotics or bleach baths and placebo on quality of life (both short‐term assessment and based on moderate‐quality evidence). </p> <p>When compared to placebo, oral antibiotics or bleach baths may make no difference to short‐term overall good or excellent improvement (low‐quality evidence). </p> <p>Low rates of adverse events were reported for all the interventions considered, but we are uncertain of the effect of our key comparisons on adverse effects (whether or not they required withdrawal from treatment) as we assessed the quality of the evidence as very low for all but one adverse event outcome: there is low‐quality evidence that there may be no difference in minor adverse events (burning/stinging or dry skin) between bleach baths and placebo (water). Common adverse events included flare of dermatitis, worsening of the condition, folliculitis, stinging, itch and digestive dysfunction. </p> <p>We are uncertain of the effect of our three key comparisons on antimicrobial resistance (all evidence was very low quality), which is a potential concern with this intervention. Although there was insufficient evidence to determine the effects of antibiotics to treat infected eczema, this does not preclude their use to treat the infection itself, which was outside the scope of this review. </p> <p>The six studies in <a href="./references#CD003871-bbs1-0003" title="">Studies awaiting classification</a> may alter the conclusions of the review, once assessed. </p> </section> <h3 class="title" id="CD003871-sec-0311">Implications for research</h3> <section id="CD003871-sec-0311"> <p>This review highlights the need for further research into the role of treating <i>S. aureus</i> in eczema. The trials included in this review were heterogeneous in terms of baseline population, interventions used, and outcomes. First, there is need to establish valid and repeatable criteria for describing clinically infected eczema, perhaps using consensus methods supported by reference images or more objective methods such as colony counts. Whilst there is likely to be good agreement between clinicians on what grossly infected eczema is, there is likely to be a lot of variability between clinicians in deciding a suitable boundary between clinically infected and non‐infected eczema. Once this is established, there is a need to clarify whether the study population has clinically infected (or just colonised) eczema or whether the eczema is clinically uninfected. Future studies need to assess for the presence or absence of <i>S. aureus</i> infection at baseline and follow‐up visits and for the presence of resistant organisms. The results of a trial of an anti‐staphylococcal intervention may differ depending on whether the eczema is infected or uninfected at baseline. </p> <p>In clinical practice, other products such as emollients and washing products are usually used. Information on this has not been documented. Collection of this information would provide a more realistic view on what is going on in clinical practice. </p> <p>Many of the trials were small leading to imprecise estimates of treatment effects; future studies must be adequately powered to detect clinically meaningful differences in outcomes. Larger trials will also reduce the risk of chance baseline imbalance. In future trials, attempts should be made to blind the participants and personnel, whenever possible; however, for certain interventions, such as bleach baths, adequate blinding may be very difficult to achieve. </p> <p>Heterogeneity of outcome measures precluded pooling of data in many cases. In future studies, the HOME initiative (<a href="./references#CD003871-bbs2-0111" title="ChalmersJR , SchmittJ , ApfelbacherC , DohilM , EichenfieldLF , SimpsonEL , et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology2014;171(6):1318‐25. [PUBMED: 24980543] ">Chalmers 2014</a>) will help to standardise outcome measures for use in trials of eczema. As well as objective measures of eczema severity, future studies of anti‐staphylococcal interventions should include measures of quality of life. Future studies also need to assess whether any benefit in terms of severity or reduction in flares is sustained following clearance of <i>S. aureus</i> (for example, following antibiotic treatment) and whether sustained benefit can be achieved by longer term use of non‐antibiotic treatments. Given the time required to recover from severe flares in eczema, follow‐up of several months would be required. Every effort should be made to maximise follow‐up of participants, as many studies in our review were potentially impacted by attrition bias. Studies should report all relevant adverse events. </p> <p>Many studies were poorly reported and future studies should be prospectively registered and adhere to CONSORT reporting guidelines (<a href="./references#CD003871-bbs2-0151" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [PUBMED: 20332509] ">Schulz 2010</a>) to ensure complete and transparent reporting and avoid selective reporting of study results. </p> <p>In view of the low quality of evidence and lack of information on quality of life and antibiotic resistance, a larger, definitive trial on steroid/antibiotic combination treatment is required. With the increased concerns about antibiotic resistance, other strategies to treat <i>S. aureus</i> infection that do not involve antibiotics should be further investigated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003871-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003871-sec-0029"></div> <div class="table" id="CD003871-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topical steroid plus topical antibiotic compared with topical steroid for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical steroid plus topical antibiotic compared with topical steroid for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with eczema </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> topical steroid plus topical antibiotic </p> <p><b>Comparison:</b> topical steroid </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical steroid</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical steroid plus topical antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 6‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b> (1.00 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One further study (n = 28), using a continuous scale, found a result favouring steroid only. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>741 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>815 per 1000</b><br/> (741 to 897) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the control group at the end of treatment decreased by<br/> 3.46 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the intervention group decreased by<br/> <b>0.18 less</b> (0.40 less to 0.04 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A different instrument (CDLQI) was used for children aged 4 years and over and showed significantly less reduction among the participants treated with topical antibiotic. There was no significant difference with either instrument at 28 days or at 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 6‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b> (0.21 to 7.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>325 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rates of adverse events were very low (zero in one study) and consequently the result is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/> (7 to 225) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.30</b> (0.12 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>218 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The risk in the control group varied hugely between the two studies that assessed this outcome. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000<sup>e</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/> (4 to 28) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000<sup>e</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b><br/> (76 to 496) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study reported the proportion of strains of <i>S. aureus</i> that were resistant to the antibiotic used ‐ these were similar between the groups. Two other studies reported results that were not able to be compared between individual treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72, objective SCORAD ranges from 0 to 83 and SCORAD ranges from 0 to 108, with higher values indicating greater severity. </p> <p>Follow‐up: 14‐56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores in the control groups were 2.5 (standard deviation 5.2 to 5.6) for EASI, 18.8 (standard deviation 13.1) for objective SCORAD, and 25.4 (standard deviation 15.9) for SCORAD. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention group was<br/> <b>0.00 standard deviations lower</b> (0.33 lower to 0.33 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a value of 0.2 to 0.5 was considered a small effect, therefore the confidence interval suggested there was unlikely to be more than a small effect, either positive or negative. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> <p>Follow‐up: 7‐56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.48</b> (0.27 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>298 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>i</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><br/> (127 to 396) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>EASI:</b> Eczema Area and Severity Index; <b>SCORAD:</b> SCORing Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on the median control group risk across studies </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (attrition bias, performance bias, and possible selective reporting) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to risk of bias (attrition bias and baseline imbalance) </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (attrition and performance bias) and imprecision of estimate (two levels due to very low number of events) </p> <p><sup>e</sup>Assumed risk based on lowest and highest control group risk across studies </p> <p><sup>f</sup>Downgraded three levels due to risk of bias (attrition bias), imprecision of estimate and heterogeneity in control group risk </p> <p><sup>g</sup>Downgraded three levels due to risk of bias (attrition bias and baseline imbalance) and imprecision of estimate (two levels due to very low numbers of events) </p> <p><sup>h</sup>Downgraded two levels due to risk of bias (attrition and performance bias) and heterogeneity in control group means </p> <p><sup>i</sup>Downgraded one level due to risk of bias (performance bias, possible selective reporting and baseline imbalance) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003871-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral antibiotic compared with placebo for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral antibiotic compared with placebo for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with atopic dermatitis </p> <p><b>Settings:</b> primary and secondary care </p> <p><b>Intervention:</b> oral antibiotic </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> </p> <p>(0.18 to 3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b><br/> (111 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life.</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the control group at the end of treatment decreased by<br/> 3.46 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the intervention group decreased by<br/> <b>0.11 less</b> (0.32 less to 0.10 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A different instrument (CDLQI) was used for children aged 4 years and over and also showed no significant difference. There was also no significant difference with either instrument at 28 days or at 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of adverse events were very low (with either zero or one event in each arm of each study) and consequently the result was too uncertain to produce a meaningful estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study reported a number of specific individual adverse events, but not the overall proportion of participants in each group experiencing any adverse event. The events included nausea, vomiting, diarrhoea, stomach pain, joint pains and new rash. Number of events were generally low in both groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported the proportion of strains of <i>S. aureus</i> that were resistant to the antibiotic used ‐ these were similar between the groups. One other study reported an increase in MRSA until 14 days following treatment but did not give numerical results. A third study reported no resistance to the antibiotic used in either treatment group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72 with higher values indicating greater severity.</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the control group at the end of treatment decreased by<br/> 3.29 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the intervention group decreased by<br/> <b>0.20 less</b> (0.52 less to 0.12 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was also no significant difference in EASI score at 28 days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>(0.46 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>144 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>824 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>626 per 1000</b> </p> <p>(379 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>IDQoL:</b> Infants' Dermatology Quality of Life Index; <b>CDLQI:</b> Children's Dermatology Life Quality Index; <b>EASI:</b> Eczema Area and Severity Index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on the median control group risk across studies </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (attrition bias) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to risk of bias (high risk of attrition bias and baseline imbalance) </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (attrition bias and baseline imbalance), and imprecision of estimate (two levels due to very low number of events) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003871-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bleach bath compared with placebo or bath emollient for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bleach bath compared with placebo or bath emollient for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with atopic dermatitis </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> bleach bath </p> <p><b>Comparison:</b> placebo or bath emollient </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or bath emollient</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bleach bath</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> (0.37 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One further study assessed this outcome using the mean IGA score and also found no significant difference. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b><br/> (185 to 815) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>CDLQI ranges from 0 to 30 with higher values indicating more impaired quality of life.</p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CDLQI in the control group at the end of treatment decreased by<br/> 1.43 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CDLQI in the intervention group decreased by<br/> <b>0.90 less</b> (3.12 less to 1.32 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of adverse events were too low to produce meaningful estimates. One further study reported no adverse events and two other studies also reported very low rates of adverse events requiring withdrawal from treatment but results could not be combined due to differing study designs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> (0.35 to 2.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two further studies reported no adverse events and one other study reported adverse events but results could not be combined due to differing study designs. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> </p> <p>(97 to 798)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study reported no significant difference in antibiotic resistance patterns but no numerical results were presented. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72 with higher values indicating greater severity.</p> <p>Follow‐up: 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the control group at the end of treatment was 13.87<sup>f.</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the intervention group was<br/> <b>2.48 lower</b> (7.36 lower to 2.40 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study assessed this outcome using the change from baseline in mean SCORAD and also found no significant difference between the groups. One study additionally followed up EASI score at 2 months and one study reported SCORAD at 3 months; both reported significantly lower scores in the intervention group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, although two studies reported no significant difference in <i>S. aureus</i> colony counts. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>IGA:</b> Investigator global assessment; <b>CDLQI:</b> Children's Dermatology Life Quality Index; <b>EASI:</b> Eczema Area and Severity Index; <b>SCORAD:</b> SCORing Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on control group of the one study reporting this outcome </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to imprecision of estimate </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate (two levels due to very low number of events) </p> <p><sup>e</sup>Downgraded three levels due to imprecision (small study) and study limitations due to selective reporting of results (two levels as numerical data not reported) so we were unable to obtain an estimate of the effect from the available evidence </p> <p><sup>f</sup>Control group mean based on median across the studies reporting this outcome </p> <p><sup>g</sup>Downgraded three levels due to risk of bias (performance bias, baseline imbalance), imprecision of estimate and heterogeneity in control group mean </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003871-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003871-sec-0030"></div> <section id="CD003871-sec-0031"> <h3 class="title" id="CD003871-sec-0031">Description of the condition</h3> <p>Eczema (syn: atopic eczema, atopic dermatitis) is a chronic, relapsing, intensely itchy, inflammatory skin disease (see <a href="#CD003871-fig-0001">Figure 1</a>), which involves the skin creases such as the folds of the elbows or behind the knees (<a href="./references#CD003871-bbs2-0166" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis.. British Journal of Dermatology1994;131(3):383‐96. [PUBMED: 7918015] ">Williams 1994</a>). Symptoms usually appear below the age of two years and around 60% of cases will be clear by early adolescence, although some will relapse or continue into adult life. Prevalence ranges from 2 to 20% and varies considerably from one country to another, and also within countries (<a href="./references#CD003871-bbs2-0142" title="OdhiamboJA , WilliamsHC , ClaytonTO , RobertsonCF , AsherMI . Global variations in prevalence of eczema symptoms in children from ISAAC phase three. Journal of Allergy and Clinical Immunology2009;124(6):1251‐8. [DOI: 10.1016/j.jaci.2009.10.009; PUBMED: 20004783 ] ">Odhiambo 2009</a>). The prevalence has also increased substantially across developed and less well developed countries worldwide for reasons that are still unclear (<a href="./references#CD003871-bbs2-0167" title="WilliamsH , StewartA , VonMutiusE , CooksonW , AndersonHR , International Study of Asthma and Allergies in Childhood (ISAAC) Phase One and Three Study Groups. Is eczema really on the increase worldwide?. Journal of Allergy and Clinical Immunology2008;121(4):947‐54.e15. [PUBMED: 18155278] ">Williams 2008</a>; <a href="./references#CD003871-bbs2-0117" title="DeckersIA , McLeanS , LinssenS , MommersM , VanSchayckCP , SheikhA . Investigating international time trends in the incidence and prevalence of atopic eczema 1990‐2010: a systematic review of epidemiological studies. PLOS One2012;7(7):e39803. [PUBMED: 22808063] ">Deckers 2012</a>). One review suggests that eczema affects around 7% to 10% of adults in the US (<a href="./references#CD003871-bbs2-0152" title="SilverbergJI . Public health burden and epidemiology of atopic dermatitis. Dermatology Clinics2017;35(3):283‐9. [PUBMED: 28577797] ">Silverberg 2017</a>). </p> <div class="figure" id="CD003871-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Eczema. Copyright © 2009 Centre of Evidence Based Dermatology: reproduced with permission." data-id="CD003871-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Eczema. Copyright © 2009 Centre of Evidence Based Dermatology: reproduced with permission.</p> </div> </div> </div> <p>Eczema often occurs in families with atopic diseases including asthma, allergic rhinitis/hay fever (and food allergy), and atopic eczema. These diseases share a common pathogenesis (mechanism of disease), and are frequently present together in the same individual and family. The word atopy refers to the genetic tendency to produce immunoglobulin E (IgE) antibodies in response to small amounts of common environmental proteins such as pollen, house dust mite, and food allergens (<a href="./references#CD003871-bbs2-0158" title="StoneKD . Atopic diseases of childhood. Current Opinion in Pediatrics2002;14(5):634‐46. [PUBMED: 12352260] ">Stone 2002</a>; <a href="./references#CD003871-bbs2-0161" title="ThomsenSF . Epidemiology and natural history of atopic diseases. European Clinical Respiratory Journal2015;2(1):24642. [DOI: 10.3402/ecrj.v2.24642; PUBMED: 26557262] ">Thomsen 2015</a>). Around 30% of people with eczema develop asthma and 35% develop allergic rhinitis (<a href="./references#CD003871-bbs2-0139" title="LuomaR , KoivikkoA , VianderM . Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years. A prospective study of 543 newborns. Allergy1983;38(5):339‐46. [PUBMED: 6614406] ">Luoma 1983</a>). However, it is known that atopy does not concurrently occur in all patients with atopic eczema. In view of this, there have been recent proposals to use the term 'eczema' to define patients both with and without atopy. Various terms are used for eczema; however, despite these synonyms, we will refer to the condition as just 'eczema' throughout the rest of this review. This is in agreement with the 'Revised nomenclature for allergy for global use' (<a href="./references#CD003871-bbs2-0131" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy and Clinical Immunology2004;113(5):832‐6. [PUBMED: 15131563] ">Johansson 2004</a>) and similar to other Cochrane Reviews evaluating eczema therapies (<a href="./references#CD003871-bbs2-0163" title="VanZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenA , ArentsBWM . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012119.pub2] ">Van Zuuren 2017</a>). </p> <p>The causes of eczema are not fully understood; however, both genetic and environmental factors are important in determining both the occurrence and the severity of disease (<a href="./references#CD003871-bbs2-0165" title="WilliamsHC . Is the prevalence of atopic dermatitis increasing?. Clinical and Experimental Dermatology1992;17(6):385‐91. [PUBMED: 1486704] ">Williams 1992</a>). Skin barrier dysfunction and immunological abnormalities play a role in its pathogenesis (<a href="./references#CD003871-bbs2-0168" title="WollenbergA , SebaA , AntalAS . Immunological and molecular targets of atopic dermatitis treatment. British Journal of Dermatology2014;170(Suppl 1):7‐11. [DOI: 10.1111/bjd.12975; PUBMED: 24720588] ">Wollenberg 2014</a>; <a href="./references#CD003871-bbs2-0108" title="BenettiC , PiacentiniGL , CapristoC , BonerAL , PeroniDG . Microorganism‐induced exacerbations in atopic dermatitis: a possible preventive role for vitamin D?. Allergy and Asthma Proceedings2015;36(1):19‐25. [DOI: 10.2500/aap.2015.36.3807; PUBMED: 25562552] ">Benetti 2015</a>). The identification of mutations in the gene coding for the skin barrier protein, filaggrin, confirmed the role of an underlying genetic predisposition (<a href="./references#CD003871-bbs2-0129" title="IrvineAD , McLeanWH . Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. Journal of Investigative Dermatology2006;126(6):1200‐2. [PUBMED: 16702964] ">Irvine 2006</a>), however, filaggrin mutations do not occur in all cases of eczema and other genes are likely to play a role. Environmental factors are important in the initial development of the condition and in triggering flares (<a href="./references#CD003871-bbs2-0121" title="GeorgeSM , MakrygeorgouA . 8th Georg Rajka International Symposium on Atopic Dermatitis: meeting report. British Journal of Dermatology2015;172(4):916‐25. [DOI: 10.1111/bjd.13718] ">George 2015</a>). </p> <section id="CD003871-sec-0032"> <h4 class="title">Staphylococcus aureus and eczema</h4> <p>An association between <i>S. aureus</i> and eczema has been recognised for many years. It has been demonstrated that <i>S. aureus</i> can be isolated from 70% of eczema skin lesions (<a href="./references#CD003871-bbs2-0162" title="TottéJE , Van derFeltzWT , HennekamM , VanBelkumA , VanZuurenEJ , PasmansSG . Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta‐analysis. British Journal of Dermatology2016;175(4):687‐95. [PUBMED: 26994362] ">Totté 2016</a>) and the density of <i>S. aureus</i> tends to increase with the clinical severity (<a href="./references#CD003871-bbs2-0164" title="WilliamsREA , GibsonAG , AitchisonTC , LeverR , MackieRM . Assessment of a contact‐plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. British Journal of Dermatology1990;123(4):493‐501. [PUBMED: 2095181] ">Williams 1990</a>). In contrast, <i>S. aureus</i> is rarely found on healthy skin (&lt; 5%), and it is less common to have severe colonisation or infection in other skin diseases, so eczema does appear to be a special case. Whilst this association is well recognised, the role of <i>S. aureus</i> in causing eczema or making it worse, as opposed to simply colonising the skin, is still under debate. However, there is increasing experimental evidence for its role in the pathogenesis of eczema. </p> </section> <section id="CD003871-sec-0033"> <h4 class="title">Clinically infected eczema</h4> <p>At one end of the spectrum, there is undoubtedly a clinical condition of 'infected eczema' manifest by oozing, crusting and presence of pus spots overlying the areas of pre‐existing eczema. This corresponds with heavy growth of bacteria in the laboratory on swabs taken from the affected areas, usually of <i>S. aureus</i> , but there are also reports of beta‐haemolytic streptococci (a type of streptococci that can split open red blood cells; some types can cause skin infections, while others live harmlessly on the skin) being isolated either alone or in combination with <i>S. aureus</i> (<a href="./references#CD003871-bbs2-0143" title="OngPY , LeungDY . Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clinical Reviews in Allergy &amp; Immunology2016;51(3):329‐37. [PUBMED: 27377298] ">Ong 2016</a>). In this situation, the overt infection responds to antibiotic treatment, although the eczema itself may not. Clinical infection is a major problem for some eczema sufferers (<a href="./references#CD003871-bbs2-0116" title="DavidTJ , CambridgeGC . Bacterial infection and atopic eczema. Archives of Disease in Childhood1986;61(1):20‐3. [PUBMED: 3954415] ">David 1986</a>). It has been reported that flares in eczema are preceded by a decrease in microbial diversity and that <i>S. aureus</i> is the main species found during a flare (<a href="./references#CD003871-bbs2-0143" title="OngPY , LeungDY . Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clinical Reviews in Allergy &amp; Immunology2016;51(3):329‐37. [PUBMED: 27377298] ">Ong 2016</a>). </p> </section> <section id="CD003871-sec-0034"> <h4 class="title">Staphylococcus aureus and non‐clinically infected eczema: coloniser or pathogen?</h4> <p>In eczema that is not overtly clinically infected, the role of <i>S. aureus</i> is much less clear. It may be that <i>S. aureus</i> simply colonises the skin, taking advantage of a favourable environment for growth. This is supported by the fact that treatment of the underlying eczema with topical steroid alone drastically reduces the number of colonies of <i>S. aureus</i> (<a href="./references#CD003871-bbs2-0156" title="StalderJF , FleuryM , SourisseM , RostinM , PhelineF , LitouxP . Local steroid therapy and bacterial skin flora in atopic dermatitis. British Journal of Dermatology1994;131(4):536‐40. [PUBMED: 7947206] ">Stalder 1994</a>). </p> <p>The role of <i>S. aureus</i> in eczema has been discussed in several review articles (<a href="./references#CD003871-bbs2-0137" title="LinYT , WangCT , ChiangBL . Role of bacterial pathogens in atopic dermatitis. Clinical Reviews in Allergy &amp; Immunology2007;33(3):167‐77. [PUBMED: 18163223] ">Lin 2007</a>; <a href="./references#CD003871-bbs2-0134" title="LeeM , VanBeverH . The role of antiseptic agents in atopic dermatitis. Asia Pacific Allergy2014;4(4):230‐40. [DOI: 10.5415/apallergy.2014.4.4.230; PUBMED: 25379483] ">Lee 2014</a>; <a href="./references#CD003871-bbs2-0143" title="OngPY , LeungDY . Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clinical Reviews in Allergy &amp; Immunology2016;51(3):329‐37. [PUBMED: 27377298] ">Ong 2016</a>; <a href="./references#CD003871-bbs2-0127" title="HepburnL , HijnenDJ , SellmanBR , MustelinT , SleemanMA , MayRD , et al. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. British Journal of Dermatology2017;177(1):63‐71. [PUBMED: 27779765] ">Hepburn 2017</a>). There are numerous ways in which <i>S. aureus</i> may potentially contribute to the pathogenesis of eczema, including via production of various proteins such as superantigens and proteases (<a href="./references#CD003871-bbs2-0134" title="LeeM , VanBeverH . The role of antiseptic agents in atopic dermatitis. Asia Pacific Allergy2014;4(4):230‐40. [DOI: 10.5415/apallergy.2014.4.4.230; PUBMED: 25379483] ">Lee 2014</a>). Superantigens penetrate the skin barrier and cause chronic inflammation through a variety of mechanisms, including: </p> <p> <ol id="CD003871-list-0001"> <li> <p>stimulation of cytokine (a type of protein used for signalling in the immune system) release from T‐cells; </p> </li> <li> <p>acting as an allergen by induction of IgE antibodies, which cause release of inflammatory mediators from mast cells (cells that release histamine during inflammatory or allergic reactions) and basophils (a type of white blood cell) </p> </li> <li> <p>stimulation of antigen‐presenting cells and keratinocytes (a type of skin cell) to release pro‐inflammatory cytokines, thereby increasing T‐cell infiltration; </p> </li> <li> <p>increasing cutaneous lymphocyte‐associated antigen receptor (a skin‐homing receptor) on T‐cells, causing migration to the skin and increasing inflammation; and </p> </li> <li> <p>increasing skin inflammation caused by other allergens.</p> </li> </ol> </p> <p>Superantigens also increase adherence of <i>S. aureus</i> to the skin by exposing extracellular matrix adhesins (a type of protein) and cause corticosteroid resistance (<a href="./references#CD003871-bbs2-0134" title="LeeM , VanBeverH . The role of antiseptic agents in atopic dermatitis. Asia Pacific Allergy2014;4(4):230‐40. [DOI: 10.5415/apallergy.2014.4.4.230; PUBMED: 25379483] ">Lee 2014</a>; <a href="./references#CD003871-bbs2-0108" title="BenettiC , PiacentiniGL , CapristoC , BonerAL , PeroniDG . Microorganism‐induced exacerbations in atopic dermatitis: a possible preventive role for vitamin D?. Allergy and Asthma Proceedings2015;36(1):19‐25. [DOI: 10.2500/aap.2015.36.3807; PUBMED: 25562552] ">Benetti 2015</a>). In a clinical study, application of one specific superantigen to the skin has been shown to induce skin changes of erythema (redness) and thickening of the skin (<a href="./references#CD003871-bbs2-0159" title="StrangeP , SkovL , LisbyS , NielsonPL , BaadsgaardO . Staphylococcal enterotoxin B applied on intact normal and intact atopic skin induces dermatitis. Archives of Dermatology1996;132(1):27‐33. [PUBMED: 8546480] ">Strange 1996</a>). </p> <p><i>S. aureus</i> also produces proteases, which cause skin barrier breakdown, allowing penetration of allergens and irritants. <i>S. aureus‐</i>derived proteases cleave endogenous protease inhibitors (proteins produced by the body that prevent the breakdown of proteins by enzymes called proteases), induce pro‐inflammatory and pro‐allergic responses, promote Th2 immune response and result in IgE production (<a href="./references#CD003871-bbs2-0134" title="LeeM , VanBeverH . The role of antiseptic agents in atopic dermatitis. Asia Pacific Allergy2014;4(4):230‐40. [DOI: 10.5415/apallergy.2014.4.4.230; PUBMED: 25379483] ">Lee 2014</a>). </p> <p>Other <i>S. aureus</i> ‐derived proteins may also contribute to skin inflammation in eczema. Phenol‐soluble modulins (a type of bacterial toxin) attract and lyse (break up) neutrophils (a type of white blood cell), making <i>S.aureus</i> more likely to cause harm (<a href="./references#CD003871-bbs2-0108" title="BenettiC , PiacentiniGL , CapristoC , BonerAL , PeroniDG . Microorganism‐induced exacerbations in atopic dermatitis: a possible preventive role for vitamin D?. Allergy and Asthma Proceedings2015;36(1):19‐25. [DOI: 10.2500/aap.2015.36.3807; PUBMED: 25562552] ">Benetti 2015</a>; <a href="./references#CD003871-bbs2-0160" title="SyedAK , ReedTJ , ClarkKL , BolesBR , KahlenbergJM . Staphylococcus aureus phenol soluble modulins stimulate the release of pro‐inflammatory cytokines from keratinocytes and are required for induction of skin inflammation. Infection and Immunity2015;83(9):3428‐37. [PUBMED: 26077761] ">Syed 2015</a>). Fibronectin‐binding protein, a type of protein produced by <i>S. aureus</i> that enables it to stick to and enter cells of the host organism, activates T–cells (a type of cell from the immune system, that plays a key role in skin inflammation). This activation results in the release of chemical messengers called cytokines that also promote skin inflammation (<a href="./references#CD003871-bbs2-0146" title="ReginaldK , WestritschnigK , LinhartB , Focke‐TejklM , Jahn‐SchmidB , Eckl‐DornaJ , et al. Staphylococcus aureus fibronectin‐binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses. Journal of Allergy and Clinical Immunology2011;128(1):82‐91. [10.1016/j.jaci.2011.02.034; PUBMED: 21513970] ">Reginald 2011</a>). </p> </section> </section> <section id="CD003871-sec-0035"> <h3 class="title" id="CD003871-sec-0035">Description of the intervention</h3> <p>A number of products with anti‐staphylococcal properties have been developed for the treatment of eczema, both clinically infected and uninfected, ranging from antibacterial soaps, impregnated clothing, to additives such as bath oils and topical corticosteroids. Some of these treatments are classed as antiseptics, substances applied to the skin which either kill or inhibit the growth of microorganisms, and others are antibiotics, which have specific effects on certain bacteria. </p> <p>Common anti‐staphylococcal interventions that are used in clinical practice include oral antibiotics, topical antibiotics used alone or in combination with a topical steroid (e.g. “Fucidin H” fusidic acid and hydrocortisone), and topical antiseptics, which can be used as a leave‐on emollient (moisturiser), soap or bath additive. Any of these interventions may be used in a primary or secondary care setting. </p> <p>The decision to use an anti‐staphylococcal intervention may be made on the observation of overt signs of clinical infection such as oozing on a background of intense erythema and pus spots, or during a flare of eczema, when staphylococcal colonisation is confirmed on bacterial culture from a skin swab. Exact regimens for topical preparations used in eczema are likely to vary depending on the patient’s condition and clinician experience. However, more specific recommendations for staphylococcal skin infection suggest using fusidic acid cream three to four times per day (<a href="./references#CD003871-bbs2-0109" title="Joint Formulary Committee. British National Formulary. www.bnf.org/products/bnf‐online/ (accessed prior to 23 October 2019). ">BNF 2019</a>). Combination steroid and antibiotic preparations are popular in the UK and are usually prescribed at a maximum frequency of twice daily for two weeks (<a href="./references#CD003871-bbs2-0141" title="National Institute for Health and Care Excellence. NICE support for commissioning for atopic eczema in children. www.nice.org.uk/guidance/qs44/resources/support‐for‐commissioning‐for‐atopic‐eczema‐in‐children‐pdf‐253673821 (accessed prior to 23 October 2019). ">NICE 2013</a>). </p> <p>For more widespread or severely infected eczema, oral antibiotics may be chosen. For an adult, this would usually be flucloxacillin at a dose of 250 mg or 500 mg four times per day for a week. For patients allergic to flucloxacillin, a macrolide antibiotic, e.g. erythromycin, can be used. Flucloxacillin commonly causes gastrointestinal side effects, such as nausea and diarrhoea (<a href="./references#CD003871-bbs2-0109" title="Joint Formulary Committee. British National Formulary. www.bnf.org/products/bnf‐online/ (accessed prior to 23 October 2019). ">BNF 2019</a>). Other less common side effects include hypersensitivity reactions, skin reactions and thrombocytopenia (low blood platelet count) (<a href="./references#CD003871-bbs2-0109" title="Joint Formulary Committee. British National Formulary. www.bnf.org/products/bnf‐online/ (accessed prior to 23 October 2019). ">BNF 2019</a>). Flucloxacillin can potentially interact with numerous other drugs, which can increase the risk of hepatotoxicity (liver damage) (<a href="./references#CD003871-bbs2-0109" title="Joint Formulary Committee. British National Formulary. www.bnf.org/products/bnf‐online/ (accessed prior to 23 October 2019). ">BNF 2019</a>). </p> <p>Many emollients are available which contain an antiseptic ingredient, such as chlorhexidine and benzalkonium chloride, present in brands such as Dermol. Some of the products are intended to be used as leave‐on emollients, which would usually be used twice a day and either prescribed for overt or suspected infection or as part of a normal emollient regimen regardless of infective status. Others are used as soap substitutes or bath additives when bathing. Skin irritation or allergic reactions may occur to the active ingredients or excipients (i.e. other inactive ingredients in the topical preparation such as a vehicle). </p> <p>Bath additives may also contain antiseptic ingredients such as chlorhexidine and benzalkonium chloride. These may be recommended for use when bathing, often as part of a normal skin care regimen for patients with eczema, especially those with recurrent skin infections. Skin irritation or allergic reactions may occur to the active ingredients or excipients. “Bleach baths” with dilute sodium hypochlorite solution are recommended for twice weekly use (<a href="./references#CD003871-bbs2-0155" title="St John's Institute of Dermatology. The use of Milton® baths in dermatology. www.guysandstthomas.nhs.uk/resources/patient‐information/dermatology/milton‐baths.pdf (accessed prior to 21 October 2019). ">St John's Institute of Dermatology 2016</a>). These may be recommended for patients with overt, suspected or frequently infected eczema. </p> <p>Therapeutic textiles with anti‐staphylococcal properties, although described in clinical trials, are not routinely used in a clinical setting for treating eczema. </p> </section> <section id="CD003871-sec-0036"> <h3 class="title" id="CD003871-sec-0036">How the intervention might work</h3> <p>The aim of treatment with anti‐staphylococcal interventions in eczema is to decrease bacterial load, thereby decreasing the amount of <i>S. aureus</i> superantigen, proteases and other protein products produced, which result in damage and inflammation of the skin barrier. </p> <section id="CD003871-sec-0037"> <h4 class="title">Possible concern about anti‐staphylococcal treatment in eczema</h4> <p>Quite apart from the fundamental question of whether anti‐staphylococcal therapies work in eczema, there are special concerns about their routine use in non‐clinically infected eczema. For the individual patient, irritant and allergic contact dermatitis can occur from topically‐applied antiseptics or antibiotic‐containing preparations. For example, allergic contact dermatitis is increasingly recognised to occur with benzalkonium chloride (<a href="./references#CD003871-bbs2-0125" title="HannS , HughesTM , StoneNM . Flexural allergic contact dermatitis to benzalkonium chloride in antiseptic bath oil. British Journal of Dermatology2007;157(4):795‐8. [PUBMED: 17714561 ] ">Hann 2007</a>) and chlorhexidine (<a href="./references#CD003871-bbs2-0132" title="KochA , WollinaU . Chlorhexidine allergy. Allergo Journal International2014;23(3):84‐6. [PUBMED: 26120519] ">Koch 2014</a>) with rare reports of anaphylaxis with the latter (<a href="./references#CD003871-bbs2-0140" title="MokaE , ArgyraE , SiafakaI , VadaloucaA . Chlorhexidine: hypersensitivity and anaphylactic reactions in the perioperative setting. Journal of Anaesthesiology, Clinical Pharmacology2015;31(2):145‐8. [DOI: 10.4103/0970‐9185.155138; PUBMED: 25948890] ">Moka 2015</a>). One study found that triclosan, a commonly used microbial agent, acted as a liver tumour promoter in mice (<a href="./references#CD003871-bbs2-0169" title="YuehMF , TaniguchiK , ChenS , EvansRM , HammockBD , KarinM , et al. The commonly used antimicrobial additive triclosan is a liver tumor promoter. Proceedings of the National Academy of Sciences of the United States of America2014;111(48):17200‐5. [DOI: 10.1073/pnas.1419119111; PUBMED: 25404284] ">Yueh 2014</a>). </p> <p>The potential for development of bacterial resistance to antibiotics, which may be needed for systemic treatment of serious infections, is also important. An increase in the prevalence of fusidic acid resistant <i>S. aureus</i> has been observed in several areas of the UK (<a href="./references#CD003871-bbs2-0145" title="ReedJ , LyonsM , WaghornD , WilkinsonJ . Fusidic acid resistance rates in South Buckinghamshire. British Journal of Dermatology1999;141(Suppl 55):57. ">Reed 1999</a>; <a href="./references#CD003871-bbs2-0144" title="RavenscroftJC , LaytonA , BarnhamM . Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clinical and Experimental Dermatology2000;25(4):327‐30. [PUBMED: 10971497] ">Ravenscroft 2000</a>; <a href="./references#CD003871-bbs2-0153" title="Simpson‐DentSL , HuntSJ , HardmanC , BarrettS , WakelinSH . Rates of fusidic acid resistance in paediatric dermatology patients ‐ a 6‐year study. British Journal of Dermatology2000;143(Suppl 57):123‐30. ">Simpson‐Dent 2000</a>; <a href="./references#CD003871-bbs2-0110" title="BrownEM , ThomasP . Fusidic acid resistance in Staphylococcus aureus isolates. Lancet2002;359(9308):803. [PUBMED: 11888633] ">Brown 2002</a>). In Harrogate, UK, fusidic acid resistance has been shown to be associated with intensive use of oral and topical fusidic acid‐containing preparations such as those marketed for eczema (<a href="./references#CD003871-bbs2-0144" title="RavenscroftJC , LaytonA , BarnhamM . Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clinical and Experimental Dermatology2000;25(4):327‐30. [PUBMED: 10971497] ">Ravenscroft 2000</a>). A subsequent study from Singapore confirmed an association between recent use of fusidic acid and fusidic acid‐resistant <i>S. aureus</i> (<a href="./references#CD003871-bbs2-0126" title="HengYK , TanKT , SenP , ChowA , LeoYS , LyeDC , et al. Staphylococcus aureus and topical fusidic acid use: results of a clinical audit on antimicrobial resistance. International Journal of Dermatology2013;52(7):876‐81. [DOI: 10.1111/j.1365‐4632.2012.05747.x; PUBMED: 23432159] ">Heng 2013</a>). Widespread use in dermatological practice may limit the use of fusidic acid combination therapies for the treatment of more serious diseases including staphylococcal bone and joint infections and systemic methicillin‐resistant <i>S. aureus</i> (MRSA) infections. </p> <p>Resistant organisms also have implications for patients with eczema. The prevalence of MRSA is increasing in patients with eczema (<a href="./references#CD003871-bbs2-0130" title="JagadeesanS , KurienG , DivakaranMV , SadanandanSM , SobhanakumariK , SarinA . Methicillin‐resistant Staphylococcus aureus colonization and disease severity in atopic dermatitis: a cross‐sectional study from South India. Indian Journal of Dermatology, Venereology and Leprology2014;80(3):229‐34. [DOI: 10.4103/0378‐6323.132250; PUBMED: 24823400] ">Jagadeesan 2014</a>; <a href="./references#CD003871-bbs2-0112" title="ChaptiniC , QuinnS , MarshmanG . Methicillin‐resistant Staphylococcus aureus in children with atopic dermatitis from 1999 to 2014: a longitudinal study. Australasian Journal of Dermatology2016;57(2):122‐7. [DOI: 10.1111/ajd.12371; PUBMED: 26172088 ] ">Chaptini 2015</a>). Furthermore, the presence of resistant <i>S. aureus</i> was found to be associated with increased disease severity (<a href="./references#CD003871-bbs2-0130" title="JagadeesanS , KurienG , DivakaranMV , SadanandanSM , SobhanakumariK , SarinA . Methicillin‐resistant Staphylococcus aureus colonization and disease severity in atopic dermatitis: a cross‐sectional study from South India. Indian Journal of Dermatology, Venereology and Leprology2014;80(3):229‐34. [DOI: 10.4103/0378‐6323.132250; PUBMED: 24823400] ">Jagadeesan 2014</a>). Mupirocin may also be used to reduce <i>S. aureus</i> carriage in patients with eczema. The use of mupirocin has also been found to correlate with mupirocin‐resistant <i>S. aureus</i> in paediatric dermatology patients (<a href="./references#CD003871-bbs2-0106" title="AntonovNK , GarzonMC , MorelKD , WhittierS , PlanetPJ , LaurenCT . High prevalence of mupirocin resistance in Staphylococcus aureus isolates from a pediatric population. Antimicrobial Agents and Chemotherapy2015;59(6):3350‐6. [DOI: 10.1128/AAC.00079‐15; PUBMED: 25824213] ">Antonov 2015</a>). </p> </section> </section> <section id="CD003871-sec-0038"> <h3 class="title" id="CD003871-sec-0038">Why it is important to do this review</h3> <p>There is a plausible theoretical rationale for use of anti‐staphylococcal agents in eczema, especially if it appears to be clinically infected. Yet existing evidence to support clinical benefit of anti‐staphylococcal agents appears to be conflicting. There are concerns regarding adverse event issues, e.g. contact and irritant dermatitis, and promoting wider drug resistance in the community. Despite these concerns, anti‐staphylococcal products are widely marketed and used by the clinical community. </p> <p>This is an update of a review 'Interventions to reduce <i>Staphylococcus aureus</i> in the management of atopic eczema' (<a href="./references#CD003871-bbs2-0170" title="BirnieAJ , Bath‐HextallFJ , RavenscroftJC , WilliamsHC . Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD003871] ">Birnie 2008</a>). The previous review found that most studies were poorly reported and study differences limited pooling of results. The authors failed to find clear evidence of benefit for antimicrobial interventions for people with eczema, despite their widespread use. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003871-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003871-sec-0039"></div> <p>To assess the effects of interventions to reduce <i>S. aureus</i> for treating eczema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003871-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003871-sec-0040"></div> <section id="CD003871-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003871-sec-0042"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), including cross‐over trials and randomised within‐patient trials. </p> </section> <section id="CD003871-sec-0043"> <h4 class="title">Types of participants</h4> <p>Anyone who has been diagnosed with atopic eczema by a medical practitioner. We regarded diagnostic criteria such as the Hanifin and Rajka definition (<a href="./references#CD003871-bbs2-0123" title="HanifinJM , RajkaG . Diagnostic features of atopic eczema. Acta Dermato‐Venerologica1980;92:44‐7. ">Hanifin 1980</a>) or the UK refinement (<a href="./references#CD003871-bbs2-0166" title="WilliamsHC , BurneyPG , HayRJ , ArcherCB , ShipleyMJ , HunterJJ , et al. The UK Working Party's diagnostic criteria for atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis.. British Journal of Dermatology1994;131(3):383‐96. [PUBMED: 7918015] ">Williams 1994</a>) as acceptable, as was diagnosis of atopic eczema by a dermatologist using the terms 'atopic eczema' or 'atopic dermatitis'. We only accepted the term 'eczema' when referring to children. Any other terms, such as 'Besnier's prurigo' or 'neurodermatitis' had to have additional descriptive evidence of atopic eczema in the flexures before inclusion. It was noted whether the participants were described as 'clinically infected' or otherwise. </p> <p>Studies in which not all participants had atopic eczema were only included if separate results were reported for the participants with atopic eczema. </p> </section> <section id="CD003871-sec-0044"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD003871-list-0002"> <li> <p>Oral antibiotic known to be active against <i>staphylococcus</i> </p> </li> <li> <p>Topical antiseptic/antibiotic</p> </li> <li> <p>Topical steroid plus antiseptic/antibiotic</p> </li> <li> <p>Topical steroid plus antibiotic and antifungal</p> </li> <li> <p>Topical calcineurin inhibitor plus antibiotic</p> </li> <li> <p>Antibacterial soap</p> </li> <li> <p>Antibacterial bath additive</p> </li> <li> <p>Antibacterial bath additive plus antibiotic</p> </li> <li> <p>Therapeutic textile</p> </li> <li> <p>Protease inhibitor</p> </li> </ol> </p> <p>We accepted as comparators a similar treatment regimen without the anti‐staphylococcal agent, i.e. placebo, no treatment, vehicle only, or untreated textile where the intervention was an anti‐staphylococcal agent alone, or an active compound where the intervention consisted of the active compound plus an anti‐staphylococcal agent (e.g. topical steroid/antibiotic combination compared against the same topical steroid without the antibiotic). On this final point, it was agreed that a vehicle was not an appropriate comparator for a steroid/antibiotic combination as it is well recognised that topical steroids are an effective treatment for inflamed eczema and thus one could not establish whether it was the addition of the antibiotic, or the steroid itself that had efficacy. </p> <p>For studies with two treatment groups of interventions from different categories compared against a single comparator group, the relevant treatment group and the same comparator group were included in both categories. </p> </section> <section id="CD003871-sec-0045"> <h4 class="title">Types of outcome measures</h4> <section id="CD003871-sec-0046"> <h5 class="title">Primary outcomes</h5> <p>(a) Global degree of improvement in symptoms or signs, or both, as rated by the participant or medical practitioner, i.e. percentage with good or excellent improvement. We included both short‐term (less than or equal to a month) improvement and long‐term (more than one month) benefit.<br/> (b) Improvement in Quality of Life questionnaires. </p> </section> <section id="CD003871-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.<br/> (b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.<br/> (c) Emergence of antibiotic‐resistant micro‐organisms. Only <i>S. aureus</i> was considered, and we only included studies if swab data before and after the intervention were available. It was planned to take duration of treatment into account when these data were interpreted. </p> <section id="CD003871-sec-0048"> <h6 class="title">Tertiary outcome measures</h6> <p>(a) Global changes in composite rating scales, using a published named scale.<br/> (b) Changes in the individual signs of eczema as assessed by a physician, e.g. erythema (redness), papules (spots that protrude from the skin surface), vesicles (water blisters), scaling.<br/> (c) Duration of remission and/or prevention of subsequent flares.<br/> (d) Change in isolation rate of <i>S. aureus</i> , i.e. isolated or not isolated.<br/> (e) Change in bacterial counts of <i>S. aureus</i> , i.e. an assessment of quantity of <i>S. aureus</i>. </p> <p>The Harmonising Outcome Measures for Eczema (HOME) initiative recommends a core outcome set of four domains for trials in eczema (<a href="./references#CD003871-bbs2-0149" title="SchmittJ , SpulsP , BoersM , ThomasK , ChalmersJ , RoekevischE , et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy2012;67(9):1111‐7. [PUBMED: 22844983] ">Schmitt 2012</a>): </p> <p> <ol id="CD003871-list-0003"> <li> <p>Clinician‐reported signs, with core outcome instrument Eczema Area &amp; Severity Index (EASI) (<a href="./references#CD003871-bbs2-0150" title="SchmittJ , SpulsPI , ThomasKS , SimpsonE , FurueM , DeckertS , et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology2014;134(4):800‐7. [PUBMED: 25282560] ">Schmitt 2014</a>). This would be included in our tertiary outcome, global changes in composite rating scales, with individual signs also captured as a separate tertiary outcome. </p> </li> <li> <p>Patient‐reported symptoms, with core outcome instrument Patient Oriented Eczema Measure (POEM) (<a href="./references#CD003871-bbs2-0154" title="SpulsPI , GerbensLAA , SimpsonE , ApfelbacherCJ , ChalmersJR , ThomasKS , et al. Patient‐Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology2017;176(4):979‐84. [PUBMED: 27858989] ">Spuls 2017</a>). This would also be included in our tertiary outcome, global changes in composite rating scales. </p> </li> <li> <p>Quality of life. This was one of our primary outcomes. HOME has yet to recommend a core outcome instrument. </p> </li> <li> <p>Long‐term control. HOME recommends that this should be captured by repeated measurement of the other three domains. We assessed all reported outcomes in both short‐ and long‐term timeframes. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD003871-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD003871-sec-0050"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised all our search strategies in line with current Cochrane Skin practices. Details of the previous search strategies are available in <a href="./references#CD003871-bbs2-0170" title="BirnieAJ , Bath‐HextallFJ , RavenscroftJC , WilliamsHC . Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD003871] ">Birnie 2008</a>. </p> <p>We searched the following databases up to 29 October 2018:</p> <p> <ul id="CD003871-list-0004"> <li> <p>the Cochrane Skin Group Specialised Register using the following search terms: (dermatitis or eczema or neurodermatitis or besnier*) and (staphylococc*) </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL); 2018, Issue 9, in the Cochrane Library using the search strategy in <a href="./appendices#CD003871-sec-0315">Appendix 1</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD003871-sec-0316">Appendix 2</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="./appendices#CD003871-sec-0317">Appendix 3</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD003871-sec-0318">Appendix 4</a>. </p> </li> </ul> </p> <section id="CD003871-sec-0051"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers up to 16 November 2018:</p> <p> <div class="table" id="CD003871-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial registry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search terms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>("Eczema" OR "Dermatitis") AND "Staphylococcus"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>("Eczema" OR "Dermatitis") AND "Staphylococcus"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>("Eczema" OR "Dermatitis") AND "Staphylococcus"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>("Eczema" OR "Dermatitis") AND "Staphylococcus"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>eczema AND staphylococcus OR dermatitis AND staphylococcus</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD003871-sec-0052"> <h4 class="title">Searching other resources</h4> <section id="CD003871-sec-0053"> <h5 class="title">References lists</h5> <p>We checked the bibliographies of all of the studies that were obtained for further references to relevant trials. </p> </section> <section id="CD003871-sec-0054"> <h5 class="title">Correspondence</h5> <p>Where possible we corresponded with trial authors (<a href="#CD003871-tbl-0004">Table 1</a>), and we contacted pharmaceutical companies who produce relevant products, in order to identify unpublished and ongoing trials. For the current update, the following companies were contacted: </p> <div class="table" id="CD003871-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Correspondence with authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Information requested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>th</sup> April 2015 </p> <p>Dear Professor Canpolat</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age – a randomized double blind pilot trial’ (Eur Rev Med Pharmacol Sci 2012; 16:1989‐93) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence in the trial?</p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. The abstract indicates that efficacy evaluation was made at ‘day 7 and weeks 2, 4 and 8’ however the results are only reported for ‘day 8’. Could you please clarify and provide any outcome data for additional time points that are available? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<sup>th</sup> April 2015 </p> <p>Dear Dr Fluhr</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study’ (Exp Dermatol 2009; 19:e9‐15) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the randomised in vivo study? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was single‐blinded. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes)? </p> <p>4. Could you clarify how and when the outcomes were assessed and who made the assessment?</p> <p>5. Did you record any clinical assessment of the severity of atopic dermatitis or of quality of life? </p> <p>6. Could you provide the values for the mean and standard error of the mean for the S. aureus colonisation changes reported in Figure 2a? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<sup>th</sup> April 2015 </p> <p>Dear Dr Gauger</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Efficacy and functionality of silver‐coated textiles in patients with atopic eczema’ (JEADV 2006; 18:534‐41) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. However, the Results state that ‘Nine of the 11 dropouts were from the placebo group, due to either systemic antibiotics or assignment to the placebo group by the patient.’ This appears to imply that patients in the placebo group were aware of their assignment. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>4. Could you supply the full results for the responses to the questionnaire (Table 2) at 1 week and at the end of the study in terms of the number of participants in each group giving each response? </p> <p>5. Could you supply the standard deviations at each time point for the general SCORAD (fig. 1), eczema extent in the SCORAD (fig. 2), subjective symptoms in SCORAD (fig. 3) and impairment of quality of life (fig. 4)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> April 2015 </p> <p>Dear Dr Chiang</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article by Hung et al, ‘Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics’ (Ann Allergy Asthma Immunol 2007; 98:51‐6) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Could you supply the full results for the outcomes reported in Figure 1 and Figure 2 (e.g. means and standard deviations or standard errors at each time point)? </p> <p>4. Could you supply the full results for each group at each time point for the other outcomes not reported in the paper – modified local SCORAD, colonisation density of S. aureus, antibiotic resistance? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> April 2015 </p> <p>Dear Dr Koller</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Action of a silk fabric treated with AEGIS<sup>TM</sup> in children with atopic dermatitis: a 3‐month trial’ (Pediatr Allergy Immunol 2009; 18:335‐8) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Did you give any instructions on washing and drying the tubes?</p> <p>4. Did you calculate a total for the modified SCORAD?</p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> October 2015 </p> <p>Dear Liz Leins,<br/> We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Our searches identified your trial on Bleach Baths for Eczema as possibly relevant for the Cochrane Systematic Review and we would be very grateful if you could send us further details of the study and any results.<br/> Many thanks for your help.<br/> Kind regards,<br/> Susannah George </p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> October 2015 </p> <p>Hi Susannah,</p> <p>The final results are unpublished so I can’t send you those, however our poster was presented at the Australasian College of Dermatologist’s annual conference and reported pilot data (although our final results are the same). </p> <p>Best,</p> <p>Liz</p> <p>[Conference poster attached]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>th</sup> April 2015 </p> <p>Dear Dr Lembo</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘L’eritromicina topica nella terapia della dermatite atopica’ (Ann Ital Dermatol Allergol 2011; 65:3) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. You have indicated that the patients were randomised into the two groups stratified by age and sex. Could you describe the method used to generate the allocation sequence within each stratum? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>th</sup> April 2015 </p> <p>Dear Dr. George.</p> <p>Sorry for writing you so late but it has been a very busy period. We are happy about your intention to include our paper in your updated review. </p> <p>This is the method we used to generate the two groups stratified for sex and age:</p> <p> <ol id="CD003871-list-0005"> <li> <p>Age and sex of patients were recorded in a word excel sheet in which patients were anonymised </p> </li> <li> <p>Patients were ordered by age</p> </li> <li> <p>Four classes were identified by age range:</p> </li> </ol> </p> <p>I: 0.5 to 3 years</p> <p>II: 4 to 7 years</p> <p>III: 8 to 11 years</p> <p>IV: 12 to 14 years.</p> <p> <ol id="CD003871-list-0006"> <li> <p>Two subclasses were identified by sex in each age class: male and female</p> </li> <li> <p>Each subject in the sex subclass was sequentially enumerated (1…2…3…4…)</p> </li> <li> <p>Pare numbers were assigned to group B and spare numbers were assigned to group A.</p> </li> </ol> </p> <p>Patients and SCORAD evaluator were blind.</p> <p>Best regards</p> <p>Claudio Lembo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<sup>th</sup> February 2017 </p> <p>Dear Professor Leyden</p> <p>I am a consultant dermatologist in the UK and I am currently updating the Cochrane systematic review on antistaphylococcal interventions in atopic dermatitis. Your paper on steroid‐antibiotic combinations from 1977 is included in the review and I am having some difficulty interpreting the detail of the results to include them in the review. </p> <p>For the comparison of Synalar vs Neo‐Synalar, you reported clinical responses of 30% excellent, 40% good and 30% fair for Synalar and 70% excellent, 20% good and 10% fair for Neo‐Synalar. However, these exact percentages do not seem possible based on the reported sample sizes of 21 and 15, respectively. I realise this study was a long time ago, however I wondered if you would be able to clarify whether the percentages reported were based on a smaller subset of patients, or whether they have been approximated/rounded off to multiples of 10%. </p> <p>Many thanks for your help.</p> <p>Kind regards</p> <p>Susannah</p> <p>Dr Susannah George</p> <p>Consultant Dermatologist</p> <p>Brighton and Sussex University Hospitals NHS Trust</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>th</sup> February 2017 </p> <p>I assume the % were rounded off</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> October 2015 </p> <p>Dear Dr Araujo</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis’ (Cutan Ocul Toxicol 2013; 32:268‐74) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Could you describe the reason why one patient in the intervention group did not complete the study? At what point did they drop out? </p> <p>4. In your study, were patients given only one set of clothes to wear continuously for the first seven days? How often were they expected to wash the clothing? Do you have any data as to whether the patients did or did not wear the clothing as instructed? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>th</sup> April 2015 </p> <p>Dear Dr Wong</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia’ (J Dermatol 2013; 40:874‐80) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. However, previous studies of bleach baths have reported that the intervention was obvious due to the smell of bleach. Did you make any attempt to address this in your study, and did you have any evidence that the participants were genuinely blinded to their treatment allocation? More generally, could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>4. Could you supply the full results for the bacteriological assessments (means and standard deviations in CFU/cm2 at baseline and follow‐up)? </p> <p>5. Could you supply the mean and standard deviation for each group at each time point for EASI (Figure 3), BSA affected (Figure 5) and itch scores (Figure 7)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> April 2015 </p> <p>Dear Dr George,</p> <p>Thank you for your email. I will try and answer all your questions as accurately as possible. </p> <p>1.Could you describe the method used to generate the allocation sequence for the trial?</p> <p>Patients were assigned randomly through computer generated simple randomised numbers to the treatment or placebo study arms. </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>I had no access to the allocation sequence. the pharmacist helping in this study, dispensed either bleach or placebo (distilled water) according to the computer generated numbers. So I didn't know which the patient got, and on all the subsequent follow‐up, the patient was assessed by me without knowledge of what treatment they were given. </p> <p>3. You have indicated that the study was double‐blind. However, previous studies of bleach baths have reported that the intervention was obvious due to the smell of bleach. Did you make any attempt to address this in your study, and did you have any evidence that the participants were genuinely blinded to their treatment allocation? More generally, could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>Both treatment and placebo were placed in identical bottles. yes, the patient may have been able to smell the bleach. but nothing else was done to mask the smell. The investigator (also assessed outcomes) was blinded, pharmacist dispensing the medication was not. This was maintained throughout the study period. </p> <p>4. Could you supply the full results for the bacteriological assessments (means and standard deviations in CFU/cm<sup>2</sup> at baseline and follow‐up)? </p> <p>‐ see excel sheet attached</p> <p>5. Could you supply the mean and standard deviation for each group at each time point for EASI (Figure 3), BSA affected (Figure 5) and itch scores (Figure 7)? </p> <p>‐ see excel sheet attached</p> <p>I hope the above answers your questions. Please do not hesitate to contact me if you need further clarification. </p> <p>Thank you.</p> <p>Regards,</p> <p>Dr Wong S</p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD003871-list-0007"> <li> <p>Dermal (Dermol 600, Dermol 200, Dermol wash emulsion, Dermol cream, Dermol 500, Emulsiderm);</p> </li> <li> <p>GSK (Trimovate, Bactroban, Retapamulin);</p> </li> <li> <p>Amdipharm mercury (Aureocort);</p> </li> <li> <p>Leo (Fucidin H, Fucibet, Fucidin);</p> </li> <li> <p>Typharm (Nystaform‐ HC);</p> </li> <li> <p>Alliance (Terra‐Cortril, Timodene);</p> </li> <li> <p>Derma UK (Synalar N);</p> </li> <li> <p>PLIVA Pharma Ltd (TEVA) (Polyfax);</p> </li> <li> <p>Smith &amp; Nephew (Flamazine);</p> </li> <li> <p>Genus (Eczmol);</p> </li> <li> <p>Stiefel (Oilatum Plus);</p> </li> <li> <p>Thornton and Ross (Zerolatum Plus).</p> </li> </ul> </p> </section> <section id="CD003871-sec-0055"> <h5 class="title">Grey literature</h5> <p>Conference proceedings from the following meetings were checked for RCTs and, where appropriate, the trial authors were contacted for further information: </p> <p> <ul id="CD003871-list-0008"> <li> <p>British Association of Dermatologists annual meeting (from 1980 to 2018);</p> </li> <li> <p>American Academy of Dermatology annual meeting (2006 to 2018); and</p> </li> <li> <p>Congresses of the European Academy of Dermatology and Venereology were searched using the term “staphylococcus aureus” for the following years: 1995, 1998, 1999, 2002, 2003, 2005, 2006, 2008‐2018. </p> </li> </ul> </p> </section> </section> </section> <section id="CD003871-sec-0056"> <h3 class="title" id="CD003871-sec-0056">Data collection and analysis</h3> <section id="CD003871-sec-0057"> <h4 class="title">Selection of studies</h4> <p>Two authors independently checked the titles and abstracts identified from the searches (JR and JP or AB for the original; SG and SK or DH for the update). If it was clear that the study did not refer to a RCT on eczema, it was excluded. If it was unclear, then the full text of the study was obtained for independent assessment by two authors (AB and HCW for the original; SG and SK or DH for the update). The authors decided which trials fitted the inclusion criteria. For the original review, any disagreement was resolved by discussion between AB and HCW and it was not necessary to refer to a third author. For the update, any disagreement was resolved by discussion between SG and SK or DH; in some cases, a consensus among all authors was obtained. We recorded excluded studies and reasons for exclusion in the <a href="./references#CD003871-sec-0330" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD003871-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>This was performed by two authors (AB and HCW for the original; SG and SK or DH for the update), who independently entered data onto a data extraction form. AB and HCW (SG and SK for the update) discussed discrepancies between themselves. Missing data were obtained from trial authors, where possible. Data were checked and entered into RevMan by AB and FBH (SG and DH for the update). The authors were not blinded to the names of trial authors, journal or institutions. </p> <p>In the original published protocol, outcomes were considered at the end of treatment and this was considered short‐term where treatment had been given for two weeks or less and long‐term for periods of one month or greater. After discussion (between AB and HCW) however, it was decided that studies of a month's duration or less would be considered as reflecting short‐term benefit and those of greater than a month as a reasonable minimal time to reflect some disease chronicity. Where the patient‐rated global assessment was not available, the medical practitioner global rating was used. Both measures were taken into account where both were available. No attempt was made to combine these measures, as they are often not well correlated. In the published protocol, skin irritation was to be reported separately as well as within the minor participant adverse events. After discussion (between AB and HCW), it was decided that it was not necessary to report on skin irritation twice and thus it was included in the "minor patient‐reported adverse events" section only. </p> </section> <section id="CD003871-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the update, two authors (SG and either DH or SK) independently assessed the risk of bias of each study, including those from the original review, using the Cochrane tool for assessing risk of bias (<a href="./references#CD003871-bbs2-0128" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 [updated March 2011]. Chichester (UK): John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). Any disagreement was resolved by discussion between these three authors. The risk of bias tool addresses the following domains: </p> <p> <ul id="CD003871-list-0009"> <li> <p>method of sequence generation;</p> </li> <li> <p>method of allocation concealment;</p> </li> <li> <p>blinding of investigators and participants;</p> </li> <li> <p>blinding of outcome assessors;</p> </li> <li> <p>presence of incomplete outcome data;</p> </li> <li> <p>presence of selective reporting; and</p> </li> <li> <p>other bias such as, for example, baseline imbalance.</p> </li> </ul> </p> <p>For each study we categorised each domain as 'low risk of bias', 'high risk of bias' or 'unclear risk of bias'. </p> </section> <section id="CD003871-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>For studies with a similar type of intervention and control (e.g. steroid/antibiotic combinations), a meta‐analysis was performed to calculate a weighted treatment effect across trials using a random‐effects model. The results were expressed as risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes, rather than odds ratio as the event rates were common and we did not wish to overestimate the effect. Continuous outcomes were expressed as either mean differences (MD and 95% CI) for cases in which the same instrument was used, or standardised mean differences (SMD) for cases in which different instruments were used. Where it had not been possible to perform a meta‐analysis, the data were described qualitatively. Where appropriate, we expressed results as number needed to treat for an additional beneficial outcome (NNTB) with 95% CI and the baseline risk to which it applied. </p> </section> <section id="CD003871-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>We did not perform techniques appropriate for paired designs for cross‐over studies due to insufficient data; however, where data from the first period were available from a cross‐over study, then they were analysed as if it were a parallel study as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003871-bbs2-0128" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 [updated March 2011]. Chichester (UK): John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). For within‐patient trials, we abstracted from the original paper the paired analysis results, if available, and reported these in the review. If cluster‐randomised trials had been identified, we would have attempted to include them using the generic inverse‐variance method, if appropriate results were reported. Where studies with multiple treatment arms were identified, if two interventions from different categories were compared against the same control group, then both pairwise comparisons were included within the relevant categories. </p> </section> <section id="CD003871-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>If results from intention‐to‐treat analyses were given, then we used them as such (see <a href="./references#CD003871-sec-0329" title="">Characteristics of included studies</a>). Where a per protocol analysis was performed by the study in question or it was clear that the number of participants completing the study were not the same as those randomised, then we performed an available case analysis (i.e. we included only those participants for whom the outcome was reported). </p> </section> <section id="CD003871-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was assessed using I². Where substantial heterogeneity (I² &gt; 50%) existed between studies for the primary outcome, we explored reasons for heterogeneity, such as differing inclusion criteria (<a href="./references#CD003871-bbs2-0128" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 [updated March 2011]. Chichester (UK): John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD003871-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We would have performed funnel plots if greater than 10 pooled studies were available (<a href="./references#CD003871-bbs2-0128" title="HigginsJPT , GreenS , (editors) . Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0 [updated March 2011]. Chichester (UK): John Wiley &amp; Sons, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD003871-sec-0065"> <h4 class="title">Data synthesis</h4> <p>A random‐effects model was used when conducting a meta‐analysis as the studies were deemed to be clinically heterogeneous. </p> </section> <section id="CD003871-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We would have performed subgroup analysis where adequate information was given. The planned subgroups were 'clinically infected eczema', 'mixed infection/colonisation with <i>S. aureus</i> and beta haemolytic <i>Streptococcus</i>', and 'non‐infected or unspecified.' Heterogeneity was assessed as above (<a href="#CD003871-sec-0063">Assessment of heterogeneity</a>). </p> </section> <section id="CD003871-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>We explored reasons for heterogeneity in studies and, if necessary, we would have performed sensitivity analyses examining the effects of excluding study subgroups, e.g. those studies with low methodological quality. </p> <section id="CD003871-sec-0068"> <h5 class="title">Summary of findings tables</h5> <p>Summary of findings tables were generated for all comparisons for which we were able to pool evidence. The outcomes selected for inclusion in the 'Summary of findings' tables were all primary and secondary outcomes, and two tertiary outcomes that were considered most important (changes in composite rating scales and changes in <i>S. aureus</i> isolation rates). For each outcome included in the 'Summary of findings' tables, the quality of the body of evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD003871-bbs2-0122" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490‐4. ">GRADE Working Group 2004</a>), which specifies four levels of quality (high, moderate, low and very low). As all studies included in the review were RCTs, the starting level for all assessments was high quality. The level was then downgraded according to the presence of the following factors: risk of bias; indirectness of evidence; unexplained heterogeneity; imprecision of results; and likelihood of publication bias. The number of levels to downgrade each body of evidence was decided by discussion and agreement between two authors (SG and DH). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003871-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003871-sec-0069"></div> <section id="CD003871-sec-0070"> <h3 class="title">Description of studies</h3> <section id="CD003871-sec-0071"> <h4 class="title">Results of the search</h4> <p>We updated the searches to October 2018. We screened 307 records from the following databases: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. A further 88 records were identified through trial registries (52), the GREAT database (34), correspondence with authors (1), and conference abstracts (1). This gave a total of 395 records. </p> <p>After duplicates were removed, there were 343 records. We excluded 285 records based on titles, abstracts and trial registration records. After screening the remaining 58 records, we included 18 new studies (see <a href="./references#CD003871-sec-0329" title="">Characteristics of included studies</a>), and excluded 33 (<a href="./references#CD003871-sec-0330" title="">Characteristics of excluded studies</a>). We identified one ongoing study, and six studies awaiting classification. </p> <p>We combined the new studies with those previously identified for this review, and for this update we have included a total of 41 trials (18 new), and excluded 57 trials (33 new). </p> <p>A summary of the search results is provided in <a href="#CD003871-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD003871-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003871-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003871-sec-0072"> <h4 class="title">Included studies</h4> <p>Twenty‐one studies were included in the original review. Of three studies awaiting classification in the original review, two were included for this update (<a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006;</a><a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>), and one was excluded (<a href="./references#CD003871-bbs2-0086" title="SentiG , SteinmannLS , FischerB , KurmanR , StorniT , JohansenP , et al. Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment. Dermatology2006;213(3):228‐33. [PUBMED: 17033173] ">Senti 2006</a>), giving a total of 23 trials from the original review. From the update searches, 18 additional studies were included, resulting in a total of 41 studies with 1753 evaluable participants included in this review and described in the <a href="./references#CD003871-sec-0329" title="">Characteristics of included studies</a> tables. </p> <section id="CD003871-sec-0073"> <h5 class="title">Study design</h5> <p>All studies were RCTs: 27 parallel group RCTs (including one 2 x 2 factorial), six cross‐over, and eight within‐patient studies. The studies involved sample sizes between four and 174 evaluable participants. </p> </section> <section id="CD003871-sec-0074"> <h5 class="title">Setting</h5> <p>Setting was specified in 38 studies and they were conducted in secondary care, except one study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>), which predominantly recruited from primary care. Three studies did not specify the setting. Twenty‐one of the studies were conducted in Western Europe, nine were in North America, seven were from the Far East and four elsewhere in the world. Nine of the studies were conducted using multiple centres, 27 were single centre and five did not specify. </p> </section> <section id="CD003871-sec-0075"> <h5 class="title">Participants</h5> <p>Twelve studies looked specifically at children and four specifically at adults, 19 included both, and, in six studies, it was not clear. Mean age ranged from 1.1 to 34.6 years across the 24 studies that reported this, with a median across studies of 14.9 years (eleven of the studies that did specify whether they recruited adults or children did not report the mean age). All of the studies included both males and females. The proportion of males ranged from 20% to 65% across the 28 studies that reported this, with a median of 48%. </p> <p>Four studies were in clinically infected eczema, 15 in uninfected eczema, and two reported a mix of infected and uninfected cases, while 20 did not specify infective status. In five studies, colonisation or infection with <i>S. aureus</i> was specified as an inclusion criterion, and across the other 18 studies that reported the proportion colonised (usually assessed on lesional skin), this varied from 38% to 100%, with a median of 83%. </p> </section> <section id="CD003871-sec-0076"> <h5 class="title">Funding sources</h5> <p>In 22 studies, the funding sources were not stated. In one study, funding was reported as "none". Nine studies were commercially funded, five studies were funded by non‐commercial research grants or institutions and one study was explicitly reported to have been funded by both a non‐commercial research grant and a pharmaceutical company. In three studies, the intervention, placebo or other research support was commercially supplied. </p> </section> <section id="CD003871-sec-0077"> <h5 class="title">Interventions</h5> <p>The included studies fell into 10 broad categories of interventions:</p> <p> <ol id="CD003871-list-0010"> <li> <p>Oral antibiotic (four studies);</p> </li> <li> <p>Topical antiseptic/antibiotic (five studies);</p> </li> <li> <p>Topical steroid plus antiseptic/antibiotic (14 studies);</p> </li> <li> <p>Topical steroid plus antibiotic and antifungal (one study);</p> </li> <li> <p>Topical calcineurin inhibitor plus antibiotic (one study);</p> </li> <li> <p>Antibacterial soap (one study);</p> </li> <li> <p>Antibacterial bath additive (seven studies);</p> </li> <li> <p>Antibacterial bath additive plus antibiotic (one study);</p> </li> <li> <p>Therapeutic textile (eight studies);</p> </li> <li> <p>Protease inhibitor (one study).</p> </li> </ol> </p> <p>One three‐arm study had two interventions included in different categories (oral antibiotic and topical steroid plus antiseptic/antibiotic) (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>), and the factorial trial also had two interventions included in different categories (topical steroid plus antiseptic/antibiotic and topical calcineurin inhibitor plus antibiotic) (<a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>). Two further studies included a third randomised arm that was not eligible for inclusion in the review (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>), one study had two additional randomised arms that were not eligible (<a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a>) and one study included an additional non‐randomised control group (<a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>). Three of the papers additionally reported a second study, which in all cases was not eligible for inclusion in the review (<a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>; <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>). </p> <p>Control groups for the studies of oral interventions were all oral placebos and topical interventions were compared against vehicle alone, another topical placebo, or no treatment. Studies of topical steroid (or topical calcineurin inhibitor) plus antiseptic/antibiotic (with or without antifungal) were only included if the controls used a topical steroid (or calcineurin inhibitor) without the antiseptic/antibiotic added. Antibacterial bath emollients were compared against the same emollient without the antibacterial component and bleach baths were compared against water or bath emollient. Therapeutic textiles were all compared against untreated placebo textiles. </p> <p>In 16 studies, plus two arms of the factorial RCT, all participants received topical steroids. In five studies, plus the other two arms of the factorial RCT, topical steroids were not permitted. In seven studies, participants could continue to use topical steroids as needed, and in four studies participants were strongly discouraged from using topical steroids or they were only permitted as ‘rescue medication’. The remaining eight studies did not report on use of topical steroids. </p> </section> <section id="CD003871-sec-0078"> <h5 class="title">Outcomes</h5> <p>The studies had multiple stated outcomes, a number of which were not reported in the results. Twenty studies reported on global improvement and five reported on quality of life, using the DLQI (Dermatology Life Quality Index, <a href="./references#CD003871-bbs2-0120" title="FinlayAY , KhanGK . Dermatology Life Quality Index (DLQI) ‐ a simple practical measure for routine clinical use. Clinical and Experimental Allergy1994;19(3):210‐6. [PUBMED: 8033378] ">Finlay 1994</a>) (two studies), CDLQI (Children's Dermatology Life Quality Index, <a href="./references#CD003871-bbs2-0135" title="Lewis‐JonesMS , FinlayAY . The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. British Journal of Dermatology1995;132(6):942‐9. [PUBMED: 7662573] ">Lewis‐Jones 1995</a>) (two studies), IDQoL (Infant's Dermatology Quality of Life Index, <a href="./references#CD003871-bbs2-0136" title="Lewis‐JonesMS , FinlayAY , DykesPJ . The Infants' Dermatitis Quality of Life Index. British Journal of Dermatology2001;144(1):104‐10. [PUBMED: 11167690] ">Lewis‐Jones 2001</a>) (one study) and DIELH (German Instrument for the assessment of Quality of Life in Skin Diseases, <a href="./references#CD003871-bbs2-0147" title="SchaferT , StaudtA , RingJ . German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness [Deutsches Instrument zur Erfassung der Lebensqualitat bei Hauterkrankungen (DIELH). Interne Konsistenz, Reliabilitat, konvergente und diskriminante Validitat und Veranderungssensitivitat]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und Verwandte Gebiete2001;52(7):624‐8. [PUBMED: 11475643] ">Schafer 2001</a>) (one study). The DLQI, CDLQI and IDQoL range from 0 to 30 and DIELH ranges from 0 to 180, with higher values on all scores indicating more impaired quality of life. Twenty‐seven studies reported on either severe and/or minor patient‐reported adverse events. A large number of studies looked at microbiological data including resistant organisms (seven studies), isolation rates (19 studies) and colony counts (17 studies) of <i>S. aureus</i>. Twenty studies assessed outcomes based on a published named scale including SCORAD (SCORing Atopic Dermatitis, <a href="./references#CD003871-bbs2-0119" title="European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report. Dermatology1993;186(1):23‐31. [PUBMED: 8435513] ">European Task Force on Atopic Dermatitis 1993</a>) (15 studies), EASI (<a href="./references#CD003871-bbs2-0124" title="HanifinJM , ThurstonM , OmotoM , CherillR , TofteSJ , GraeberM , EASI Evaluator Group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology2001;10(1):11‐8. [PUBMED: 11168575] ">Hanifin 2001</a>) (five studies), SASSAD (Six Area, Six Sign Atopic Dermatitis, <a href="./references#CD003871-bbs2-0148" title="SchmittJ , LanganS , WilliamsHC , European Dermato‐Epidemiology Network. What are the best outcome measurements for atopic eczema?‐ a systematic review. Journal of Allergy and Clinical Immunology2007;120(6):1389‐98. [PUBMED: 17910890] ">Schmitt 2007</a>) (one study) and POEM (<a href="./references#CD003871-bbs2-0113" title="CharmanCR , VennAJ , WilliamsHC . The patient‐oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Archives of Dermatology2004;140(12):1513‐9. [PUBMED: 15611432] ">Charman 2004</a>) (one study). SCORAD ranges from 0 to 103 (0 to 83 for the objective component), EASI from 0 to 72, SASSAD from 0 to 108, and POEM from 0 to 28, with higher values on all scores indicating greater severity. </p> <p>For comparisons of oral antibiotic versus placebo and topical steroid plus topical antibiotic versus topical steroid, we were able to pool studies in groups of up to seven studies for some outcome measures. For the remaining categories, either the studies were not sufficiently similar to pool or the studies did not report the same outcome measures. For the initial pooling we did not take into consideration whether it was infected or non‐infected eczema that was being treated. </p> </section> <section id="CD003871-sec-0079"> <h5 class="title">Trial periods</h5> <p>Treatment durations ranged from 10 minutes to 3 months (mean: 26 days). Three studies had less than one week duration of treatment, seven were of one week, 11 of two weeks, one of three weeks, 10 of four weeks, and nine of greater than four weeks duration. Only the nine studies with greater than four weeks treatment duration were considered a reasonable time to reflect disease chronicity (<a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a>; <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>; <a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a>; <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>; <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>; <a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a>). We considered the remainder to provide short‐term data. Seven studies reported follow‐up data beyond the final day of treatment: <a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a> (3 weeks follow‐up after 6 weeks treatment); <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a> (7 weeks follow‐up after 1 week treatment); <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> (8 weeks follow‐up after 4 weeks treatment); <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a> (4 weeks follow‐up after 8 weeks treatment); <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> (3 months follow‐up after 1 week treatment); <a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> (4 weeks follow‐up after 5 days treatment); and <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a> (6 weeks follow‐up after 2 weeks treatment). Only 15 studies reported the total study duration, ranging from 15 weeks to 27 months (median: 10 months). </p> </section> </section> <section id="CD003871-sec-0080"> <h4 class="title">Excluded studies</h4> <p>We excluded 57 studies and their details can be found in the <a href="./references#CD003871-sec-0330" title="">Characteristics of excluded studies</a> tables. Twenty‐one were not RCTs, and 19 were excluded as they were not studies of atopic eczema or there were no separate results for atopic eczema. Fourteen studies were not of anti‐staphylococcal interventions and 11 were excluded as they only compared anti‐staphylococcal agents against each other or against an inappropriate control. Some studies were excluded for more than one reason. </p> <section id="CD003871-sec-0081"> <h5 class="title">Ongoing studies</h5> <p>One study, to evaluate the efficacy of a combination of topical antibiotic, steroid and moisturiser (supiroban 2% cream and fluocinolone acetonide) compared to steroid alone in children aged two to nine years with severe atopic dermatitis (SCORAD 50 or above), was registered on Clinicaltrials.gov in 2017 (<a href="./references#CD003871-bbs2-0105" title="NCT03052348 . Efficacy of combining topical antibiotic/steroid/moisturizer therapy compared to active comparator in atopic dermatitis. clinicaltrials.gov/ct2/show/NCT03052348 (first received 10 February 2017). ">NCT03052348</a>). The investigators planned to assess change in SCORAD from baseline to weeks 4, 8 and 12, frequency of atopic dermatitis relapse episodes, and change in IDQoL index from baseline to weeks 4, 8, and 12. However, at the last update of Clinicaltrials.gov in September 2017, this had not yet begun recruitment. </p> </section> <section id="CD003871-sec-0082"> <h5 class="title">Studies awaiting classification</h5> <p>Six studies are included in the section of studies awaiting classification. <a href="./references#CD003871-bbs2-0099" title="ACTRN12610000438055 . A randomised, double‐blind, placebo‐controlled phase I study to determine the safety and efficacy of recombinant human ß defensin 2 (rHuB[beta]D2 cream) in the treatment of staphylococcus aureus and other infections in the skin of patients with atopic dermatitis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335452 (first received 6 May 2010). ">ACTRN12610000438055</a> is a parallel group RCT of participants aged 18 to 50 years with mild to moderate atopic dermatitis (SCORAD 20‐50), colonised with <i>S. aureus</i> . The intervention was Recombinant Human ß Defensin 2 cream, which was being compared to placebo cream. The study planned to collect data on safety and tolerability, change in local SCORAD at end of treatment (day 14), change in <i>S. aureus</i> colonisation rate at end of treatment, change in the colonisation rate of any bacteria at end of treatment, and symptomatic relief using a Likert scale. Recruitment was reported to be complete in September 2011. The trials authors were emailed, but there was no response. </p> <p><a href="./references#CD003871-bbs2-0100" title="2006‐004233‐15 . Multicentric, randomized, double‐blinded, vehicle‐controlled, phase III‐bilateral comparative study for treatment of staphylococcus superinfection in atopic dermatitis with hydrophobic Triclosan‐cream 2% (InfectoDermaSept). www.clinicaltrialsregister.eu/ctr‐search/search?query=2006‐004233‐15 (first received 16 April 2009). ">EudraCT 2006‐004233‐15</a> is a within‐patient (left/right) RCT of patients aged 6 months to 50 years with eczema affecting the limbs with an ESCORAD (SCORAD of extremities) between 5 and 12 and staphylococcus superinfection. The participants were randomised to triclosan cream versus placebo. The trial evaluated changes in ESCORAD from baseline to day 14, changes in log staphylococcus count and changes in ESCORAD from baseline to day 7, changes in single‐ESCORAD of erythema, oedema/papulation, oozing/crusting, excoriation, lichenification and clinical and microbiological response rates for day 7 and 14, evaluation of skin parameters, side effects, tolerance, efficacy, and compliance. Recruitment was reported to be complete in May 2009 and, in July 2019, the EU Clinical Trials Register was updated with the addition of a link to the results in German. </p> <p><a href="./references#CD003871-bbs2-0101" title="2008‐005890‐37 . Assessment of the effects on barrier impairment, clinical features and bacterial colonization of topical formulations in patients with atopic eczema; a phase IIa, single‐center, randomized, observer‐blinded study. www.clinicaltrialsregister.eu/ctr‐search/search?query=2008‐005890‐37 (first received 20 October 2008). ">EudraCT 2008‐005890‐37</a> is a within‐patient RCT of patients aged 18 or older with mild to moderate atopic eczema and two comparable lesional areas of 20‐50 cm² and TEWL (transepidermal water loss) of at least 12 g/m²h in lesional areas. The study compared K201 cream [Lactic acid (5%), Propylene glycol (20%), Urea (5%)] and placebo. Outcomes assessed were barrier impairment (TEWL measurements), clinical skin condition (corneometric measurements and clinical assessments) and bacterial colonisation of <i>S. aureus</i> over a four‐week treatment period. Recruitment was reported to be complete in April 2009 and in February 2019 a synopsis of the results was added to the EU Clinical Trials Register. </p> <p><a href="./references#CD003871-bbs2-0102" title="NCT03009734 . Evaluation of ATx201 as a topical antibiotic agent. clinicaltrials.gov/ct2/show/NCT03009734 (first received 20 March 2018). ">NCT03009734</a> is a parallel group RCT of patients aged 18 to 70 years with localised atopic dermatitis with two separate lesions of 10‐200 cm² each of which has an IGA (Investigator Global Assessment) of 1‐3 and an additional localised lesion of the same size and severity range, total localised disease not &gt; 20% BSA (body surface area) and colonisation with <i>S. aureus</i> . The trial was comparing a topical antibiotic, ATx201, with placebo. Outcomes were treatment‐related adverse events, IGA score, treatment success (100‐fold reduction in <i>S. aureus</i> colony count), and local dermal tolerability. Recruitment was reported to be complete in March 2018. </p> <p><a href="./references#CD003871-bbs2-0103" title="NCT03047954 . Broncho‐Vaxom (OM 85 BV) in children suffering from atopic dermatitis. clinicaltrials.gov/ct2/show/NCT03047954 (first received 9 February 2017). ">NCT03047954</a> is a parallel group RCT involving children aged 6 months to 7 years with atopic dermatitis with affected BSA 15‐70% and SCORAD 25‐70. The trial is comparing Broncho‐Vaxom 1 capsule (3.5 mg) per day and placebo. Outcomes were number of atopic dermatitis flares and changes in SCORAD over nine months of treatment, area of eczema involvement and amount of corticosteroids used. Recruitment was reported to be complete in December 2006, although the trial was not registered until February 2017. </p> <p><a href="./references#CD003871-bbs2-0104" title="NCT02840955 . The effect of gladskin on disease severity and the skin microbiome, including Staphylococcus aureus, in patients with atopic dermatitis. clinicaltrials.gov/ct2/show/NCT02840955 (first received 11 July 2016). TottéJ , DeWitJ , PardoL , SchurenF , VanDoornM , PasmansS . Targeted anti‐staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial). Trials2017;18(1):404. [PUBMED: 28859690] ">Totté 2017</a> is a parallel group RCT of adults aged 18 or older with moderate to severe atopic dermatitis (EASI 7.1 to 50). The trial was comparing Staphefekt SA 100 cream (Gladskin) and placebo. The outcomes assessed were corticosteroid use and changes in EASI, POEM, IGA, Pruritus Numerical Rating Scale, Skindex 29, reduction in bacteria and serious adverse events. Recruitment was reported to be complete in February 2018. </p> </section> </section> </section> <section id="CD003871-sec-0083"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall methodological quality of the studies was variable, and was generally better in more recent studies. 'Risk of bias' assessment for each individual study is reported in the <a href="./references#CD003871-sec-0329" title="">Characteristics of included studies</a> and summarised in <a href="#CD003871-fig-0003">Figure 3</a> and <a href="#CD003871-fig-0004">Figure 4</a>. Since no meta‐analyses were performed involving more than four studies, sensitivity analysis based on methodological quality was not performed. </p> <div class="figure" id="CD003871-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003871-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003871-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003871-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003871-sec-0084"> <h4 class="title">Allocation</h4> <p>The method of random sequence generation was frequently not specified (two‐thirds of studies). For the remaining one third of studies (n = 13), random sequence generation was judged to have a low risk of bias. </p> <p>Eleven of the 41 studies were judged to have a low risk of selection bias from allocation concealment. In one study, risk of bias was assessed as high as one of the investigators had an opportunity to influence the sequence of treatments (<a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a>). The other 29 studies were considered as having unclear risk of selection bias from allocation concealment. </p> </section> <section id="CD003871-sec-0085"> <h4 class="title">Blinding</h4> <p>The majority of studies attempted to blind participants and personnel. However, in nine studies, either participants and/or personnel were not blinded and these studies were therefore judged to have a high risk of bias (<a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>; <a href="./references#CD003871-bbs2-0015" title="HizawaT , SanoH , EndoK , FukuzumiT , KataokaY , AokiT . Is povidone‐iodine effective to the lesions of atopic dermatitis. Hifu [Skin Research]1998;40(Suppl 20):134‐9. [CENTRAL: CN‐00499393] ">Hizawa 1998</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>; <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>; <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>; <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a>). One study noted that the creams were different colours and was therefore judged to have a high risk of bias (<a href="./references#CD003871-bbs2-0007" title='FattahAA , ElShiemyS , FarisR . A comparative clinical evaluation of a new topical steroid "Halcinonide" and hydrocortisone in steroid responsive dermatoses. Journal of International Medical Research1976;4(4):228‐31. [CENTRAL: CN‐00697652] '>Fattah 1976</a>). Of five studies evaluating bleach baths versus placebo, only one study (<a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a>) gave an adequate description of how they had attempted to blind participants to the different odours of the bleach and placebo. This study was therefore judged to have a low risk of bias, whereas the other four (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>; <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>; <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a>; <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a>) were judged to have a high risk of bias. In addition to <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a>, sixteen other studies (<a href="./references#CD003871-bbs2-0016" title="HjorthN , SchmidtH , ThomsenK . Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmacotheraputica1985;4(2):126‐31. [CENTRAL: CN‐00259287] ">Hjorth 1985</a>; <a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a>; <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a>; <a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a>; <a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a>; <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a>; <a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a>; <a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a>; <a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a>; <a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>; <a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) were judged to have a low risk of bias. In the remaining 10 studies, the success of blinding was unclear. </p> <p>In over half of studies (n = 23), the blinding of outcome assessment was judged to be unclear as the success of blinding of participants could not be guaranteed and the results included patient‐reported outcomes. The remaining 18 studies were judged to have a low risk of bias. </p> </section> <section id="CD003871-sec-0086"> <h4 class="title">Incomplete outcome data</h4> <p>Seventeen studies were judged to have a low risk of bias for incomplete outcome data as either all participants were accounted for in the analysis or numbers of dropouts were low and reasons were similar between the groups. Twelve studies were judged to have a high risk due to very high rates of attrition overall, disproportionately high numbers between the groups, or different reasons for dropouts between the groups (<a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a>; <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>; <a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a>; <a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a>; <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>; <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>; <a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>). For the remaining 12 studies, the reasons for dropouts or distribution between the groups were unclear. </p> </section> <section id="CD003871-sec-0087"> <h4 class="title">Selective reporting</h4> <p>Trial registrations were only available for six studies (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>; <a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a>; <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>; <a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>; <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a>). Of these, for only one study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) were all outcomes clearly described in the registration and reported in the paper. This study was therefore judged to have a low risk of bias. For one study (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>), the primary outcome was changed between the registration and reporting, and for one study (<a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a>), a "co‐primary outcome" from the registration was reported as a secondary outcome. These two studies were therefore judged to have a high risk of bias. For the other three studies with registrations available, there was insufficient information to make a judgement. </p> <p>Of the remaining studies, some outcomes described in the methods were frequently either not reported at all (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a>; <a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a>; <a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>), not reported at all stated time points (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>), or reported only in terms of statistical significance, precluding pooling (<a href="./references#CD003871-bbs2-0016" title="HjorthN , SchmidtH , ThomsenK . Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmacotheraputica1985;4(2):126‐31. [CENTRAL: CN‐00259287] ">Hjorth 1985</a>; <a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>; <a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a>; <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a>; <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a>; <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a>). All these studies were judged to have a high risk of bias, with the remaining 20 studies judged as unclear. </p> </section> <section id="CD003871-sec-0088"> <h4 class="title">Other potential sources of bias</h4> <p>Unsurprisingly, given the small sample sizes, substantial imbalance in potentially important baseline characteristics was present in a number of studies. Six studies (<a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>; <a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>; <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>; <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a>) reported baseline imbalance in severity of eczema and three studies (<a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) reported baseline imbalance in presence or colonisation density of <i>S. aureus</i>. These were judged to have a high risk of bias. Baseline severity was not reported in 12 studies (<a href="./references#CD003871-bbs2-0007" title='FattahAA , ElShiemyS , FarisR . A comparative clinical evaluation of a new topical steroid "Halcinonide" and hydrocortisone in steroid responsive dermatoses. Journal of International Medical Research1976;4(4):228‐31. [CENTRAL: CN‐00697652] '>Fattah 1976</a>; <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; <a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>; <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>; <a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a>; <a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a>; <a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a>; <a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a>; <a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a>; <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a>; <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a>) and 17 studies did not report presence of <i>S. aureus</i> at baseline (<a href="./references#CD003871-bbs2-0007" title='FattahAA , ElShiemyS , FarisR . A comparative clinical evaluation of a new topical steroid "Halcinonide" and hydrocortisone in steroid responsive dermatoses. Journal of International Medical Research1976;4(4):228‐31. [CENTRAL: CN‐00697652] '>Fattah 1976</a>; <a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>; <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>; <a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>; <a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a>; <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a>; <a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a>; <a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a>; <a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a>; <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>; <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a>; <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a>). These were judged to have an unclear risk of bias (unless other potential sources of bias were identified, as described below). The remaining studies, which were well‐balanced on both severity and presence of <i>S. aureus</i>, were judged to have a low risk of bias (unless other potential sources of bias were identified, as described below). </p> <p><a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a> performed subgroup analysis at the end of the study which was not part of the predetermined outcomes. <a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a> and <a href="./references#CD003871-bbs2-0015" title="HizawaT , SanoH , EndoK , FukuzumiT , KataokaY , AokiT . Is povidone‐iodine effective to the lesions of atopic dermatitis. Hifu [Skin Research]1998;40(Suppl 20):134‐9. [CENTRAL: CN‐00499393] ">Hizawa 1998</a> report statistical comparisons only as significant differences from baseline and not between groups. <a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> changed inclusion criteria after recruitment to exclude participants aged &lt; 18 years. <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> and <a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a> did not include a washout period between treatments in cross‐over trials. In addition, <a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a> used an unusual (inverse sine) data transformation and it was not clear if this was preplanned. All these studies were therefore graded as having a high risk of bias. </p> <p>We were unable to assess for publication bias as there were not enough studies to perform a funnel plot. There were two duplicate publications. In both cases, identical results were published in both English and German (<a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> and <a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a>). </p> </section> </section> <section id="CD003871-sec-0089"> <h3 class="title" id="CD003871-sec-0089">Effects of interventions</h3> <p>See: <a href="./full#CD003871-tbl-0001"><b>Summary of findings for the main comparison</b> Topical steroid plus topical antibiotic compared with topical steroid for eczema</a>; <a href="./full#CD003871-tbl-0002"><b>Summary of findings 2</b> Oral antibiotic compared with placebo for eczema</a>; <a href="./full#CD003871-tbl-0003"><b>Summary of findings 3</b> Bleach bath compared with placebo or bath emollient for eczema</a> </p> <p>Please see table of <a href="./references#CD003871-sec-0329" title="">Characteristics of included studies</a>. </p> <p>Subgroup analysis was not performed due to the limited number of studies available to pool in a meta‐analysis. </p> <section id="CD003871-sec-0090"> <h4 class="title">1. Oral antibiotic ‐ four studies</h4> <p>We included four studies comparing oral antibiotics against placebo; results for this comparison are reported in <a href="./full#CD003871-tbl-0002">summary of findings Table 2</a>. <a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a> was a cross‐over study evaluating cefuroxime axetil among 20 patients (children and adults) with moderate to severe eczema with <i>S. aureus</i> isolated from the skin, but excluding overt clinical infection. The duration of the condition was not stated. In this study, participants were randomised to either receiving cefuroxime axetil orally (dose not stated) twice daily or placebo orally twice daily for two weeks, each with one week washout in between. A moderate potency topical steroid was used in all participants. </p> <p><a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> was a parallel group RCT evaluating flucloxacillin in 50 children (46 evaluable) with uninfected eczema. The severity and duration of the condition were not stated. In this study, participants were randomised to receive either flucloxacillin 250 mg four times daily (n = 25) or placebo (n = 25) for four weeks (dose halved for &lt; 10 yrs old). Topical steroids were used as needed. </p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> was a three‐arm parallel group RCT evaluating flucloxacillin and 2% fusidic acid in 113 children (101 evaluable) with clinically infected eczema (70 evaluable children in flucloxacillin and placebo groups included in this category). The severity and duration of the condition was not stated. This study used the following regimens: oral antibiotic (flucloxacillin four times per day for 7 days, 125 mg in 2.5 mL for children aged three months to two years, 250 mg in 5 mL for children aged &gt; two years to &lt; eight years) and topical placebo (n = 36) versus topical antibiotic (2% fusidic acid cream three times per day for seven days) and oral placebo (n = 37) versus oral and topical placebo (n = 40). All treatment groups received topical steroids (clobetasone butyrate 0.05% cream or ointment for use on trunk/limbs and/or hydrocortisone 1% cream or ointment for use on face, applied once daily for 14 days) and were encouraged to use emollients that did not contain antimicrobial agents. </p> <p><a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a> was a parallel group RCT evaluating cefadroxil in 33 children (30 evaluable) with eczema with <i>S. aureus</i> isolated from the skin, with 28 of the 30 participants having clinical infection. The severity of the condition was not stated. Patients in the intervention group had eczema for a mean duration of 3.2 years and in the placebo group 2.6 years. Participants were randomised to receive either cefadroxil 50 mg/kg/day in two equal doses (n = 16) or placebo (n = 17) for two weeks. No information was provided on topical steroid use. </p> <section id="CD003871-sec-0091"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0092"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0093"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by participant or medical practitioner</b></p> <p>Two studies (<a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>) reported global degree of improvement in signs and symptoms as rated by the medical practitioner. <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> found a significantly lower rate of good or excellent outcomes in the flucloxacillin group compared to placebo, whereas <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a> found a non‐significant improvement in the cefadroxil group compared to placebo. Pooling these studies gave an estimate of a non‐significantly lower rate of good or excellent outcomes with oral antibiotic compared to placebo, with substantial imprecision and statistical heterogeneity (RR 0.80; 95% CI 0.18 to 3.50, I² = 92%) (<a href="./references#CD003871-fig-0005" title="">Analysis 1.1</a>). Differences between the studies that may have contributed to the heterogeneity included the use of different antibiotics, although both have activity against <i>S. aureus</i>, and also one study recruited only patients with uninfected eczema whereas, in the other study, most patients had clinical infection. </p> <p>One study (<a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a>) reported no change in clinical severity, but provided no data. <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> did not report any data for this outcome. </p> </section> <section id="CD003871-sec-0094"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>One study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>), comparing flucloxacillin to placebo, reported changes in quality of life using the IDQoL questionnaire for children aged three months to &lt; four years and the CDLQI questionnaire for children aged four years to &lt; eight years. At two weeks, there was no significant difference between the groups in the change from baseline on either IDQoL (MD 0.11; 95% CI ‐0.10 to 0.32) (<a href="./references#CD003871-fig-0006" title="">Analysis 1.2</a>) or CDLQI (MD 0.43; 95% CI ‐0.16, 1.02) (<a href="./references#CD003871-fig-0007" title="">Analysis 1.3</a>). The other three studies did not report any data for this outcome. </p> </section> </section> <section id="CD003871-sec-0095"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0096"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>One study (<a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a>) reported no adverse events. <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> reported one withdrawal in the oral antibiotic group (loose stools) and one withdrawal in the placebo group (Henoch‐Schönlein purpura). <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported one withdrawal in each group due to the eczema worsening. <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a> reported one withdrawal in the oral antibiotic group due to an adverse event, but the nature of the event was not specified. Pooled analysis of these studies showed no clear differences for adverse events requiring withdrawal (RR 1.43; 95% CI 0.28 to 7.36, I² = 0%) (<a href="./references#CD003871-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD003871-sec-0097"> <p><b>(b) Minor patient‐reported adverse events. These included mild skin irritation not sufficient to require cessation of treatment</b></p> <p>One study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) reported minor patient‐reported adverse events. There were no clear differences between the groups in any of the adverse events reported (nausea 2/33 versus 3/35, vomiting 4/33 versus 6/35, diarrhoea 5/33 versus 5/35, stomach pain 3/33 versus 2/35, joint pains 1/33 versus 0/35, new rash 4/33 versus 8/35). </p> </section> <section id="CD003871-sec-0098"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>See long‐term results.</p> </section> </section> <section id="CD003871-sec-0099"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0100"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p>One study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) reported changes in both the POEM and EASI scores. At two weeks, there was no clear difference between the groups in the change from baseline on either POEM (MD 1.52; 95% CI ‐1.35 to 4.40) (<a href="./references#CD003871-fig-0009" title="">Analysis 1.5</a>) or EASI (MD 0.20; 95% CI ‐0.12 to 0.52) (<a href="./references#CD003871-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD003871-sec-0101"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>Two studies (<a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>; <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>) found no significant difference in erythema in the control groups compared to oral antibiotic (MD in erythema scores: 0.40; 95% CI ‐0.03 to 0.83) (<a href="./references#CD003871-fig-0011" title="">Analysis 1.7</a>), (number of people with erythema: RR 0.93; 95% CI 0.38 to 2.28) (<a href="./references#CD003871-fig-0012" title="">Analysis 1.8</a>). The two studies could not be pooled because one used a continuous and the other a dichotomous measure (score). One study (<a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>) found significantly fewer clinically apparent infections in the treatment group at the end of the study compared to control (RR 0.06; 95% CI 0.00 to 0.94) (<a href="./references#CD003871-fig-0013" title="">Analysis 1.9</a>). </p> </section> <section id="CD003871-sec-0102"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0103"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>Two studies (<a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) found no significant differences in isolation rates of <i>S. aureus</i> for flucloxacillin compared with placebo; one study (<a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>) found a significantly lower rate of <i>S. aureus</i> among participants treated with cefadroxil compared with placebo. The pooled result of all three studies was not significant (RR 0.76; 95% CI 0.46 to 1.26, I² = 66%) (<a href="./references#CD003871-fig-0014" title="">Analysis 1.10</a>). A potential source of the heterogeneity in this result was a baseline imbalance in the rate of <i>S. aureus</i> colonisation in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> resulting in a higher isolation rate of <i>S. aureus</i> in the antibiotic group at the end of the study despite a greater reduction from baseline. <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported a change from baseline at two weeks (end of treatment) of ‐30.4% (95% CI ‐51.6% to ‐9.2%) in the flucloxacillin group compared with ‐15.9% (‐39.1% to 7.4%) in the placebo group; the difference between the groups was not statistically significant (mean difference ‐14.5%; 95% CI ‐46.0% to 17.0%) (<a href="./references#CD003871-fig-0015" title="">Analysis 1.11</a>). In <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>, the isolation rates of <i>S. aureus</i> from affected skin reduced from 24/24 participants to 15/22 in the flucloxacillin group and from 24/25 to 22/24 in the placebo group, but a change from baseline analysis was not undertaken. </p> </section> <section id="CD003871-sec-0104"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>One study (<a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>) found a non‐significant difference in the log <i>S. aureus</i> counts/cm² in the flucloxacillin group compared to placebo (MD ‐1.40; 95% CI ‐3.09 to 0.29) (<a href="./references#CD003871-fig-0016" title="">Analysis 1.12</a>). They reported that the difference between groups in change from baseline among the 18 participants in each group with both baseline and follow‐up measurements recorded was statistically significant (P = 0.008), although further details of this analysis were not reported. Another study (<a href="./references#CD003871-bbs2-0002" title="BoguniewiczM , SampsonH , LeungSB , HarbeckR , LeungDYM . Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. Journal of Allergy and Clinical Immunology2001;108(4):651‐2. [CENTRAL: CN‐00374302] ">Boguniewicz 2001</a>) suggested that addition of an antibiotic resulted in a reduction in colony counts, however, when the antibiotic was discontinued, the skin was quickly recolonised. </p> </section> </section> </section> <section id="CD003871-sec-0105"> <h5 class="title">Long‐term:</h5> <section id="CD003871-sec-0106"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0107"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>There were no results given for this outcome in any of the four studies.</p> </section> <section id="CD003871-sec-0108"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>One study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) continued to follow up participants to three months. There was no significant difference between the groups in the change from baseline on either IDQoL (MD ‐0.21; 95% CI ‐0.44 to 0.02) (<a href="./references#CD003871-fig-0017" title="">Analysis 1.13</a>) or CDLQI (MD ‐0.14; 95% CI ‐0.97 to 0.69) (<a href="./references#CD003871-fig-0018" title="">Analysis 1.14</a>). The other three studies did not report any data for this outcome. </p> </section> </section> <section id="CD003871-sec-0109"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0110"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0111"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0112"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p><a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> reported that the number of methicillin‐resistant strains (MRSA) increased in the treatment group up until 14 days after treatment, but did not give numerical results. Any increase in the number of MRSA had returned to almost baseline at day 56. Another study <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported resistance of <i>S. aureus</i> to flucloxacillin, erythromycin and fusidic acid at baseline, week two (end of treatment) and three months. Erythromycin was included for participants who were allergic to penicillin, however, no participants received erythromycin. Fusidic acid was included as this was the other active treatment in this three‐arm trial. Among participants treated with flucloxacillin with <i>S. aureus</i> identified from skin swabs, 1/30, 0/18 and 1/8 strains were resistant to flucloxacillin at baseline, two weeks and three months, respectively. No strains were resistant to flucloxacillin in the placebo group (of 24, 16 and 10 positive skin swabs at each time point). No flucloxacillin‐resistant strains were identified from the nose or mouth. <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a> reported on resistance to cephadroxil. Of 33 participants, 16 were randomised to receive cephadroxil, but three were withdrawn, in one case due to the presence of a resistant organism at baseline. At the end of the study, none of the participants in either the intervention or placebo group were found to have a resistant organism. </p> </section> </section> <section id="CD003871-sec-0113"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0114"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported longer term changes in the POEM score. At three months, there was no significant difference between the groups in the change from baseline (MD ‐0.21; 95% CI ‐3.12, 2.70) (<a href="./references#CD003871-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD003871-sec-0115"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p><a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> reported no significant difference in erythema at 56 days post‐treatment with oral flucloxacillin compared to placebo (MD ‐0.10; 95% CI ‐0.59, 0.39) (<a href="./references#CD003871-fig-0021" title="">Analysis 1.17</a>). </p> </section> <section id="CD003871-sec-0116"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0117"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported a change from baseline in the percentage of participants with <i>S. aureus</i> on the skin at three months of ‐52.6% (95% CI ‐74.1% to ‐31.0%) in the flucloxacillin group compared with ‐20.0% (‐45.4% to 5.4%) in the placebo group; the difference between the groups was not statistically significant (mean difference ‐32.6%; 95% CI ‐65.9% to 0.7%) (<a href="./references#CD003871-fig-0020" title="">Analysis 1.16</a>). </p> </section> <section id="CD003871-sec-0118"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>In one study (<a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>), bacterial counts returned to almost pretreatment levels by 14 days after completion of treatment. </p> </section> </section> </section> </section> <section id="CD003871-sec-0119"> <h4 class="title">2. Topical antiseptic/antibiotic ‐ five studies</h4> <p>Five studies compared topical antiseptics/antibiotics versus placebo. Of these, one study (<a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a>) evaluated a topical antibiotic. This was a cross‐over study evaluating 1% erythromycin in Vaseline in 38 children (19 evaluable) with uninfected eczema. The severity and duration were not stated. In this study, there was no use of topical or systemic medications during the first week with the intervention beginning from day eight onwards. The intervention was 1% erythromycin (Sigma‐Aldrich S.r.l., Milano) in white Vaseline on the whole skin surface twice daily from day 8 to day 21 and Vaseline from day 22 to 35 versus Vaseline from day 8 to 21 on the whole skin surface twice daily and erythromycin from day 22 to 35. Participants did not use topical steroids in this study. </p> <p>The remaining four studies compared various topical products with antiseptic/antibacterial properties, and no attempt was made to pool them. <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a> was a parallel group RCT evaluating hypochlorous acid compared with no treatment in 30 patients with eczema and itch (infective status not specified). Participants were included if they scored more than 2 on an itch severity scale. The duration of the condition was not stated. In this study, participants were randomised to the application of hypochlorous acid‐containing solution twice daily or, as required, for 72 hours versus no treatment. No information was provided on topical steroid use. </p> <p><a href="./references#CD003871-bbs2-0015" title="HizawaT , SanoH , EndoK , FukuzumiT , KataokaY , AokiT . Is povidone‐iodine effective to the lesions of atopic dermatitis. Hifu [Skin Research]1998;40(Suppl 20):134‐9. [CENTRAL: CN‐00499393] ">Hizawa 1998</a> was a right‐and‐left comparison evaluating povidone iodine 10% in 15 children and adults with mild to moderate eczema (without purulent skin infection). The duration of the condition was not stated. Povidone iodine 10% versus an unspecified placebo was applied twice daily for one week. No information was provided on topical steroid use. </p> <p><a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a> was a right‐and‐left comparison evaluating 0.2% farnesol + 5% xylitol in 17 patients with mild to moderate eczema (infective status not specified). The duration of the condition was not stated. In this study, participants were randomised to receive either FX cream (0.2% farnesol + 5% xylitol) or a placebo cream (identical in appearance) for seven days. The frequency of application was not stated. No information was provided on topical steroid use. </p> <p><a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a> was a right‐and‐left comparison evaluating hyperforin 1.5% cream in 21 children and adults (18 evaluable) with 'subacute' eczema (infective status not specified) with a SCORAD of &lt; 80. The duration of the condition was not stated. In this study, participants were randomised to receive either hyperforin 1.5% cream or a placebo (identical vehicle with added chromogenic substances to colour the vehicle for the purpose of blinding). These were applied twice daily for four weeks. No participants used concomitant topical steroids. </p> <section id="CD003871-sec-0120"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0121"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0122"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>None of the studies evaluating a topical antibiotic reported global degree of improvement. <a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a> reported that both participant global assessment (PGA) and IGA improved between baseline and 72 hours, in favour of the hypochlorous acid‐treated group; however, results were only reported as P values (PGA 0.128, IGA 0.012). <a href="./references#CD003871-bbs2-0015" title="HizawaT , SanoH , EndoK , FukuzumiT , KataokaY , AokiT . Is povidone‐iodine effective to the lesions of atopic dermatitis. Hifu [Skin Research]1998;40(Suppl 20):134‐9. [CENTRAL: CN‐00499393] ">Hizawa 1998</a> reported that there was a statistically significant improvement in the povidone iodine group for appearance of skin lesions; however, no numbers were given and no between‐group analysis was done. </p> </section> <section id="CD003871-sec-0123"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome in any of the included studies.</p> </section> </section> <section id="CD003871-sec-0124"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0125"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p><a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a> reported that none of the participants had any adverse reaction to the 1% erythromycin in Vaseline or placebo. </p> <p><a href="./references#CD003871-bbs2-0001" title="BermanB , NestorM . An investigator blinded randomized study evaluating hypochlorous acid (HOCl) in the treatment of atopic dermatitis‐associated pruritus. Journal of Clinical and Aesthetic Dermatology2018;11(5 Supplement 1):S13. ">Berman 2018</a> reported no treatment‐related discontinuations or severe adverse events in either the hypochlorous acid or no treatment‐group. <a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a> reported that three participants in the left‐and‐right comparison of hyperforin 1.5% cream withdrew from treatment due to acute episodes of atopic dermatitis; whether this was present on the actively‐treated or placebo‐treated side of the body was not specified. </p> </section> <section id="CD003871-sec-0126"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p><a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a> reported that one participant developed contact eczema in the placebo group. </p> </section> <section id="CD003871-sec-0127"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results give for this outcome.</p> </section> </section> <section id="CD003871-sec-0128"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0129"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p>For the first period of the cross‐over study, <a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a> reported a reduction in mean SCORAD from 47.6 (SD 12.0) to 43.2 (11.3) for the 1% erythromycin group compared with a reduction from 45.4 (11.4) to 43.9 (10.6) for the placebo group; this difference was reported to be statistically significant. </p> <p><a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a> reported a significant difference in the median reduction in modified SCORAD on the Hyperforin 1.5%‐treated side of 6.5 compared to 2.5 on the placebo‐treated side. </p> </section> <section id="CD003871-sec-0130"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p><a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a> stated that scores of dryness and scaling were significantly improved in both the 0.2% farnesol + 5% xylitol cream and placebo groups, but no data were provided. </p> </section> <section id="CD003871-sec-0131"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0132"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0034" title="SchemppCM , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison [Behandlung der subakuten atopischen Dermatitis mit Johanniskraut‐Creme. Eine randomisierte, placebokontrollierte Doppelblindstudie im Halbsetendesign]. Hautarzt2003;54(3):248‐53. [CENTRAL: CN‐00509733] SchemppCM , WindeckT , HezelS , SimonJC . Topical treatment of atopic dermatitis with St John's wort cream ‐ a randomized, placebo controlled, double blind half‐side comparison. Phytomedicine2003;10(Suppl IV):31‐7. [CENTRAL: CN‐00438398] ">Schempp 2003</a> reported a reduction in colonisation with <i>S. aureus</i> from 17/18 to 16/18 on the Hyperforin 1.5%‐treated side compared with no change (17/18 to 17/18) on the placebo‐treated side. </p> </section> <section id="CD003871-sec-0133"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p><a href="./references#CD003871-bbs2-0015" title="HizawaT , SanoH , EndoK , FukuzumiT , KataokaY , AokiT . Is povidone‐iodine effective to the lesions of atopic dermatitis. Hifu [Skin Research]1998;40(Suppl 20):134‐9. [CENTRAL: CN‐00499393] ">Hizawa 1998</a> reported that there was a statistically significant improvement in <i>S. aureus</i> colony counts in the povidone iodine group; however, no numbers were given and no between‐group analysis was done. <a href="./references#CD003871-bbs2-0029" title="MasakoK , YusukeK , HideyukiI , AtsukoM , YoshikiM , KayokoM , et al. A novel method to control the balance of skin microflora. Part 2. A study to assess the effect of a cream containing farnesol and xylitol on atopic dry skin. Journal of Dermatological Science2005;38(3):207‐13. [CENTRAL: CN‐00740969] ">Masako 2005b</a> reported that, at end of treatment, there was a significant difference in the number of <i>S. aureus</i> in favour of 0.2% farnesol + 5% xylitol cream compared with placebo. </p> </section> </section> </section> <section id="CD003871-sec-0134"> <h5 class="title">Long‐term:</h5> <p>There were no long‐term data presented relevant to our outcomes.</p> </section> </section> <section id="CD003871-sec-0135"> <h4 class="title">3. Topical steroid plus antiseptic/antibiotic ‐ 14 studies</h4> <p>There were 14 studies, with a total of 895 evaluable participants in the relevant arms, comparing topical steroids plus antiseptics/antibiotics versus topical steroids alone. Twelve of these studies compared a topical steroid plus topical antibiotic against topical steroid alone, and results for this comparison are summarised in <a href="./full#CD003871-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p><a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a> was a parallel group RCT evaluating hydrocortisone plus mupirocin compared with hydrocortisone alone in 53 infants with mild to moderate eczema (infective status not specified). The duration of the condition was not stated. In this study, participants were randomised to hydrocortisone plus mupirocin (n = 27) or hydrocortisone (n = 26) applied twice daily (hydrocortisone in the morning and evening and mupirocin at noon and night) by parents to areas affected with atopic dermatitis at least two hours before bathing for up to seven days. </p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> was a three‐arm parallel group RCT evaluating flucloxacillin and 2% fusidic acid in 113 children (101 evaluable) with clinically infected eczema, in which all children received clobetasone butyrate 0.05% cream or ointment for use on trunk/limbs and/or hydrocortisone 1% cream for use on face (67 evaluable children in fusidic acid and placebo groups included in this category). The duration and severity were not stated. This study used the following regimens: oral antibiotic (flucloxacillin four times per day for seven days, 125 mg in 2.5 mL for children aged three months to two years, 250 mg in 5 mL for children aged &gt; two years to &lt; eight years) and topical placebo (n = 36) versus topical antibiotic (2% fusidic acid cream three times per day for seven days) and oral placebo (n = 37) versus oral and topical placebo (n = 40). All treatment groups received topical steroids (clobetasone butyrate 0.05% cream or ointment for use on trunk/limbs and/or hydrocortisone 1% cream or ointment for use on face, applied once daily for 14 days) and were encouraged to use emollients that did not contain antimicrobial agents. </p> <p><a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a> was a parallel group RCT evaluating hydrocortisone butyrate plus mupirocin compared with hydrocortisone butyrate plus vehicle ointment in 327 participants (children and adults), of whom 119 had atopic eczema and are included in the review (infective status not specified). The severity and duration of the condition were not stated. In this study, participants were randomised to hydrocortisone butyrate ointment and mupirocin ointment (n = 58) or hydrocortisone butyrate ointment and vehicle ointment (n = 61) applied once daily (with two to three hours between products) for 28 days. </p> <p><a href="./references#CD003871-bbs2-0016" title="HjorthN , SchmidtH , ThomsenK . Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmacotheraputica1985;4(2):126‐31. [CENTRAL: CN‐00259287] ">Hjorth 1985</a> was a right‐and‐left comparison evaluating 0.1% betamethasone 17‐valerate plus 2% microcrystalline fusidic acid compared with 0.1% betamethasone 17‐valerate alone in 81 patients (children and adults), of whom 60 had atopic eczema and were included in the review (infective status not specified). The severity and duration of the condition were not stated. Treatments were applied twice daily for seven days. </p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> was a 2 x 2 factorial RCT comparing fluticasone versus tacrolimus with or without fusidic acid in 60 children and adults (54 evaluable) with moderate to severe uninfected eczema. The duration of the condition was not stated. In this study, the following treatments were compared: 0.05% fluticasone propionate cream (Cutivate) (n = 15) versus 0.05% fluticasone propionate cream with 2% fusidic acid cream (Fucidin) (n = 15) versus 0.03% tacrolimus ointment (Protopic) (n = 15) versus 0.03% tacrolimus ointment with 2% fusidic acid cream (n = 15) applied twice daily for eight weeks. Fusidic acid cream was applied first followed by fluticasone or tacrolimus 20 minutes later without occlusive dressings. Oral antihistamine was given to all participants. Twenty‐eight evaluable participants in the fluticasone plus fusidic acid versus fluticasone alone comparison were included in this category. </p> <p><a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> was a cross‐over study evaluating 0.05% clobetasol butyrate ointment plus either 2% mupirocin or placebo in 49 children and adults (45 evaluable) with eczema (infective status not specified). The duration and severity of the condition were not stated. In this study, 2% mupirocin ointment followed by placebo (polyethylene glycol ointment) or vice versa were applied once daily for two weeks. All participants received 0.05% clobetasol butyrate ointment twice daily during the two‐week pre‐trial period and once daily while using mupirocin/placebo. </p> <p><a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a> was a parallel group RCT evaluating fluocinolone acetonide plus 0.5% neomycin sulphate compared with fluocinolone acetonide cream in 36 patients (mainly children) with 'rather severe' eczema (infective status not specified). The duration of the condition was not stated. In this study, participants were randomised to fluocinolone acetonide plus 0.5% neomycin sulphate (Neo‐Synalar) cream (n = 15) versus fluocinolone acetonide (Synalar) cream (n = 21) applied twice daily for one week. </p> <p><a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a> was a parallel group RCT evaluating the betamethasone plus neomycin cream compared with clobetasol in 30 children and adults (28 evaluable) with moderate to severe uninfected eczema. The duration of the condition was not stated. In this study, participants were randomised to betamethasone plus neomycin cream applied to all affected areas except the face twice daily for one week then once daily for one week (n = 15 evaluable) or clobetasol cream applied twice daily on days 1, 2, 3, 4, 8, 9, 12 and 14 (n = 13 evaluable). </p> <p><a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a> was a four‐arm, four‐period cross‐over study evaluating 0.5% prednisolone plus 0.5% neomycin versus 0.5% prednisolone versus 1% hydrocortisone versus petrolatum base in 24 patients (14 evaluable) with uninfected eczema (the 0.5% prednisolone plus 0.5% neomycin versus 0.5% prednisolone being eligible for the review). The severity of the condition was not stated. Duration was described as “longstanding.” Treatments were applied for one week, or until the ointment was used up. The frequency of application was not stated. </p> <p><a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a> was a parallel group RCT in 186 patients (174 evaluable) with mild to moderate eczema (infective status not specified). The duration of the condition was not stated. In the trial, participants were randomised to fusidic acid 2% plus 1% hydrocortisone cream (n = 91 evaluable) or 1% hydrocortisone cream (n = 83 evaluable) for two weeks. The frequency of application was not stated. </p> <p><a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a> was a parallel group RCT in 44 adults with moderate to severe uninfected eczema (SCORAD 25 or more). The duration of the condition was not stated. The study evaluated 0.1% triamcinolone acetonide in oculentum simplex FNA (an ointment base containing cetostearylalcohol, lanolin, vaseline and paraffin) plus 3% tetracycline (n = 22) compared with 0.1% triamcinolone acetonide in oculentum simplex FNA alone (n = 22). The treatments were applied all over the body twice daily for two weeks. </p> <p><a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a> was a parallel group RCT in 83 patients (79 evaluable) with moderate to severe clinically infected eczema. The duration of the condition was not stated. The trial randomised participants to betamethasone valerate (Betnovate) plus gentamicin cream (n = 25 evaluable) versus betamethasone valerate cream (n = 27 evaluable) versus gentamicin cream (n = 27 evaluable). Treatments were applied three times daily for 22 days. Only the 52 evaluable participants in the betamethasone valerate plus gentamicin versus betamethasone valerate cream comparison were eligible for the review. </p> <p>The remaining two studies evaluated antiseptics.</p> <p><a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a>, was a parallel group RCT. The severity and duration of the condition were not stated. The study evaluated prednicarbate 0.25% cream plus the antiseptic didecyldimethylammonium chloride 0.25% compared with prednicarbate 0.25% cream, in 143 adults (117 evaluable) with eczema with heavy <i>S. aureus</i> colonisation. The prednicarbate 0.25% cream plus didecyldimethylammonium chloride 0.25% or prednicarbate 0.25% cream were applied twice daily for five days. </p> <p><a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a> was a parallel group RCT evaluating 0.0025% betamethasone valerate cream plus either 1% triclosan or vehicle alone in 60 patients (children and adults) with mild to moderate eczema (infective status not specified). The median duration of the condition of patients in the intervention group was 12 years and in the control group, 9 years. Participants were randomised to an emollient containing 1% triclosan (n = 30) or the vehicle alone (n = 30) applied twice daily to the whole body for 27 days. Following a washout period of one week, all participants were provided with 0.0025% betamethasone valerate cream for the first 27 days and asked to apply a thin layer of the corticosteroid cream over the eczematous areas for the first 27 days followed by either study cream or vehicle on the whole body. Following this, participants who still had persistent eczema were allowed to continue use of the steroid, if necessary. Participants were provided with emulsifying ointment as cleansers and instructed not to use any systemics or topical antibiotics, antibacterial soap or antibacterial shampoo. </p> <p>The different studies used a number of different corticosteroid potencies and the majority added an antibiotic to a corticosteroid and compared it to the same corticosteroid. However, <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a> evaluated a potent steroid (betamethasone) combined with an antibiotic and compared it against a super‐potent steroid (clobetasol). Only two studies (<a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a>; <a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a>) evaluated an antiseptic; we did not pool these with studies of antibiotics. Two studies (<a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a>; <a href="./references#CD003871-bbs2-0016" title="HjorthN , SchmidtH , ThomsenK . Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmacotheraputica1985;4(2):126‐31. [CENTRAL: CN‐00259287] ">Hjorth 1985</a>) gave no data for the outcomes of interest. </p> <section id="CD003871-sec-0136"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0137"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0138"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>Five studies of antibiotic/steroid combination compared to steroid alone (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>) reported global degree of improvement, but results from only three studies could be pooled. The other seven studies did not report global degree of improvement. Three studies (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>) reported non‐significantly greater improvements in global outcomes at the end of treatment for steroid plus antibiotic versus steroid alone. When these three studies were pooled (one in clinically infected eczema and two unspecified), the combination treatment showed a borderline improvement compared to steroid alone (RR 1.10; 95% CI 1.00 to 1.21, I² = 0%) (<a href="./references#CD003871-fig-0022" title="">Analysis 2.1</a>). <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a> reported a good or excellent response among 90% of those in the combination group compared with 70% in the steroid‐only group, but denominators were not reported and correspondence with the author confirmed that these figures were likely to have been rounded to the nearest 10%, making it impossible to extract the raw values for pooling. <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a> found a significant improvement in global outcome in favour of steroid only using a subjective interval scale self‐evaluation (MD 1.20; 95% CI 0.25 to 2.15) (<a href="./references#CD003871-fig-0023" title="">Analysis 2.2</a>). </p> <p><a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> reported a non‐significantly greater improvement in global outcomes at the end of treatment for steroid plus antiseptic versus steroid alone; no numerical results were reported. <a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a> did not report global degree of improvement. </p> </section> <section id="CD003871-sec-0139"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported changes in quality of life using the IDQoL questionnaire for children aged three months to &lt; four years and the CDLQI questionnaire for children aged four years to &lt; eight years. At two weeks, there was no significant difference between the groups in the change from baseline on IDQoL (MD 0.18; 95% CI ‐0.04 to 0.40) (<a href="./references#CD003871-fig-0024" title="">Analysis 2.3</a>) but significantly less improvement of symptoms in the combined treatment group for CDLQI (MD 0.70; 95% CI 0.12 to 1.28) (<a href="./references#CD003871-fig-0025" title="">Analysis 2.4</a>). None of the other studies reported any data for this outcome. </p> </section> </section> <section id="CD003871-sec-0140"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0141"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported five withdrawals in the fusidic acid group (four condition worsened, one intolerant to medication) and one in the placebo group (condition worsened). There were no adverse events requiring withdrawal of treatment in either of the two eligible treatment combinations in <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>. <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a> reported one adverse event requiring withdrawal from treatment in the steroid plus antibiotic group ("flare of dermatitis" ‐ no further information provided) and three in the steroid‐alone group (two "flare of dermatitis", one burning and soreness). <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a> reported one adverse event requiring withdrawal from treatment in each group (both folliculitis). Pooled results from these studies showed no clear difference between groups (RR 1.24; 95% CI 0.21 to 7.25, I² = 42%) (<a href="./references#CD003871-fig-0026" title="">Analysis 2.5</a>). In addition, <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> reported that one participant in the cross‐over trial reacted adversely to both 2% mupirocin and placebo and stopped treatment. </p> <p><a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a> reported no withdrawals due to adverse events in either the 1% triclosan or placebo group. </p> </section> <section id="CD003871-sec-0142"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p><a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a> reported two adverse events not requiring cessation of treatment in the steroid plus antibiotic group (one itching, one flare of dermatitis) and three in the steroid‐alone group (one stinging and irritation, one folliculitis, one flare of dermatitis). <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a> reported three minor adverse events in the steroid plus antibiotic group and 13 in the steroid alone group (all folliculitis). Pooled results from these two studies showed significantly fewer minor adverse events not requiring withdrawal from treatment in the combination treatment group compared to the steroid‐alone control, (RR 0.30; 95% CI 0.12 to 0.78, I² = 0%) (<a href="./references#CD003871-fig-0027" title="">Analysis 2.6</a>). In addition, <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported individual minor patient‐reported adverse events; there were no significant differences between the groups in any of the adverse events reported (nausea 1/29 versus 3/35, vomiting 2/29 versus 6/35, diarrhoea 5/29 versus 5/35, stomach pain 3/29 versus 2/35, joint pains 2/29 versus 0/35, new rash 5/29 versus 8/35). This study could not have been included in the pooled result as some participants experienced multiple different events. <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> reported that, in addition to the one participant that withdrew, one other participant reported stinging and an exacerbation of symptoms with both 2% mupirocin and placebo. </p> <p><a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a> reported a total of 27 adverse events among 15 participants (not split by group), of which four (three stinging pain after application in the 1% triclosan group, one pruritus after application in the placebo group) were considered treatment‐related. </p> </section> <section id="CD003871-sec-0143"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>See long‐term outcomes.</p> </section> </section> <section id="CD003871-sec-0144"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0145"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported changes in both the POEM and EASI scores. At two weeks, there was no significant difference between the groups in the change from baseline on POEM (MD 1.49; 95% CI ‐1.55 to 4.53) (<a href="./references#CD003871-fig-0029" title="">Analysis 2.8</a>). The reduction in EASI in the fusidic acid group was slightly less than that in the placebo group (MD 0.42; 95% CI 0.09 to 0.75) (<a href="./references#CD003871-fig-0028" title="">Analysis 2.7</a>). <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a> reported that both hydrocortisone and mupirocin and hydrocortisone alone showed significant within‐group improvement in EASI scores, however, at the end of treatment there was no significant difference. <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported a reduction in mean SCORAD from 50.1 (SD 12.8) to 24.7 (16.5) in the fluticasone plus fusidic acid group compared with 54.8 (16.5) to 25.4 (15.9) with fluticasone alone (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>). <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a> reported no significant difference in objective SCORAD at the end of treatment between 3% tetracycline plus 0.1% triamcinolone and 0.1% triamcinolone. Pooling results of these four studies for the mean composite rating (using EASI , SCORAD or objective SCORAD) at the end of treatment using the standardised mean difference showed no difference between the groups (SMD ‐0.00; 95% CI ‐0.33 to 0.33, I² = 38%) (<a href="./references#CD003871-fig-0030" title="">Analysis 2.9</a>). <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a> reported no significant difference in SCORAD at the end of treatment but a significant difference in EASI for hydrocortisone and mupirocin compared with hydrocortisone alone; however standard deviations were not reported precluding inclusion in the pooled analysis. </p> <p><a href="./references#CD003871-bbs2-0038" title="TanWP , SureshS , TeyHL , ChiamLY , GoonAT . A randomized double‐blind controlled trial to compare a triclosan‐containing emollient with vehicle for the treatment of atopic dermatitis. Clinical and Experimental Dermatology2010;35(4):e109‐12. [CENTRAL: CN‐00762014; PUBMED: 19843084] ">Tan 2009</a> reported a greater reduction from baseline in mean SCORAD at day 14 for the 1% triclosan group compared with the placebo group (‐8.86 versus ‐4.75; MD ‐4.11; 95% CI ‐8.58 to 0.32), but this became non‐significant at later time points. </p> </section> <section id="CD003871-sec-0146"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p><a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a> reported a reduction in mean inflammation score (out of 10) from 5.8 to 0.7 (standard deviations not reported) in the betamethasone valerate plus gentamicin group compared with 5.9 to 1.4 in the betamethasone valerate‐only group; other individual signs were evaluated but not reported. </p> </section> <section id="CD003871-sec-0147"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0148"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>Pooled analysis of seven studies (<a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>; <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a>; <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>; <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a>; <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) showed a 52% reduction in the isolation rate of <i>S. aureus</i> in the combination group compared to steroid‐alone at the end of treatment (RR 0.48; 95% CI 0.27, 0.85, I² = 47%) (<a href="./references#CD003871-fig-0031" title="">Analysis 2.10</a>). <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported a change from baseline at two weeks (end of treatment) of ‐31.2% (95% CI ‐54.8% to ‐9.2%) in the fusidic acid group compared with ‐15.9% (‐39.1% to 7.4%) in the placebo group; the difference between the groups was not statistically significant (mean difference ‐15.3%; 95% CI ‐48.4% to 17.8%) (<a href="./references#CD003871-fig-0032" title="">Analysis 2.11</a>). <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a> reported that isolation rates of <i>S. aureus</i> reduced from 14/15 in the combination group and 12/13 in the steroid group to zero in both groups. <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a> reported that the rate of <i>S. aureus</i> in the entire trial cohort decreased from 59.7% at baseline to 14.8% at day seven of treatment; however, results were not split by treatment group, other than a statement that there was no significant difference between intervention and control groups, or reported for later time points. </p> <p><a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> reported that the number of participants with <i>S. aureus</i> at an initially lesional site reduced from 47 to 5 in the prednicarbate 0.25% cream plus didecyldimethylammonium chloride 0.25% group and from 54 to 7 in the steroid‐only group; denominators were not reported. </p> <p><i>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</i> </p> <p>In one study of 30 participants (<a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>), both steroid plus antibiotic and steroid alone completely cleared <i>S. aureus</i> (presented as log counts). <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported a greater decrease in colony counts of <i>S. aureus</i> for participants treated with fusidic acid, but results for the individual treatment combinations were not reported. <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a> reported that the geometric mean counts/cm² decreased from 420,000 to 350 for steroid plus antibiotic and from 200,000 to 65,000 for steroid alone. </p> <p><a href="./references#CD003871-bbs2-0023" title="KortingHC , ZienickeH , Braun‐FalcoO , BoekK , MilbradtR , NoltingS , et al. Modern topical glucocorticoids and anti‐infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?. Infection1994;22(6):390‐3. [CENTRAL: CN‐00499406] ZienickeH . Topical glucocorticoids and anti‐infectives: a rational combination?. Current Problems in Dermatology1993;21:186‐91. [CENTRAL: CN‐00098710] ">Korting 1994</a> reported that the mean colony forming units/cm² decreased from 50 (SD 130) to 34 (SD 170) in the prednicarbate 0.25% cream plus didecyldimethylammonium chloride 0.25% group and from 89 (200) to 7.1 (22) in the steroid‐only group. </p> </section> </section> </section> <section id="CD003871-sec-0149"> <h5 class="title">Long‐term:</h5> <section id="CD003871-sec-0150"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0151"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>There were no results given for this outcome in any of the 14 studies.</p> </section> <section id="CD003871-sec-0152"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>One study (<a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) continued to follow up participants to three months. There was no significant difference between the groups in the change from baseline on either IDQoL (MD ‐0.07; 95% CI ‐0.31 to 0.17) (<a href="./references#CD003871-fig-0033" title="">Analysis 2.12</a>) or CDLQI (MD ‐0.13; 95% CI ‐0.96 to 0.70) (<a href="./references#CD003871-fig-0034" title="">Analysis 2.13</a>). None of the other studies reported any data for this outcome. </p> </section> </section> <section id="CD003871-sec-0153"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0154"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0155"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0156"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported resistance of <i>S. aureus</i> to flucloxacillin, erythromycin and fusidic acid at baseline, week two (end of treatment) and three months. Among participants treated with fusidic acid with <i>S. aureus</i> identified from skin swabs, 8/24, 8/11 and 2/8 strains were resistant to fusidic acid at baseline, two weeks and three months, respectively, compared with 6/24, 5/16 and 2/10 in the placebo group. <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported that, of five participants with persistent <i>S. aureus</i> colonisation, two (40%) developed fusidic‐acid resistant strains after eight weeks of fusidic acid treatment. Results were not broken down into the fluticasone plus fusidic acid and tacrolimus plus fusidic acid groups and no comparative figures were reported for the fluticasone alone or tacrolimus alone groups. <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> included 45 participants in a cross‐over trial of mupirocin versus placebo. <i>S. aureus</i> resistant to mupirocin was isolated in one participant four weeks after stopping mupirocin. <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a> reported no cases of MRSA. </p> </section> </section> <section id="CD003871-sec-0157"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0158"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported longer term changes in the POEM score. At three months, there was no significant difference between the groups in the change from baseline (MD ‐1.13; 95% CI ‐4.32 to 2.06) (<a href="./references#CD003871-fig-0035" title="">Analysis 2.14</a>). </p> </section> <section id="CD003871-sec-0159"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0160"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0161"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> reported a change from baseline in the percentage of participants with <i>S. aureus</i> on the skin at three months of ‐28.6% (95% CI ‐55.3% to ‐1.9%) in the flucloxacillin group compared with ‐20.0% (‐45.4% to 5.4%) in the placebo group; the difference between the groups was not statistically significant (mean difference ‐8.6%; 95% CI ‐45.4% to 28.2%) (<a href="./references#CD003871-fig-0036" title="">Analysis 2.15</a>). </p> </section> <section id="CD003871-sec-0162"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>There were no results given for this outcome.</p> </section> </section> </section> </section> <section id="CD003871-sec-0163"> <h4 class="title">4. Topical steroid plus antibiotic and antifungal ‐ one study</h4> <p>One study (<a href="./references#CD003871-bbs2-0007" title='FattahAA , ElShiemyS , FarisR . A comparative clinical evaluation of a new topical steroid "Halcinonide" and hydrocortisone in steroid responsive dermatoses. Journal of International Medical Research1976;4(4):228‐31. [CENTRAL: CN‐00697652] '>Fattah 1976</a>) compared 0.1% halcinonide with neomycin plus nystatin versus 1% hydrocortisone cream in a right‐and‐left comparison of eight people with uninfected steroid‐responsive dermatoses, of whom four had atopic eczema and were included in the review. The severity of the eczema was not stated. The mean duration of the condition for all participants in the trial was reported to be 14 weeks, but no breakdown of figures was given for those with atopic eczema. In the trial, participants were randomised to 0.1% halcinonide cream with 0.25% neomycin and 100000u/g nystatin versus 1% hydrocortisone both applied three times daily for not more than three weeks. </p> <section id="CD003871-sec-0164"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0165"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0166"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>The study showed no significant difference in global outcome; out of a total of four participants, three achieved a good or excellent response with the combination treatment and two with hydrocortisone alone. </p> </section> <section id="CD003871-sec-0167"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome.</p> <p>No results were reported for any of the other outcomes of interest.</p> </section> </section> </section> <section id="CD003871-sec-0168"> <h5 class="title">Long‐term:</h5> <p>There were no long‐term data presented relevant to our outcomes.</p> </section> </section> <section id="CD003871-sec-0169"> <h4 class="title">5. Topical calcineurin inhibitor plus antibiotic ‐ one study</h4> <p>One study (<a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>) evaluated a topical calcineurin inhibitor plus antibiotic. This was a 2 x 2 factorial RCT comparing fluticasone versus tacrolimus with or without fusidic acid in 60 children and adults (54 evaluable) with moderate to severe uninfected eczema. The duration of the condition was not stated. In this study, the following treatments were compared: 0.05% fluticasone propionate cream (Cutivate) (n = 15) versus 0.05% fluticasone propionate cream with 2% fusidic acid cream (Fucidin) (n = 15) versus 0.03% tacrolimus ointment (Protopic) (n = 15) versus 0.03% tacrolimus ointment with 2% fusidic acid cream (n = 15) applied twice daily for eight weeks. Fusidic acid cream was applied first followed by fluticasone or tacrolimus 20 minutes later without occlusive dressings. Oral antihistamine was given to all participants. Twenty‐six evaluable participants in the tacrolimus plus fusidic acid versus tacrolimus‐alone comparison were included in this category. </p> <section id="CD003871-sec-0170"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0171"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0172"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0173"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0174"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0175"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported that two participants receiving tacrolimus plus fusidic acid withdrew because of intolerance to a burning sensation (RR 5.00; 95% CI 0.26 to 96.13) (<a href="./references#CD003871-fig-0037" title="">Analysis 3.1</a>). </p> </section> <section id="CD003871-sec-0176"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0177"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported that, of five participants with persistent <i>S. aureus</i> colonisation, two (40%) developed fusidic acid‐resistant strains after eight weeks of fusidic acid treatment. Results were not broken down into the fluticasone plus fusidic acid and tacrolimus plus fusidic acid groups and no comparative figures were reported for the fluticasone‐alone or tacrolimus‐alone groups. </p> </section> </section> <section id="CD003871-sec-0178"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0179"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported a reduction in mean SCORAD from 60.0 (SD 15.8) to 31.5 (SD 17.6) in the tacrolimus plus fusidic acid group compared with 56.8 (SD 14.0) to 32.9 (SD 19.4) with tacrolimus alone (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>). The difference in mean SCORAD at the end of treatment was not significant (MD ‐1.4; 95% CI ‐15.6 to 12.8) (<a href="./references#CD003871-fig-0038" title="">Analysis 3.2</a>). </p> </section> <section id="CD003871-sec-0180"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0181"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0182"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported that the number of participants with <i>S. aureus</i> isolated reduced from 12/13 to 2/13 in the tacrolimus plus fusidic acid group compared with a reduction from 12/13 to 7/13 with tacrolimus alone. The difference at the end of treatment was not significant (RR 0.29; 95% CI 0.07 to 1.13) (<a href="./references#CD003871-fig-0039" title="">Analysis 3.3</a>). </p> <p><i>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</i> </p> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> reported a greater decrease in colony counts of <i>S. aureus</i> for participants treated with fusidic acid, but results for the individual treatment combinations were not reported. </p> </section> </section> </section> <section id="CD003871-sec-0183"> <h5 class="title">Long‐term:</h5> <p>There were no long‐term data presented relevant to our outcomes.</p> </section> </section> <section id="CD003871-sec-0184"> <h4 class="title">6. Antibacterial soap ‐ one study</h4> <p>One very poor quality study (<a href="./references#CD003871-bbs2-0003" title="BrenemanDL , HanifinJM , BergeCA , KeswickBH , NeumannPB . The effect of antibacterial soap with 1.5% triclocarban on Staphylococcus aureus in patients with atopic dermatitis. Cutis2000;66(4):296‐300. [CENTRAL: CN‐00372699] ">Breneman 2000</a>) compared daily washing with a bar of 1.5% triclocarban soap versus placebo in 50 adults with moderately severe eczema (infective status and the number in each group were not specified) and provided few data to substantiate claims of efficacy. The duration of the condition was not stated. During the trial, participants were required to wash the whole body at least daily for 42 days. Topical steroids were used as needed. </p> <section id="CD003871-sec-0185"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0186"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0187"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>Global degree of improvement was presented as a mean score on a scale from ‐5 (severe worsening) to 5 (total clearing) with 0 representing no change from baseline. At the end of treatment, the mean global improvement score was 2.7 in the 1.5% triclocarban soap group compared with 2.2 in the placebo group (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>); standard deviations or CIs were not reported. </p> </section> <section id="CD003871-sec-0188"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0189"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0190"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>One participant from the 1.5% triclocarban soap group withdrew because of worsening dermatitis. </p> </section> <section id="CD003871-sec-0191"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>Other than the one withdrawal, there were no study‐related adverse events.</p> </section> <section id="CD003871-sec-0192"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0193"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0194"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0195"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>Significant improvements were reported in individual signs, but no numerical values were given. </p> </section> <section id="CD003871-sec-0196"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0197"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>There were no results given for this outcome.</p> <p>(e) Change in bacterial counts of <i>S. aureus</i> , i.e. an assessment of quantity of <i>S. aureus</i> </p> <p>Among the 50% of participants with <i>S. aureus</i> at baseline, the mean log<sub>10</sub> colony forming units reduced from 2.0 to 0.5 in the 1.5% triclocarban soap group and from 2.6 to 1.1 in the placebo group (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>). </p> </section> </section> </section> <section id="CD003871-sec-0198"> <h5 class="title">Long‐term:</h5> <p>There were no long‐term data presented relevant to our outcomes.</p> </section> </section> <section id="CD003871-sec-0199"> <h4 class="title">7. Antibacterial bath additive ‐ seven studies</h4> <p>Two studies compared a mineral oil‐based bath emollient incorporating triclosan and benzalkonium chloride (Oilatum Plus) versus the same emollient without the triclosan and benzalkonium chloride (Oilatum) (<a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>; <a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a>). <a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a> was a cross‐over study of 30 children (26 evaluable) with eczema with recurrent infection and/or frequent exacerbations. The severity of the condition was not stated. The duration of the condition was not stated but, in 19 participants, onset of eczema occurred before one year. In this study, participants were randomised to Oilatum Plus or Oilatum (15 mL in an 8‐inch bath of water, soaking for 10 to 15 minutes daily for four weeks). Topical steroids were used as needed. </p> <p><a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a> was a parallel group RCT of 15 patients (children and adults) with moderate to severe eczema with <i>S. aureus</i> isolated from the skin. The duration of the condition was not stated. Participants were randomised to either Oilatum Plus (containing triclosan and benzalkonium chloride) (n = 7) or Oilatum (n = 8) (15 mL in eight inches of water from 10 to 15 minutes, soaking daily for four weeks). Information was not provided on topical steroid use. </p> <p>Results for the first period of the cross‐over study (<a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>) were not given which precluded the pooling of results. </p> <p>Five studies compared sodium hypochlorite (bleach) baths versus placebo (water) (<a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>; <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a>; <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a>; <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a>) or bath emollient (<a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a>), and results for this comparison are summarised in <a href="./full#CD003871-tbl-0003">summary of findings Table 3</a>. </p> <p><a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> was a parallel group RCT of 21 children (18 evaluable) with moderate to severe uninfected eczema. Duration of the condition was not stated. Participants were randomised to receiving either bleach baths (bottle of bleach diluted with bath water 2 times per week to achieve a 0.005% sodium hypochlorite concentration) plus topical corticosteroid (n = 10) or placebo (bottle of water) plus topical corticosteroid (n = 11) for four weeks. </p> <p><a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> was a cross‐over study of 40 children with moderate to severe eczema (as assessed by SCORAD) with previous <i>S. aureus</i> colonisation. The duration of the condition was not stated. Participants were randomised to bleach bath (0.005% sodium hypochlorite) or placebo (water). Participants were instructed to bathe for 10 minutes two to three times per week. There was a four‐week treatment period, followed by a four‐week washout then a four‐week cross‐over treatment period. Topical steroids were used as rescue medication only. </p> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> was a parallel group RCT of 19 children with moderate to severe eczema with SCORAD &gt; 25 (infective status not specified). The duration of the condition was not stated. In this study, patients were randomised to bleach bath (sodium hypochlorite 0.005%) three times per week or bath emollient (bath oil containing liquid paraffin 95% volume per volume). All participants received a course of oral antibiotics. Information on topical steroid use was not provided. </p> <p><a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a> was a right‐and‐left comparison of 10 patients (children and adults) with eczema (infective status not specified). The severity and duration of the condition were not specified. Participants were randomised to a bleach bath (sodium hypochlorite 0.005%) or placebo (tap water). Each arm was immersed for 10 minutes. </p> <p><a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> was a parallel group RCT of 42 children and adults (36 evaluable) with moderate to severe uninfected eczema. The duration of the condition was not stated. Participants were randomised to bleach baths (100 mL of sodium hypochlorite (bleach) in 100 L (or roughly half a tub) of water, sodium hypochlorite 0.005%) (n = 21) or placebo (100 mL of distilled water in 100 L of water) (n = 21). For children under twelve years old, 50 mL bleach was added to a quarter tub of water. Participants were instructed to soak from the neck down in the diluted baths for 10 minutes twice a week for two months, rinsing off with normal tap water after each bath. They were maintained on a stable regimen of topical anti‐inflammatory and emollient therapy and used aqueous cream as a soap substitute. </p> <section id="CD003871-sec-0200"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0201"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0202"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>One study of Oilatum Plus (<a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a>) suggested, in the text, that there was no statistically significant difference between the treatment groups. The results given are difficult to interpret since baseline data were absent and no firm numbers were given for the individual participant groups. The other study did not report any data for this outcome (<a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a>). </p> <p>For bleach baths, two studies reported improvements in both groups but with no significant difference between the groups. In <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>, seven of 18 participants reported being "better" or "much better" in the bleach bath group at one month compared with nine of 18 in the placebo group (RR 0.78; 95% CI 0.37 to 1.63) (<a href="./references#CD003871-fig-0040" title="">Analysis 4.1</a>). <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> reported results as the mean IGA score at four weeks (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>), with a mean of 0.54 in the bleach bath group compared with 1.08 in the placebo group (MD ‐0.54; 95% CI ‐1.79 to 0.71) (<a href="./references#CD003871-fig-0041" title="">Analysis 4.2</a>). The other two studies did not report any data for this outcome. </p> </section> <section id="CD003871-sec-0203"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>No results on quality of life were reported for the studies of Oilatum Plus. <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported a reduction from baseline (improvement) in the CDLQI of 0.53 following the bleach bath period compared with 1.43 following the placebo period (MD 0.90; 95% CI ‐1.32 to 3.12) (<a href="./references#CD003871-fig-0042" title="">Analysis 4.3</a>). The other three studies of bleach baths did not report any data for this outcome. </p> </section> </section> <section id="CD003871-sec-0204"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0205"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p><a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a> reported that one participant withdrew from the study due to severe pruritus while receiving Oilatum Plus and one participant withdrew due to a deterioration in eczema severity while receiving Oilatum. </p> <p>Among the bleach bath studies, <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported no adverse events. <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported that one participant withdrew from the placebo group due to worsening itch; there were no withdrawals due to adverse events in the bleach bath group (RR 0.33; 95% CI 0.01 to 7.74) (<a href="./references#CD003871-fig-0043" title="">Analysis 4.4</a>). <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported that one participant withdrew from treatment during the bleach bath period due to itch and one participant withdrew from treatment during the placebo period due to dryness; however, results were not presented for the first period of the cross‐over, so these could not be included in pooled analysis. <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a> reported no adverse events severe enough to require withdrawal of treatment in the left‐and‐right comparison. </p> </section> <section id="CD003871-sec-0206"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p><a href="./references#CD003871-bbs2-0014" title="HarperJ . Double‐blind comparison of an antiseptic oil‐based bath additive (Oilatum Plus) with regular Oilatum (Oilatum Emollient) for the treatment of atopic eczema. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:42‐47. [CENTRAL: CN‐00184126] ">Harper 1995</a> reported that three participants experienced adverse events (all pruritus) while receiving Oilatum Plus (it was unclear whether this included the one participant that withdrew due to pruritus) and five participants experienced adverse events (four pruritus, one unspecified) while receiving Oilatum (including one participant that experienced pruritus with both preparations). </p> <p>Among the bleach bath studies, <a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported no adverse events. <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported that five participants in each group experienced burning/stinging or dry skin (RR 1.00; 95% CI 0.35 to 2.87) (<a href="./references#CD003871-fig-0044" title="">Analysis 4.5</a>). <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported that seven participants experienced one or more minor adverse events during the bleach bath period (two stinging, three itch, two dry skin, one erythema, one urticaria, one oozing) and 12 participants experienced one or more minor adverse events during the placebo period (four stinging, five itch, one erythema, one urticaria, one dizziness), but these were not reported by period of the cross‐over. <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a> reported no adverse events. </p> </section> <section id="CD003871-sec-0207"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p><a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported no significant difference in antibiotic resistance patterns between the bleach bath and placebo periods; numerical results were not presented. </p> </section> </section> <section id="CD003871-sec-0208"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0209"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p>Both studies of Oilatum Plus used non‐standard rating scales. For the bleach bath studies, <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported a significant within‐group reduction from baseline in mean EASI score at one month in the bleach bath group but no significant difference between the groups. On correspondence, the numerical values (presented graphically in the paper) were confirmed as a reduction from 29.5 (SD 10.3) to 20.2 (SD 11.8) in the bleach bath group and from 34.3 (SD 14.3) to 25.4 (SD 13.1) in the placebo group. <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> reported that both EASI and local EASI improved significantly in both groups but there was no difference between the groups, with a mean of 1.38 in the bleach bath group at one month compared with 2.34 in the placebo group (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>). Pooling the results from these two studies confirmed a non‐significantly lower EASI score at one month in the bleach bath group compared with the placebo group (MD ‐2.48; 95% CI ‐7.36 to 2.40) (<a href="./references#CD003871-fig-0045" title="">Analysis 4.6</a>). <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported a mean change from baseline in objective SCORAD of ‐0.50 (SD 10.63) during the bleach bath period compared with ‐3.95 (SD 10.54) during the placebo period; the difference between the groups was not statistically significant (MD 3.45; 95% CI ‐1.66 to 8.56) (<a href="./references#CD003871-fig-0046" title="">Analysis 4.7</a>). </p> </section> <section id="CD003871-sec-0210"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p><a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported that "scores for erythema, papulation, lichenification and excoriation showed a significant improvement" but numerical results were not presented. <a href="./references#CD003871-bbs2-0036" title="ShiVY , FooladN , OrnelasJN , HassounLA , MonicoG , TakedaN , et al. Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial. British Journal of Dermatology2016;175(1):212‐4. [CENTRAL: CN‐01383031; PUBMED: 26875771] ">Shi 2016</a> reported "no increased erythema or signs of irritation". </p> </section> <section id="CD003871-sec-0211"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0212"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> reported a change in isolation rate of <i>S. aureus</i> from 36/40 at baseline to 27/40 during the bleach bath period and 31/40 during the placebo period. This difference was not statistically significant; a treatment effect from a paired analysis was not reported. </p> </section> <section id="CD003871-sec-0213"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p><a href="./references#CD003871-bbs2-0017" title="HollandKT , BojarRA , CunliffeWJ . A comparison of the effect of treatment of atopic eczema with and without antimicrobial compounds. In: LeverR , LevyJ editor(s). The Bacteriology of Eczema: Round Table Series. Vol. 37, The Royal Society of Medicine Press Ltd, 1995:37‐40. [CENTRAL: CN‐00747631] ">Holland 1995</a> reported a significant within‐group reduction in median log<sub>10</sub> colony forming units/cm² from 4.3 (IQR (interquartile range) 4.2 to 6.8) at baseline to 3.8 (IQR 0.8 to 5.1) at the end of treatment for the Oilatum Plus group and no significant change (from 4.7 (IQR 2.8 to 5.5) to 4.3 (IQR 4.0 to 5.6)) in the Oilatum group; there was no statistically significant difference between the groups. </p> <p>For bleach baths, <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported a change in mean colony forming units/cm² from 16.8 (SD 15.7) at baseline to 9.7 (SD 12.4) at one month in the bleach bath group compared with a change from 7.5 (SD 13.6) to 10.4 (SD 13.6) in the placebo group (MD at one month ‐0.70; 95% CI ‐9.20 to 7.80) (<a href="./references#CD003871-fig-0047" title="">Analysis 4.8</a>). <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a> also reported no significant difference in colony counts, but numerical results were not presented. <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> reported that <i>S. aureus</i> counts reduced in both groups in both lesional and non‐lesional skin; however, results were reported by sample and not by participant. </p> </section> </section> </section> <section id="CD003871-sec-0214"> <h5 class="title">Long‐term:</h5> <section id="CD003871-sec-0215"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0216"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>In <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>, 11 of 18 participants reported being "better" or "much better" in the bleach bath group at two months compared with nine of 18 in the placebo group (RR 0.78; 95% CI 0.37 to 1.63) (<a href="./references#CD003871-fig-0048" title="">Analysis 4.9</a>). None of the other studies reported any long‐term results. </p> </section> <section id="CD003871-sec-0217"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome in any of the seven studies.</p> </section> </section> <section id="CD003871-sec-0218"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0219"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported no adverse events at 12 weeks. </p> </section> <section id="CD003871-sec-0220"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported no adverse events at 12 weeks. </p> </section> <section id="CD003871-sec-0221"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0222"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0223"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported a significant difference in mean SCORAD at 12 weeks between the bleach bath and emollient groups; however, after adjustment for baseline imbalance, the difference was no longer significant. <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported a significant difference in mean EASI score at two months between the bleach bath and placebo groups. Numerical results were confirmed on correspondence with the authors (MD at two months: ‐12.70; 95% CI ‐20.06 to ‐5.34). Pooling results of these two studies resulted in a significant reduction in severity in the bleach bath compared with the placebo/emollient group (SMD ‐1.11; 95% CI ‐1.68 to ‐0.53) (<a href="./references#CD003871-fig-0049" title="">Analysis 4.10</a>). </p> </section> <section id="CD003871-sec-0224"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0225"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0226"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> reported that bleach baths 'did not eradicate <i>S. aureus</i>'; no further results were reported. </p> </section> <section id="CD003871-sec-0227"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p><a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> reported a change in mean colony forming units/cm² from 16.8 (SD 15.7) at baseline to 7.8 (SD 11.6) at two months in the bleach bath group compared with a change from 7.5 (13.6) to 6.2 (10.7) in the placebo group (MD at two months 1.60; 95% CI ‐5.69 to 8.89) (<a href="./references#CD003871-fig-0050" title="">Analysis 4.11</a>). </p> </section> </section> </section> </section> <section id="CD003871-sec-0228"> <h4 class="title">8. Antibacterial bath additive plus antibiotic ‐ one study</h4> <p>One study (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>), a parallel group RCT, compared bleach and mupirocin versus water and placebo ointment in 31 children (25 evaluable) with moderate to severe infected eczema, as determined by IGA. The duration of the condition was not stated. Participants were randomised to bleach and mupirocin (n = 15) or water and placebo ointment (n = 16). A half cup of 6% bleach (final concentration 0.005%) or water was added to a full bathtub (40 gallons) of water. The amount of administered bleach solution/water was adjusted by the family on the basis of the bath tub size and estimated height of bath tub water. Participants were instructed to bathe in the dilute bleach bath or placebo for five to ten minutes twice weekly. Participants and their household members were instructed to apply mupirocin ointment (Centany (OrthoNeutrogena, Skillman, NJ)) (treatment group) or petrolatum (control group) intranasally twice daily for five consecutive days of each month for three months. Topical steroids were used as needed. </p> <section id="CD003871-sec-0229"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0230"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0231"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>The study reported significantly lower IGA scores in the treatment group compared with the placebo at one month (P = 0.024) but numerical results were not reported. </p> </section> <section id="CD003871-sec-0232"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0233"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0234"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>No participants withdrew from treatment due to adverse events.</p> </section> <section id="CD003871-sec-0235"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>One participant in the treatment group experienced itching and irritation of the skin.</p> </section> <section id="CD003871-sec-0236"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>At one month, one participant (of 11) in the treatment group had developed MRSA compared with none (of 13) in the placebo group (RR 3.50; 95% CI 0.16, 78.19) (<a href="./references#CD003871-fig-0051" title="">Analysis 5.1</a>). </p> </section> </section> <section id="CD003871-sec-0237"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0238"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a> reported a significantly greater reduction in mean EASI score at one month in the treatment group compared with the placebo group (MD ‐7.90; 95% CI ‐14.22, ‐1.58) (<a href="./references#CD003871-fig-0052" title="">Analysis 5.2</a>). </p> </section> <section id="CD003871-sec-0239"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0240"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0241"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>At one month, 55% (6/11) in the treatment group had <i>S. aureus</i> isolated compared with 77% (10/13) in the placebo group (RR 0.71; 95% CI 0.38 to 1.31) (<a href="./references#CD003871-fig-0053" title="">Analysis 5.3</a>). </p> </section> <section id="CD003871-sec-0242"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>There were no results given for this outcome.</p> </section> </section> </section> <section id="CD003871-sec-0243"> <h5 class="title">Long‐term:</h5> <section id="CD003871-sec-0244"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0245"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>At three months, 67% (6/9) of participants in the treatment group showed reductions in IGA scores compared with 15% (2/13) in the placebo group (RR 4.33; 95% CI 1.12 to 16.82) (<a href="./references#CD003871-fig-0054" title="">Analysis 5.4</a>). </p> </section> <section id="CD003871-sec-0246"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0247"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0248"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0249"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0250"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>At three months, one participant (of 8) in the treatment group had developed MRSA compared with one (of 13) in the placebo group (RR 1.63; 95% CI 0.12 to 22.50) (<a href="./references#CD003871-fig-0055" title="">Analysis 5.5</a>). </p> </section> </section> <section id="CD003871-sec-0251"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0252"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a> reported a significantly greater reduction in mean EASI score at three months in the treatment group compared with the placebo group (MD ‐12.10; 95% CI ‐20.18 to ‐4.02) (<a href="./references#CD003871-fig-0056" title="">Analysis 5.6</a>). </p> </section> <section id="CD003871-sec-0253"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0254"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0255"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>At three months, 88% (7/8) in the treatment group had <i>S. aureus</i> isolated compared with 77% (10/13) in the placebo group (RR 1.14; 95% CI 0.77 to 1.69) (<a href="./references#CD003871-fig-0057" title="">Analysis 5.7</a>). </p> </section> <section id="CD003871-sec-0256"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>There were no results given for this outcome.</p> <p>In summary, the one small study of bleach baths plus antibiotics suggested possible clinical benefit in infected eczema but with one case of antibiotic resistance identified. </p> </section> </section> </section> </section> <section id="CD003871-sec-0257"> <h4 class="title">9. Therapeutic textile ‐ eight studies</h4> <p>Eight studies, with a total of 265 evaluable participants, compared various treated or impregnated textiles against placebo. Five parallel group RCTs compared clothing impregnated with silver (<a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>; <a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>). Two of the products (<a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>) additionally included seaweed or algae‐based fibres/treatment. </p> <p><a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a> evaluated 16 children and adults with uninfected eczema. The severity and duration were not stated. Participants were randomised to wearing silver‐impregnated long vests and long johns (Juzo Skin Protect Silver ®, Julius Zorn, Aichach, Germany) (n = 7) or the same textiles without silver (Juzo Skin Protect) (n = 9). These were worn for four weeks continuously, day and night. The garments were washed every two days and participants brought used garments to clinic once a week for testing. No information was provided on concomitant topical steroid use. </p> <p><a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a> evaluated 37 children and adults with mild to moderate eczema (infective status not specified). Participants who had a score of ten or more on the Erlangen Atopy Score were included in the study. The duration of the condition was not stated. Participants were randomised to wear silver‐loaded seaweed‐based fibre (SeaCell® Active) as a long‐sleeved t‐shirt (n = 19) or placebo (cotton; n = 18) for eight weeks. No information was provided on concomitant topical steroid use. </p> <p><a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a> evaluated 57 children and adults (of 68 randomised) with moderate to severe eczema with a SCORAD of 20 or more (infective status not specified). Duration of the condition was not stated. Participants were randomised to wear silver‐coated textiles as verum (Padycare ®, consisting of micromesh material, 82% polyamide, 18% Lycra, with woven silver filaments with a silver content of 20% in total) as all in one suits for children and long‐sleeved and long‐legged clothes for adults (n = 37) or placebo (textiles made of pure cotton of equal size) (n = 31). Study clothes were worn daily for two weeks (in the day, like underwear and at night, like pyjamas). Topical steroids were used as needed. </p> <p><a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a> evaluated 30 children and adults with uninfected eczema. The severity of the condition in the participants in the study was not reported. The median duration of the condition in the intervention group was 20.5 years and 25.5 years in the control group. Participants were randomised to wearing a long‐sleeved undershirt and long underpants with silver thread (n = 10) or identical garment with polyester thread (n = 10) or prednicarbate 0.25% ointment (n = 10) for 14 days. Only comparison of silver textile versus silver‐free textile was eligible for this review. Topical steroids were used as needed. </p> <p><a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a> evaluated 18 children (of 19 randomised) with eczema (infective status not specified). The severity and duration of the condition were not stated. Participants were randomised to Skintoskin textiles® (70% cotton, 20% cellulose with algae extracts, 10% silver activated algal cellulose; 6000 ppm, 0.6% silver (n = 12) or 100% cotton (woven similarly to the trial textile (n = 7) as babygrows for babies around one year old and pyjamas and socks for older participants. These were worn continuously for seven days following which they were only worn at night (until day 90). Topical steroids were used as rescue medication only. </p> <p>Two studies (<a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a>; <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a>) reported right‐and‐left comparisons of Dermasilk® (sericin‐free silk treated with AEGIS AEM5772/5) compared with untreated silk or cotton. <a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a> evaluated 22 children with mild to moderate eczema (infective status not specified). The duration of the condition was not stated. Participants were randomised to Dermasilk® (sericin‐free silk treated with AEGIS AEM5772/5) for 12 weeks or simple silk fabric (sericin‐free silk without AEGIS AEM5772/5) for two weeks followed by cotton for 10 weeks. Participants were given three different 'arm tubes'. "For the first 2 wk of the study, parents were advised to dress one arm of their children with simple silk fabric and the other one with the Dermasilk® fabric. After 2 wk ‐ throughout the rest of the study ‐ one arm had to be covered with the cotton and the other with the Dermasilk® tube." No concomitant topical steroids were used. </p> <p><a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a> evaluated 26 children and adults (of 30 randomised) with uninfected eczema. The severity and duration of the condition were not stated. Participants were randomised to wear tubular sleeves made from knitted fibrin silk bonded with AEGIS AEM 5772/5 (DermaSilk®) or an identical product without the bonded AEGIS AEM 5772/5. Each participant received four pairs of tubular sleeves (with different coloured seams) and parents/participants were asked to dress their arms with the sleeves all night and day, changing them once a day and washing them with a mild detergent, with the same coloured sleeve always on the same arm. An assigned emollient was permitted and a gentle, non‐irritating skin cleanser without antiseptics/antimicrobial products was provided. No topical steroids were used. </p> <p>One parallel group RCT (<a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a>) compared cotton pyjamas coated with the natural biopolymer chitosan with untreated cotton in 78 children and adults (69 evaluable) with uninfected eczema. The severity was not stated. The median duration of eczema in the intervention group was 18 years and in the control group, 12 years. Participants were randomised to cotton pyjamas coated with chitosan (ChitoClear CG‐800) (n = 43) or uncoated cotton pyjamas (n = 35). These consisted of long‐sleeved top and long pants. Pyjamas were worn at night for the duration of the study (two‐week run‐in period and eight‐week intervention period). Topical steroids were used for rescue medication only. </p> <section id="CD003871-sec-0258"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0259"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0260"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p><a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a> reported no significant difference in the overall disease control of eczema in the silver textile group compared with the non‐silver textile as assessed by the participant or their carer (RR 2.40; 95% CI 0.91 to 6.36) (<a href="./references#CD003871-fig-0058" title="">Analysis 6.1</a>). There were no data reported for this outcome in any of the other seven studies. </p> </section> <section id="CD003871-sec-0261"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p><a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a> reported within‐group improvements in mean quality of life using the DIELH at the end of the intervention (two weeks) from 55.7 to 45.2 for silver textile group and from 53.3 to 44.2 for the placebo group but no significant difference between the groups. There were no short‐term data reported for this outcome in any of the other seven studies. </p> </section> </section> <section id="CD003871-sec-0262"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0263"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>Four studies reported no adverse reactions to silver textiles (<a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>) or Dermasilk® (<a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a>; <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a>). <a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported that one participant withdrew due to an eczema flare in the chitosan‐coated textile group compared with no withdrawals in the placebo group (RR 2.45; 95% CI 0.10 to 58.45) (<a href="./references#CD003871-fig-0059" title="">Analysis 6.2</a>). </p> </section> <section id="CD003871-sec-0264"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p><a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a> reported that two out of ten participants in each group reported dryness of skin (RR 1.00; 95% CI 0.17 to 5.77) (<a href="./references#CD003871-fig-0060" title="">Analysis 6.3</a>). </p> </section> <section id="CD003871-sec-0265"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0266"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0267"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p>Five studies (<a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a>; <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a>; <a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a>; <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a>; <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a>) reported short‐term changes in SCORAD. <a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a> reported a reduction in the mean SCORAD from baseline to day 14 from 72.7 to 36.1 in the silver textile group and from 51.5 to 45.9 in the placebo group; the difference between groups in change in SCORAD was statistically significant using a non‐parametric U‐test, however, the mean values at day 14 were not significantly different (mean difference ‐9.8; 95% CI ‐27.3 to 7.7) (<a href="./references#CD003871-fig-0061" title="">Analysis 6.4</a>). <a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a> reported a significant within‐group reduction in mean SCORAD from baseline to week two from 47.8 to 34.7 in the silver textile group and a non‐significant reduction from 45.9 to 38.4 in the placebo group; the difference between groups was not statistically significant (standard deviations and CIs were not reported, precluding pooling). <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a> also reported a substantial reduction in mean SCORAD from baseline to seven days from 43.8 to 32.5 in the silver/seaweed textile group and from 41.5 to 35.2 in the placebo group (standard deviation and CI were not reported for the placebo group). <a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a> reported a significant difference at four weeks in both intensity of itching score and subjective score of SCORAD between the arm treated with Dermasilk and the arm treated with untreated silk/cotton; the median intensity of itching score decreased from 9 to 6.5 in the Dermasilk arm and from 9.5 to 8 in the untreated silk/cotton arm and the median subjective score decreased from 5 to 4 in the Dermasilk arm and increased from 5 to 5.5 in the untreated silk/cotton arm. <a href="./references#CD003871-bbs2-0037" title="StincoG , PiccirilloF , ValentF . A randomized double‐blind study to investigate the clinical efficacy of adding a non‐migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology2008;217(3):191‐5. [CENTRAL: CN‐00668416; PUBMED: 18583910] ">Stinco 2008</a> reported a significant reduction in mean local SCORAD from baseline to day 28 from 47.35 to 26.32 in the arm treated with Dermasilk and from 46.68 to 35.70 in the placebo group; the difference in mean reduction from baseline between the groups was statistically significant (mean difference ‐10.05; 95% CI ‐13.60 to ‐6.50) (<a href="./references#CD003871-fig-0062" title="">Analysis 6.5</a>). </p> </section> <section id="CD003871-sec-0268"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0269"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0270"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0271"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p><a href="./references#CD003871-bbs2-0021" title="JuengerM , LadwigA , StaeckerS , ArnoldA , KramerA , DaeschleinG , et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Current Medical Research and Opinion2006;22(4):739‐50. [CENTRAL: CN‐00565217] ">Juenger 2006</a> reported no difference in <i>S. aureus</i> counts at day 14 in the silver textile and placebo groups (MD 0.0 log CFU/cm²; 95% CI ‐0.93 to 0.93) (<a href="./references#CD003871-fig-0063" title="">Analysis 6.6</a>), however, the baseline count in the silver textile group was considerably higher (3.1 versus 1.8 log CFU/cm²). <a href="./references#CD003871-bbs2-0005" title="DaeschleinG , AssadianO , ArnoldA , HaaseH , KramerA , JungerM . Bacterial burden of worn therapeutic silver textiles for neurodermitis patients and evaluation of efficacy of washing. Skin Pharmacology and Physiology2010;23(2):86‐90. [CENTRAL: CN‐00731215; PUBMED: 20016250] ">Daeschlein 2010</a> reported lower bacterial counts of <i>S. aureus</i> after two days in the silver textile group than the placebo group; however, the difference was not statistically significant (MD 9.90k CFU/cm²; 95% CI ‐41.83 to 22.03) (<a href="./references#CD003871-fig-0064" title="">Analysis 6.7</a>) and no baseline counts were reported. </p> </section> </section> </section> <section id="CD003871-sec-0272"> <h5 class="title">Long‐term:</h5> <section id="CD003871-sec-0273"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0274"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>There were no results given for this outcome in any of the eight studies.</p> </section> <section id="CD003871-sec-0275"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p><a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported a significant within‐group improvement in quality of life using the DLQI at the end of the eight‐week study period for chitosan‐coated cotton and a non‐significant improvement for untreated cotton; the difference between the groups was not statistically significant (MD ‐0.80; 95% CI ‐3.32 to 1.72) (<a href="./references#CD003871-fig-0065" title="">Analysis 6.8</a>). There were no long‐term data reported for this outcome in any of the other seven studies. </p> </section> </section> <section id="CD003871-sec-0276"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0277"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0278"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0279"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0280"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0281"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported a significant reduction in mean SCORAD from baseline to end of treatment (eight weeks) from 44.2 (95% CI 34.5 to 53.9) to 29.4 (21.4 to 37.4) in the chitosan‐coated textile group and from 41.4 (34.3 to 48.6) to 25.7 (18.3 to 33.1) in the placebo group; the difference between the groups was not statistically significant (MD 3.70; 95% CI ‐7.20 to 14.60) (<a href="./references#CD003871-fig-0066" title="">Analysis 6.9</a>). <a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a> reported a significant reduction in mean SCORAD from baseline to end of treatment (90 days) from 43.8 (SD 12.1) to 24.0 (SD 12.5) in the silver/seaweed textile group compared with 41.5 (11.6) to 24.2 (12.5) in the placebo group; the difference between the groups was not statistically significant (MD ‐0.20; 95% CI ‐12.05 to 11.65) (<a href="./references#CD003871-fig-0067" title="">Analysis 6.10</a>). </p> </section> <section id="CD003871-sec-0282"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0283"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p><a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported a median of 0 flares (IQR 0 to 1) during the eight‐week study period in both the chitosan‐coated textile and placebo groups. </p> </section> <section id="CD003871-sec-0284"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p><a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported no significant difference in the percentage of participants with <i>S. aureus</i> isolated at the end of treatment (eight weeks) between the chitosan‐coated textile and placebo groups (RR 1.01; 95% CI 0.69, 1.46) (<a href="./references#CD003871-fig-0068" title="">Analysis 6.11</a>). </p> </section> <section id="CD003871-sec-0285"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p><a href="./references#CD003871-bbs2-0028" title="LopesC , SoaresJ , TavariaF , DuarteA , CorreiaO , SokhatskaO , et al. Chitosan coated textiles may improve atopic dermatitis severity by modulating skin staphylococcal profile: a randomized controlled trial. PLOS One2015;10(11):e0142844. [CENTRAL: CN‐01168830; PUBMED: 26618557] ">Lopes 2015</a> reported a small increase in mean log<sub>10</sub> colony forming units/cm² of <i>S. aureus</i> between baseline and end of treatment (eight weeks) from 3.5 (SD 1.4) to 4.0 (SD 1.8) in chitosan‐coated textile group and from 3.3 (1.5) to 3.8 (1.6) in the placebo group (data extracted from graph using WebPlotDigitizer, <a href="https://automeris.io/WebPlotDigitizer/" target="_blank">https://automeris.io/WebPlotDigitizer/</a>); neither the within‐group changes from baseline nor the difference between the groups was statistically significant (MD 0.20; 95% CI ‐0.65 to 1.05) (<a href="./references#CD003871-fig-0069" title="">Analysis 6.12</a>). </p> <p>In summary, therapeutic textiles showed no clear benefit in either infected or uninfected eczema. </p> </section> </section> </section> </section> <section id="CD003871-sec-0286"> <h4 class="title">9. Protease inhibitor ‐ one study</h4> <p>One study (<a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a>), a parallel group RCT, compared a novel protease inhibitor (SRD441) ointment against placebo in 93 adults with mild to moderate eczema, with an IGA of 2 to 3 and a current exacerbation requiring a step up in treatment (infective status not specified). The duration of the condition was not specified. Participants were randomised to receive the study drug SRD441 ointment (mixture of white soft paraffin and Miglyol 812N, a medium chain triglyceride, and 1 mg/g SRD441) (n = 45) or the vehicle ointment (white soft paraffin and Miglyol 812N) (n = 48). The study drug or vehicle were applied to all affected areas and commonly affected body areas up to a maximum of 20% BSA for up to 28 days. Unmedicated emollients and moisturisers were permitted during the screening period and on all nontreated skin during the treatment phase. Topical steroids were used as rescue medication only. </p> <section id="CD003871-sec-0287"> <h5 class="title">Short‐term:</h5> <section id="CD003871-sec-0288"> <h6 class="title">(1) Primary outcome measures</h6> <section id="CD003871-sec-0289"> <p><b>(a) Global degree of improvement in symptoms and/or signs as rated by patient or medical practitioner</b></p> <p>The study reported no significant difference in the proportions of participants with a score of 0 (clear) or 1 (almost clear) on a 6‐point investigator's global assessment scale (RR 0.89; 95% CI 0.29 to 2.71) (<a href="./references#CD003871-fig-0070" title="">Analysis 7.1</a>). </p> </section> <section id="CD003871-sec-0290"> <p><b>(b) Improvement in Quality of Life questionnaires</b></p> <p>At 28 days, <a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a> reported a decrease in the mean DLQI of 0.8 points in the protease inhibitor group compared with 3.2 points in the placebo group; the difference was not statistically significant (standard deviations and CIs were not reported). </p> </section> </section> <section id="CD003871-sec-0291"> <h6 class="title">(2) Secondary outcome measures</h6> <section id="CD003871-sec-0292"> <p><b>(a) Severe adverse events, i.e. severe enough to require withdrawal of treatment, including severe skin irritation</b></p> <p>Seven participants in the protease inhibitor group (15.6%) and 11 participants in the placebo group (22.9%) experienced an adverse event that resulted in discontinuation of the study medication (RR 0.68; 95% CI 0.68, 1.60) (<a href="./references#CD003871-fig-0071" title="">Analysis 7.2</a>). The most frequent adverse events requiring withdrawal of treatment were application site reaction (n = 6), application site dryness (n = 4), "atopic dermatitis" (despite all participants having this at baseline; hence, we are not clear what this means), application site pruritus and pruritus (all, n = 3), and application site irritation, application site swelling, application site urticaria and pain (all, n = 2). The types of adverse events were not reported by treatment group. </p> </section> <section id="CD003871-sec-0293"> <p><b>(b) Minor patient‐reported adverse events. This included mild skin irritation not sufficient to require cessation of treatment.</b></p> <p>Twenty participants in the protease inhibitor group (44.4%) and 23 participants in the placebo group (47.9%) experienced minor adverse events (RR 0.93; 95% CI 0.60, 1.44) (<a href="./references#CD003871-fig-0072" title="">Analysis 7.3</a>). Full details of these adverse events were not reported. </p> </section> <section id="CD003871-sec-0294"> <p><b>(c) Emergence of antibiotic‐resistant micro‐organisms</b></p> <p>There were no results given for this outcome.</p> </section> </section> <section id="CD003871-sec-0295"> <h6 class="title">(3) Tertiary outcome measures</h6> <section id="CD003871-sec-0296"> <p><b>(a) Global changes in composite rating scales, using a published named scale</b></p> <p><a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a> reported a 17.2% decrease from baseline in SCORAD in the protease inhibitor group compared with 13.9% in the placebo group; the difference was not statistically significant (standard deviations and CIs were not reported). </p> </section> <section id="CD003871-sec-0297"> <p><b>(b) Changes in the individual signs of eczema as assessed by a physician</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0298"> <p><b>(c) Duration of remission and/or prevention of subsequent flares</b></p> <p><a href="./references#CD003871-bbs2-0009" title="Foelster HolstR , ReitamoS , YankovaR , WormM , KadurinaM , ThaciD , et al. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy2010;65(12):1594‐9. [CENTRAL: CN‐00772211; PUBMED: 21039597] ">Foelster Holst 2010</a> reported no difference in the number and severity of new exacerbations, but numerical results were not presented. </p> </section> <section id="CD003871-sec-0299"> <p><b>(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated</b></p> <p>There were no results given for this outcome.</p> </section> <section id="CD003871-sec-0300"> <p><b>(e) Change in bacterial counts of S. aureus, i.e. an assessment of quantity of S. aureus</b></p> <p>There were no results given for this outcome.</p> </section> </section> </section> <section id="CD003871-sec-0301"> <h5 class="title">Long‐term:</h5> <p>There were no long‐term outcomes reported.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003871-sec-0302" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003871-sec-0302"></div> <section id="CD003871-sec-0303"> <h3 class="title" id="CD003871-sec-0303">Summary of main results</h3> <p>This review included 41 studies with a total of 1753 participants analysed. Of the ten types of intervention considered in this review, we found the most substantial body of evidence for the comparison of topical steroids plus topical antibiotics compared with topical steroids alone (see <a href="./full#CD003871-tbl-0001">summary of findings Table for the main comparison</a>). In total, 14 studies addressed this comparison of which only three reported the first primary outcome, and pooled analysis indicated that the combination group may lead to a slightly increased proportion with good or excellent global degree of improvement in symptoms or signs, as rated by the patient or medical practitioner (follow‐up: 6 to 28 days; one of these studies was in clinically infected eczema and the other two studies did not specify; low‐quality evidence). Only one study from this comparison reported the review’s second primary outcome of change from baseline in quality of life and there is probably little or no difference between groups (follow‐up: 14 days; infected eczema; moderate‐quality evidence). Rates of adverse events requiring withdrawal from treatment were extremely low in the four studies from this comparison evaluating this outcome (both groups reported flare of dermatitis, worsening of the condition, and folliculitis), and consequently there is considerable uncertainty in the effect estimate (follow‐up: 6 to 28 days; studies’ infective status: not stated (one study), uninfected (two studies), infected (one study); very low‐quality evidence). Pooled analysis of the two studies reporting minor adverse events not requiring withdrawal from treatment showed fewer adverse events, such as flare of dermatitis, stinging, itch, folliculitis, in the combination group, but we are uncertain of the validity of this result (follow‐up: 14 days; studies’ infective status: not stated and uninfected; very low‐quality evidence). One study in this comparison reported the proportion of strains of <i>S. aureus</i> that were resistant to the antibiotic used; these were similar between the groups, but we are not confident in this result (follow‐up: three months; infected eczema; very‐low quality of evidence). </p> <p>Of the four studies comparing oral antibiotics with placebo (<a href="./full#CD003871-tbl-0002">summary of findings Table 2</a>), two studies evaluated good or excellent global improvement and indicated that there may be no difference between the groups (follow‐up: 14 to 28 days; studies’ infective status: uninfected and mainly infected, low‐quality evidence). Only one study in this comparison reported quality of life and there is probably little or no difference between the groups (follow‐up: 14 days; infected eczema; moderate‐quality evidence). The rates of adverse events requiring withdrawal from treatment were very low (e.g. eczema worsening (both groups), loose stools (antibiotic group), and Henoch‐Schönlein purpura (placebo group)) in the four studies that assessed this outcome in this comparison, resulting in an extremely imprecise estimate of the treatment effect. Thus, we are uncertain if there is a difference between groups (follow‐up: 14 to 28 days; studies’ infective status: uninfected (two studies), infected (one study), mainly infected (one study: 28/30 participants); very low‐quality evidence). The only information regarding minor adverse events for this comparison was from one study, which again showed similar results (low number of events) between the groups. However, we are uncertain if there is a difference between groups. Minor adverse events included nausea, vomiting, diarrhoea, and stomach and joint pains (follow‐up: 28 days; infected eczema; very low‐quality evidence). Based on two studies, antibiotic resistance was found to be similar in both groups, but the evidence was uncertain (follow‐up: 14 days; studies’ infective status: infected and uninfected; very low‐quality evidence). </p> <p>Of the five studies comparing bleach baths with placebo or bath emollient (<a href="./full#CD003871-tbl-0003">summary of findings Table 3</a>), one evaluated the percentage of participants with good or excellent global improvement and found there may be no difference between bleach baths or placebo (follow‐up: one month; uninfected eczema; low‐quality evidence). One study reported change from baseline in quality of life and found that there was probably little or no difference between groups (bleach baths or placebo) (follow‐up: at 28 days; unspecified infective status; moderate‐quality evidence). One study reported just one dropout due to worsening itch; the numbers of events requiring withdrawal from treatment were very low in the studies within this comparison, and we are uncertain if there is a difference between bleach baths or placebo (follow‐up: two months; uninfected eczema; very‐low quality evidence). Based on one study in this comparison, some minor adverse events such as burning, stinging, and dry skin were reported by participants in both groups; there may be no difference in this outcome between bleach baths and placebo (follow‐up: two months; uninfected eczema; low‐quality evidence). Based on one study, we are uncertain if antibiotic resistance was different between groups (bleach baths and placebo) (follow‐up: four weeks; unspecified infective eczema; very low‐quality evidence). </p> <p>Quality of life and antibiotic resistance were the most under‐represented of our core outcomes. Although other outcomes were more frequently reported, heterogeneity often precluded pooling. Most studies assessed short‐term eczema control, so we are uncertain of the effects of included treatments in the long term. Although the included studies assessed iinterventions currently used in clinical practice, many interventions were assessed by single studies; these included the following groups: topical steroid plus antibiotic and antifungal; topical calcineurin inhibitor plus antibiotic; antibacterial soap; antibacterial bath additive plus antibiotic; and protease inhibitor. Although we found moderate‐quality evidence for the assessment of quality of life for our three key comparisons, our other key outcomes were mainly reported by trials of low or very low quality. </p> <p><b>Antibiotic resistance</b> </p> <p>Of the 18 studies evaluating antibiotics, only six reported on the emergence of resistant organisms. These included three studies of oral antibiotics (<a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>; <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>), three studies of topical steroids plus topical antibiotics (<a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a>; <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>), one study of topical calcineurin inhibitor plus topical antibiotic (<a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>) and one study of bleach bath plus antibiotic (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>), including two studies each reporting on two interventions. </p> <p>In the studies of oral antibiotics, numbers of resistant organisms to the study drugs were low; however, these were based on small numbers of participants (<a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>). One study of flucloxacillin reported an increase in MRSA in the treatment group but did not give numerical results (<a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a>). </p> <p>In the studies of topical steroids or topical calcineurin inhibitor plus topical fusidic acid, cases of resistance to fusidic acid were reported in 25% to 73% of strains isolated from the intervention groups (<a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>); however, these were based on small numbers of participants and, in one of the studies, comparative figures were not given for the participants that did not receive fusidic acid. In the one study that also reported rates of fusidic acid resistance in the control group, 20% to 31% of strains were resistant. In the study of mupirocin, only one participant had a resistant strain of <i>S. aureus</i> following treatment (<a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a>); however, as this was a cross‐over trial, it was impossible to produce comparative results for mupirocin versus placebo. </p> <p>In the study of bleach bath plus mupirocin (<a href="./references#CD003871-bbs2-0019" title="HuangJT , AbramsM , TlouganB , RademakerA , PallerAS . Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics2009;123(5):e808‐14. [CENTRAL: CN‐00700251; PUBMED: 19403473] HuangJT , RademakerA , PallerAS . Dilute bleach baths for Staphylococcus aureus colonization in atopic dermatitis to decrease disease severity. Archives of Dermatology2011; Vol. 147, issue 2:246‐7. [PUBMED: 21339459] ">Huang 2009</a>), one participant (of 11) developed MRSA in the intervention group compared with none (of 13) in the control group; however, the numbers were too small to draw any meaningful conclusions. </p> </section> <section id="CD003871-sec-0304"> <h3 class="title" id="CD003871-sec-0304">Overall completeness and applicability of evidence</h3> <p>Although we identified studies of relevance to our review question, these were insufficient to address all of the review's objectives. This review included several different interventions designed to reduce <i>S. aureus</i> in eczema; however, the studies were generally small and poorly reported. Furthermore, while a broad range of treatment categories were included, covering all anti‐staphylococcal interventions currently used in clinical practice, half of these were assessed by single studies: </p> <p> <ul id="CD003871-list-0011"> <li> <p>four studies of oral antibiotics included a total of 166 participants;</p> </li> <li> <p>five studies of topical antiseptics/antibiotics versus placebo included only 99 participants;</p> </li> <li> <p>one study of an antibiotic and antifungal combined with a topical steroid compared with topical steroid alone included only four participants with atopic eczema; </p> </li> <li> <p>one study included 26 participants evaluating a topical calcineurin inhibitor plus antibiotic compared with topical calcineurin inhibitor alone; </p> </li> <li> <p>one study included 50 participants evaluating antibacterial soap;</p> </li> <li> <p>seven studies of antibacterial bath additives included a total of 164 participants;</p> </li> <li> <p>one study of an antibacterial bath additive (bleach) combined with an antibiotic included 25 participants; </p> </li> <li> <p>eight studies, with a total of 265 participants, compared various treated or impregnated textiles against placebo; and </p> </li> <li> <p>one study, with 93 participants, compared a novel protease inhibitor (SRD441) ointment against placebo. </p> </li> </ul> </p> <p>The most well‐represented treatment group was topical steroids plus antiseptics/antibiotics versus topical steroids alone, which was assessed in 14 studies; these studies (34% of the included studies) contributed over 50% of the review's evaluable participants. However, even when comparisons included an adequate number of studies, variation between studies in the specific interventions and in the outcomes reported precluded any meaningful conclusions regarding their usefulness. </p> <p>Twenty‐one studies were conducted in Western Europe, nine in North America, seven in the Far East, and four elsewhere in the world. Environmental factors may influence the severity of the eczema, bathing behaviour, and tendency to infection. Furthermore, living conditions between different countries influence the usefulness of the intervention in different populations. For example, in <a href="./references#CD003871-bbs2-0018" title="HonKL , TsangYC , LeeVW , PongNH , HaG , LeeST , et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate‐to‐severe eczema: a randomized, placebo‐controlled cross‐over trial. Journal of Dermatological Treatment2016;27(2):156‐62. [CENTRAL: CN‐01132944; PUBMED: 26270469] ">Hon 2016</a>, participants did not routinely have bath tubs in their homes and had to be supplied with portable bathtubs in order to participate in the trial. In practice, if most of the population do not have a bath tub, this intervention would be difficult to implement. </p> <p>The majority of studies, 19, included both children and adults, 12 only included children, four only included adults and in six studies, the age of the participants was not reported. Severity of the eczema, when mentioned, ranged from mild to severe. The method of assessing severity was often not described and, when it was, this ranged from subjective global assessments to objective scoring systems such as SCORAD. </p> <p>In clinical practice, patients with clinically obvious, infected eczema will often be given antibiotic treatment to clear the infection, leading to an improvement in their eczema. A systematic review found that the pooled prevalence of <i>S. aureus</i> amongst patients with eczema was 70% for lesional skin, 39% for non‐lesional skin, and 62% for nasal colonisation (<a href="./references#CD003871-bbs2-0162" title="TottéJE , Van derFeltzWT , HennekamM , VanBelkumA , VanZuurenEJ , PasmansSG . Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta‐analysis. British Journal of Dermatology2016;175(4):687‐95. [PUBMED: 26994362] ">Totté 2016</a>). The inclusion criteria of the studies in our review varied widely. Nine studies required evidence of colonisation or infection, with five requiring microbiological evidence of <i>S. aureus</i> and another four requiring clinically infected eczema. Fourteen studies excluded participants with acutely infected eczema, or those requiring oral antibiotics, while the remainder (19 studies) did not mention this in their inclusion or exclusion criteria. The differences in inclusion criteria make the studies difficult to compare and it is difficult to draw conclusions about the role of clearing <i>S. aureus</i> in clinically infected eczema versus treating <i>S. aureus</i> in patients without evidence of clinical infection. </p> <p>In clinical practice, most people with eczema will use accessory care such as emollients or specific cleansing products; however, other aspects of clinical care were not recorded in the included studies. </p> <p>Very few trials looked at quality of life, long‐term control of eczema, or antibiotic resistance. Just under half of the studies reported on the primary outcome, global improvement. Only five studies addressed quality of life. Twenty‐seven studies reported on either severe or minor participant‐reported adverse events, or both. Seven studies looked at microbiological data including sensitivity of or resistant organisms (the secondary outcome emergence of antibiotic‐resistant micro‐organisms). </p> <p>Few studies reported the same outcome measures, and outcomes were assessed using different instruments and at different time points; therefore, it was impossible to perform pooled analyses for many interventions. </p> <p>For three of the key comparisons of oral antibiotic versus placebo, topical steroid plus topical antibiotic versus topical steroid, and bleach bath versus placebo, we were able to pool studies in groups of up to seven studies for some outcome measures. For the remaining categories, either the studies were not sufficiently similar to pool or the studies did not report the same outcome measures. For the initial pooling, we did not take into consideration whether it was infected or non‐infected eczema that was being treated. </p> <p>Arguably one of the most important outcomes in the treatment of eczema is long‐term control. Only nine studies in our review were longer than one month’s treatment duration, which was considered a reasonable time to reflect disease chronicity. The problem of measuring long‐term control has been highlighted as part of the HOME initiative (<a href="./references#CD003871-bbs2-0111" title="ChalmersJR , SchmittJ , ApfelbacherC , DohilM , EichenfieldLF , SimpsonEL , et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology2014;171(6):1318‐25. [PUBMED: 24980543] ">Chalmers 2014</a>). Several different methods of measuring long‐term control have been employed in RCTs (<a href="./references#CD003871-bbs2-0107" title="BarbarotS , RogersNK , AbuabaraK , AubertH , ChalmersJ , FlohrC , et al. Strategies used for measuring long‐term control in atopic dermatitis trials: a systematic review. Journal of the American Academy of Dermatology2016;75(5):1038‐44. [PUBMED: 27522613] ">Barbarot 2016</a>). More recently there have been attempts to validate measures of long‐term control in eczema by assessing “well‐controlled weeks” (<a href="./references#CD003871-bbs2-0133" title="LanganSM , StuartB , BradshawL , SchmittJ , WilliamsHC , ThomasKS . Measuring long‐term disease control in patients with atopic dermatitis: a validation study of well‐controlled weeks. Journal of Allergy and Clinical Immunology2017;140(6):1580‐6. [DOI: 10.1016/j.jaci.2017.02.043; PUBMED: 28456619] ">Langan 2017</a>). </p> <section id="CD003871-sec-0305"> <h4 class="title">Antibiotic resistance</h4> <p>Of 18 studies evaluating antibiotics, only six reported on antibiotic resistance. The numbers of events were too low and the studies of insufficient duration to establish whether changes were genuine or to draw any meaningful conclusions. </p> <p>The concern about the use of antibiotics for eczema leading to development of resistant organisms has led clinicians to seek alternative strategies to decrease <i>S. aureus</i> in eczema. This review includes five studies of bleach baths and one study in which they were combined with nasal mupirocin. Another strategy to decrease <i>S. aureus</i> in eczema is the use of endolysin, a trial of which was recently completed at the time of writing and is yet to report (<a href="./references#CD003871-bbs2-0104" title="NCT02840955 . The effect of gladskin on disease severity and the skin microbiome, including Staphylococcus aureus, in patients with atopic dermatitis. clinicaltrials.gov/ct2/show/NCT02840955 (first received 11 July 2016). TottéJ , DeWitJ , PardoL , SchurenF , VanDoornM , PasmansS . Targeted anti‐staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial). Trials2017;18(1):404. [PUBMED: 28859690] ">Totté 2017</a>). </p> </section> </section> <section id="CD003871-sec-0306"> <h3 class="title" id="CD003871-sec-0306">Quality of the evidence</h3> <p>Many of the studies were small, with 37 of the 41 studies including fewer than 100 participants, and two studies (<a href="./references#CD003871-bbs2-0016" title="HjorthN , SchmidtH , ThomsenK . Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmacotheraputica1985;4(2):126‐31. [CENTRAL: CN‐00259287] ">Hjorth 1985</a>; <a href="./references#CD003871-bbs2-0031" title="PolanoMK , DeVriesHR , DelverA . Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments. Dermatologica1960;120:191‐9. [CENTRAL: CN‐00360818] ">Polano 1960</a>) provided no data for the outcomes of interest. The quality of reporting was frequently poor. More than one‐quarter of studies were assessed as having high risk of bias for blinding of participants and personnel, incomplete outcome data and selective reporting. </p> <p>For the comparison of topical steroid plus topical antibiotic versus topical steroid alone, the evidence regarding the global outcome was judged to be of moderate quality because of the risk of bias in included studies (lack of blinding and possible selective reporting in <a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a>; high risk of attrition bias in <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; possible selective reporting in <a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>). The evidence regarding change from baseline in quality of life was judged to be of moderate quality because of risk of bias (high risk of attrition bias and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>). The evidence regarding adverse events requiring withdrawal of treatment was judged to be of very low quality because of risk of bias (high risk of attrition bias and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>; lack of blinding in <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; high risk of attrition bias in <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>) and imprecision of the estimate (downgraded two levels due to the very low numbers of events). The evidence regarding minor adverse events was also judged to be of very low quality, this time, because of risk of bias (high risk of attrition bias in <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a>), imprecision of the estimate and heterogeneity of the control group risk (which varied from 3.6% in <a href="./references#CD003871-bbs2-0033" title="RamsayCA , SavoieJM , GilbertM , GidonM , KidsonP . The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. Journal of the European Academy of Dermatology and Venereology1996;7(Suppl 1):S15‐22. [CENTRAL: CN‐00172818] ">Ramsay 1996</a> to 59.1% in <a href="./references#CD003871-bbs2-0035" title="SchuttelaarML , CoenraadsP‐J . A randomised, double‐blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide (class II corticosteroid) in the treatment of moderate to severe atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2008;22(9):1076‐82. [CENTRAL: CN‐00667932] ">Schuttelaar 2005</a>). The evidence regarding global change in composite rating scales was judged to be of low quality because of risk of bias (high risk of attrition bias and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>; high risk of attrition bias in <a href="./references#CD003871-bbs2-0012" title="GongJQ , LinL , LinT , HaoF , ZengFQ , BiZG , et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial. British Journal of Dermatology2006;155(4):680‐7. [CENTRAL: CN‐00572111] ">Gong 2006</a>; lack of blinding in <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>) and heterogeneity in control group means. The evidence regarding <i>S. aureus</i> isolation rates was judged to be of moderate quality because of risk of bias (high risk of attrition bias and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>; lack of blinding in <a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a>; lack of a washout period and baseline imbalance in severity in <a href="./references#CD003871-bbs2-0026" title="LeverR , HadleyK , DowneyD , MackieR . Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. British Journal of Dermatology1988;119(2):189‐98. [CENTRAL: CN‐00055801] ">Lever 1988</a>; baseline imbalance in <i>S. aureus</i> colonisation in <a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a>; lack of blinding in <a href="./references#CD003871-bbs2-0030" title="NilssonEJ , HenningCG , MagnussonJ , SundsvallBS . Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. Journal of the American Academy of Dermatology1992;27(1):29‐34. [CENTRAL: CN‐00360692] ">Nilsson 1992</a>; possible selective reporting in <a href="./references#CD003871-bbs2-0039" title="WachsGN , MaibachHI . Co‐operative double‐blind trial of an antibiotic/corticosteroid combination in impetiginized atopic dermatitis. British Journal of Dermatology1976;95(3):323‐8. [CENTRAL: CN‐00014807] ">Wachs 1976</a>). </p> <p>For the comparison of oral antibiotics versus placebo, the evidence regarding the global outcome was judged to be of low quality because of risk of bias (high risk of attrition bias in both <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> and <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>) and imprecision of the estimate. The evidence regarding change from baseline in quality of life and global change in composite rating scales was judged to be of moderate quality because of risk of bias (high risk of attrition bias and baseline imbalance in severity and rates of <i>S. aureus</i> in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>). The evidence regarding adverse events requiring withdrawal of treatment was judged to be of very low quality because of risk of bias (high risk of attrition bias in <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>, <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> and <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>, and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) and imprecision of the estimate (downgraded two levels due to the very low number of events). The evidence regarding <i>S. aureus</i> isolation rates was judged to be of low quality because of risk of bias (high risk of attrition bias in <a href="./references#CD003871-bbs2-0040" title="WeinbergE , FourieB , AllmannB , ToerienA . The use of cefadroxil in superinfected atopic dermatitis. Current Therapeutic Research, Clinical and Experimental1992;52(5):671‐6. [CENTRAL: CN‐00195530] ">Weinberg 1992</a>, <a href="./references#CD003871-bbs2-0006" title="EwingCI , AshcroftC , GibbsACC , JonesGA , ConnorPJ , DavidTJ . Flucloxacillin in the treatment of atopic dermatitis. British Journal of Dermatology1998;138(6):1022‐9. [CENTRAL: CN‐00155038] ">Ewing 1998</a> and <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a> and baseline imbalance in <a href="./references#CD003871-bbs2-0010" title="FrancisNA , RiddMJ , Thomas‐JonesE , ShepherdV , ButlerCC , HoodK , et al. A randomised placebo‐controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. Health Technology Assessment2016;20(19):i‐xxiv, 1‐84. [CENTRAL: CN‐01259966; PUBMED: 26938214] ">Francis 2016</a>) and imprecision of the estimate. </p> <p>For the comparison of bleach baths versus placebo, the evidence regarding global outcome and <i>S. aureus</i> isolation rates was judged to be of low quality because of risk of bias (likely ineffectiveness of blinding and baseline imbalance in <i>S. aureus</i> rates in <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>) and imprecision of the estimate. The evidence regarding change from baseline in quality of life was judged to be of moderate quality because of imprecision of the estimate. The evidence regarding adverse events requiring withdrawal of treatment was judged to be of very low quality because of risk of bias (likely ineffectiveness of blinding and baseline imbalance in <i>S. aureus</i> rates in <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>) and imprecision of the estimate (downgraded two levels due to the very low numbers of events). The evidence regarding minor adverse events was judged to be of low quality because of risk of bias (likely ineffectiveness of blinding and baseline imbalance in <i>S. aureus</i> rates in <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>) and imprecision of the estimate. The evidence regarding global change in composite rating scales was judged to be of very low quality because of risk of bias (likely ineffectiveness of blinding in both studies, and baseline imbalance in severity in <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> and <i>S. aureus</i> rates in <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>), imprecision of the estimate and heterogeneity in the control group means (from 2.3 in <a href="./references#CD003871-bbs2-0013" title="GonzalezME , SchafferJV , OrlowSJ , GaoZ , LiH , AlekseyenkoAV , et al. Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis. Journal of the American Academy of Dermatology2016;75(3):481‐493.e8. [CENTRAL: CN‐01368690; PUBMED: 27543211] ">Gonzalez 2016</a> to 25.4 in <a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a>). </p> </section> <section id="CD003871-sec-0307"> <h3 class="title" id="CD003871-sec-0307">Potential biases in the review process</h3> <p>Our searches identified a number of studies, which at first may have appeared eligible for the review; however, studies with no placebo group that compared two anti‐staphylococcal interventions were ineligible according to our protocol. Exclusion of such studies might potentially have resulted in the omission of additional evidence. To include such studies would require more complex techniques such as network meta‐analysis. </p> <p>The other decision we faced in selection of studies was whether studies which reported reduction in <i>S. aureus</i>, but used an intervention that was not specifically anti‐staphylococcal (e.g. trials of vitamin D or probiotics) should be included. We opted not to include such studies. </p> <p>We attempted to conduct a comprehensive search for studies, but the fact that six studies are awaiting classification and have not yet been incorporated may be a source of potential bias. Several of these studies appear to have been completed some time ago but have never been published. </p> </section> <section id="CD003871-sec-0308"> <h3 class="title" id="CD003871-sec-0308">Agreements and disagreements with other studies or reviews</h3> <p>Other than the previous version of this review, there have been no other systematic reviews covering all interventions to reduce <i>S. aureus</i> in eczema. A systematic review of bleach baths (<a href="./references#CD003871-bbs2-0114" title="ChopraR , VakhariaPP , SacotteR , SilverbergJI . Efficacy of bleach baths in reducing severity of atopic dermatitis: a systematic review and meta‐analysis. Annals of Allergy, Asthma &amp; Immunology2017;119(5):435‐40. [PUBMED: 29150071] ">Chopra 2017</a>) concluded that "while bleach baths are effective in reducing AD severity, they do not appear to be more effective than water bath alone." However, the finding that bleach baths reduce severity was based on non‐randomised, within‐group comparisons. The conclusion that bleach baths do not appear more effective than water alone is consistent with our results. A systematic review of functional textiles (<a href="./references#CD003871-bbs2-0138" title="LopesC , SilvaD , DelgadoL , CorreiaO , MoreiraA . Functional textiles for atopic dermatitis: a systematic review and meta‐analysis. Pediatric Allergy and Immunology2013;24(6):603‐13. [PUBMED: 23980847] ">Lopes 2013</a>) concluded that recommendation for their use in treating eczema is weak, with low‐quality evidence of effectiveness. This is consistent with our findings. </p> <p>A recent narrative review summarised the current and future treatment strategies (<a href="./references#CD003871-bbs2-0127" title="HepburnL , HijnenDJ , SellmanBR , MustelinT , SleemanMA , MayRD , et al. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. British Journal of Dermatology2017;177(1):63‐71. [PUBMED: 27779765] ">Hepburn 2017</a>). Potential future treatments for <i>S. aureus</i> infection include monoclonal antibodies, vaccines, endolysins, vitamin D and probiotics (<a href="./references#CD003871-bbs2-0127" title="HepburnL , HijnenDJ , SellmanBR , MustelinT , SleemanMA , MayRD , et al. The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies. British Journal of Dermatology2017;177(1):63‐71. [PUBMED: 27779765] ">Hepburn 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003871-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Eczema. Copyright © 2009 Centre of Evidence Based Dermatology: reproduced with permission." data-id="CD003871-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Eczema. Copyright © 2009 Centre of Evidence Based Dermatology: reproduced with permission.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003871-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003871-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003871-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 1 Global outcome (good or excellent) at end of treatment." data-id="CD003871-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 1 Global outcome (good or excellent) at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 2 Change from baseline in IDQoL at end of treatment." data-id="CD003871-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 2 Change from baseline in IDQoL at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 3 Change from baseline in CDLQI at end of treatment." data-id="CD003871-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 3 Change from baseline in CDLQI at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 4 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 4 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 5 Change from baseline in POEM at end of treatment." data-id="CD003871-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 5 Change from baseline in POEM at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 6 Change from baseline in EASI at end of treatment." data-id="CD003871-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 6 Change from baseline in EASI at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 7 Mean erythema scores as assessed by a physician at end of treatment." data-id="CD003871-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 7 Mean erythema scores as assessed by a physician at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 8 Number of people with erythema at end of treatment." data-id="CD003871-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 8 Number of people with erythema at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 9 Presence of clinically apparent infection at end of treatment." data-id="CD003871-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 9 Presence of clinically apparent infection at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 10 Number of patients in whom S. aureus was isolated at end of treatment." data-id="CD003871-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 10 Number of patients in whom <i>S. aureus</i> was isolated at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 11 Change from baseline in isolation rate of S. aureus at end of treatment." data-id="CD003871-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 11 Change from baseline in isolation rate of <i>S. aureus</i> at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 12 Mean log of S. aureus counts from lesional skin at end of treatment." data-id="CD003871-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 12 Mean log of <i>S. aureus</i> counts from lesional skin at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 13 Change from baseline in IDQoL at 3 months." data-id="CD003871-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 13 Change from baseline in IDQoL at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 14 Change from baseline in CDLQI at 3 months." data-id="CD003871-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 14 Change from baseline in CDLQI at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 15 Change from baseline in POEM at 3 months." data-id="CD003871-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 15 Change from baseline in POEM at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 16 Change from baseline in isolation rate of S. aureus at 3 months." data-id="CD003871-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 16 Change from baseline in isolation rate of <i>S. aureus</i> at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral antibiotic vs placebo, Outcome 17 Mean erythema scores as assessed by physician 56 days post‐treatment." data-id="CD003871-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Oral antibiotic vs placebo, Outcome 17 Mean erythema scores as assessed by physician 56 days post‐treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 1 Global outcome (good or excellent) at end of treatment." data-id="CD003871-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 1 Global outcome (good or excellent) at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 2 Global outcome (mean self‐assessment score) at end of treatment." data-id="CD003871-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 2 Global outcome (mean self‐assessment score) at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 3 Change from baseline in IDQoL at end of treatment." data-id="CD003871-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 3 Change from baseline in IDQoL at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 4 Change from baseline in CDLQI at end of treatment." data-id="CD003871-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 4 Change from baseline in CDLQI at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 5 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 5 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 6 Minor adverse events not requiring withdrawal from treatment." data-id="CD003871-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 6 Minor adverse events not requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 7 Change from baseline in EASI at end of treatment." data-id="CD003871-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 7 Change from baseline in EASI at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 8 Change from baseline in POEM at end of treatment." data-id="CD003871-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 8 Change from baseline in POEM at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 9 Mean value of composite rating scale at end of treatment." data-id="CD003871-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 9 Mean value of composite rating scale at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 10 No of patients in whom S. aureus was isolated at end of treatment." data-id="CD003871-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 10 No of patients in whom <i>S. aureus</i> was isolated at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 11 Change from baseline in isolation rate of S. aureus at end of treatment." data-id="CD003871-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 11 Change from baseline in isolation rate of <i>S. aureus</i> at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 12 Change from baseline in IDQoL at 3 months." data-id="CD003871-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 12 Change from baseline in IDQoL at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 13 Change from baseline in CDLQI at 3 months." data-id="CD003871-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 13 Change from baseline in CDLQI at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 14 Change from baseline in POEM at 3 months." data-id="CD003871-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 14 Change from baseline in POEM at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 15 Change from baseline in isolation rate of S. aureus at 3 months." data-id="CD003871-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Topical steroid plus topical antibiotic vs topical steroid, Outcome 15 Change from baseline in isolation rate of <i>S. aureus</i> at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 1 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 1 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 2 Mean SCORAD at end of treatment." data-id="CD003871-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 2 Mean SCORAD at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 3 No of patients in whom S. aureus was isolated at end of treatment." data-id="CD003871-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor, Outcome 3 No of patients in whom <i>S. aureus</i> was isolated at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 1 Global outcome (good or excellent) at 1 month." data-id="CD003871-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 1 Global outcome (good or excellent) at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 2 Global outcome (mean IGA score) at 4 weeks." data-id="CD003871-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 2 Global outcome (mean IGA score) at 4 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 3 Change from baseline in CDLQI at end of treatment." data-id="CD003871-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 3 Change from baseline in CDLQI at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 4 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 4 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 5 Minor adverse events not requiring withdrawal from treatment." data-id="CD003871-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 5 Minor adverse events not requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 6 Mean EASI score at 1 month." data-id="CD003871-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 6 Mean EASI score at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 7 Change from baseline in objective SCORAD at end of treatment." data-id="CD003871-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 7 Change from baseline in objective SCORAD at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 8 Mean S. aureus counts from lesional skin at 1 month." data-id="CD003871-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 8 Mean <i>S. aureus</i> counts from lesional skin at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 9 Global outcome (not good or excellent) at 2 months." data-id="CD003871-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 9 Global outcome (not good or excellent) at 2 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 10 Mean value of composite rating scale at 2‐3 months." data-id="CD003871-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 10 Mean value of composite rating scale at 2‐3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 11 Mean S. aureus counts from lesional skin at 2 months." data-id="CD003871-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 11 Mean <i>S. aureus</i> counts from lesional skin at 2 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 1 Number of patients in whom MRSA was isolated at 1 month." data-id="CD003871-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 1 Number of patients in whom MRSA was isolated at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 2 Change from baseline in EASI at 1 month." data-id="CD003871-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 2 Change from baseline in EASI at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 3 Number of patients in whom S. aureus was isolated at 1 month." data-id="CD003871-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 3 Number of patients in whom <i>S. aureus</i> was isolated at 1 month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 4 Number of patients with a reduction in IGA at 3 months." data-id="CD003871-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 4 Number of patients with a reduction in IGA at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 5 Number of patients in whom MRSA was isolated at 3 months." data-id="CD003871-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 5 Number of patients in whom MRSA was isolated at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 6 Change from baseline in EASI at 3 months." data-id="CD003871-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 6 Change from baseline in EASI at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 7 Number of patients in whom S. aureus was isolated at 3 months." data-id="CD003871-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Bleach bath plus antibiotic vs placebo, Outcome 7 Number of patients in whom <i>S. aureus</i> was isolated at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 1 Number of patients in complete remission or well under control at end of study." data-id="CD003871-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 1 Number of patients in complete remission or well under control at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 2 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 2 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 3 Minor adverse events not requiring withdrawal from treatment." data-id="CD003871-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 3 Minor adverse events not requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 4 Mean SCORAD at end of treatment." data-id="CD003871-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 4 Mean SCORAD at end of treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 5 Change from baseline in local SCORAD at end of treatment." data-id="CD003871-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 5 Change from baseline in local SCORAD at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 6 Mean log of S. aureus counts from lesional skin at end of treatment." data-id="CD003871-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 6 Mean log of <i>S. aureus</i> counts from lesional skin at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 7 Mean S. aureus counts (thousands) from lesional skin at end of treatment." data-id="CD003871-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 7 Mean <i>S. aureus</i> counts (thousands) from lesional skin at end of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 8 Mean DLQI at 8 weeks." data-id="CD003871-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 8 Mean DLQI at 8 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 9 Mean SCORAD at 8 weeks." data-id="CD003871-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 9 Mean SCORAD at 8 weeks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 10 Mean SCORAD at 90 days." data-id="CD003871-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 10 Mean SCORAD at 90 days.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 11 No of patients in whom S. aureus was isolated at 8 weeks." data-id="CD003871-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 11 No of patients in whom <i>S. aureus</i> was isolated at 8 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Therapeutic textile vs placebo, Outcome 12 Mean log of S. aureus counts at 8 weeks." data-id="CD003871-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 Therapeutic textile vs placebo, Outcome 12 Mean log of <i>S. aureus</i> counts at 8 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Protease inhibitor vs placebo, Outcome 1 Global outcome (good or excellent)." data-id="CD003871-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Protease inhibitor vs placebo, Outcome 1 Global outcome (good or excellent).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Protease inhibitor vs placebo, Outcome 2 Adverse events requiring withdrawal from treatment." data-id="CD003871-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Protease inhibitor vs placebo, Outcome 2 Adverse events requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003871-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/urn:x-wiley:14651858:media:CD003871:CD003871-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_t/tCD003871-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Protease inhibitor vs placebo, Outcome 3 Adverse events not requiring withdrawal from treatment." data-id="CD003871-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Protease inhibitor vs placebo, Outcome 3 Adverse events not requiring withdrawal from treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/media/CDSR/CD003871/image_n/nCD003871-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003871-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topical steroid plus topical antibiotic compared with topical steroid for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Topical steroid plus topical antibiotic compared with topical steroid for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with eczema </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> topical steroid plus topical antibiotic </p> <p><b>Comparison:</b> topical steroid </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical steroid</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Topical steroid plus topical antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 6‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b> (1.00 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>224 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One further study (n = 28), using a continuous scale, found a result favouring steroid only. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>741 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>815 per 1000</b><br/> (741 to 897) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the control group at the end of treatment decreased by<br/> 3.46 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the intervention group decreased by<br/> <b>0.18 less</b> (0.40 less to 0.04 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A different instrument (CDLQI) was used for children aged 4 years and over and showed significantly less reduction among the participants treated with topical antibiotic. There was no significant difference with either instrument at 28 days or at 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 6‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.24</b> (0.21 to 7.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>325 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rates of adverse events were very low (zero in one study) and consequently the result is very uncertain. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38 per 1000</b><br/> (7 to 225) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.30</b> (0.12 to 0.78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>218 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>f</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The risk in the control group varied hugely between the two studies that assessed this outcome. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000<sup>e</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/> (4 to 28) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>636 per 1000<sup>e</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>191 per 1000</b><br/> (76 to 496) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study reported the proportion of strains of <i>S. aureus</i> that were resistant to the antibiotic used ‐ these were similar between the groups. Two other studies reported results that were not able to be compared between individual treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72, objective SCORAD ranges from 0 to 83 and SCORAD ranges from 0 to 108, with higher values indicating greater severity. </p> <p>Follow‐up: 14‐56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores in the control groups were 2.5 (standard deviation 5.2 to 5.6) for EASI, 18.8 (standard deviation 13.1) for objective SCORAD, and 25.4 (standard deviation 15.9) for SCORAD. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean score in the intervention group was<br/> <b>0.00 standard deviations lower</b> (0.33 lower to 0.33 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>h</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>As a rule of thumb, a value of 0.2 to 0.5 was considered a small effect, therefore the confidence interval suggested there was unlikely to be more than a small effect, either positive or negative. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> <p>Follow‐up: 7‐56 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.48</b> (0.27 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>298 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>i</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><br/> (127 to 396) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>EASI:</b> Eczema Area and Severity Index; <b>SCORAD:</b> SCORing Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on the median control group risk across studies </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (attrition bias, performance bias, and possible selective reporting) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to risk of bias (attrition bias and baseline imbalance) </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (attrition and performance bias) and imprecision of estimate (two levels due to very low number of events) </p> <p><sup>e</sup>Assumed risk based on lowest and highest control group risk across studies </p> <p><sup>f</sup>Downgraded three levels due to risk of bias (attrition bias), imprecision of estimate and heterogeneity in control group risk </p> <p><sup>g</sup>Downgraded three levels due to risk of bias (attrition bias and baseline imbalance) and imprecision of estimate (two levels due to very low numbers of events) </p> <p><sup>h</sup>Downgraded two levels due to risk of bias (attrition and performance bias) and heterogeneity in control group means </p> <p><sup>i</sup>Downgraded one level due to risk of bias (performance bias, possible selective reporting and baseline imbalance) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Topical steroid plus topical antibiotic compared with topical steroid for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003871-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral antibiotic compared with placebo for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral antibiotic compared with placebo for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with atopic dermatitis </p> <p><b>Settings:</b> primary and secondary care </p> <p><b>Intervention:</b> oral antibiotic </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Oral antibiotic</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.80</b> </p> <p>(0.18 to 3.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>75 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>619 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>495 per 1000</b><br/> (111 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life.</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the control group at the end of treatment decreased by<br/> 3.46 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean IDQoL in the intervention group decreased by<br/> <b>0.11 less</b> (0.32 less to 0.10 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A different instrument (CDLQI) was used for children aged 4 years and over and also showed no significant difference. There was also no significant difference with either instrument at 28 days or at 3 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of adverse events were very low (with either zero or one event in each arm of each study) and consequently the result was too uncertain to produce a meaningful estimate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study reported a number of specific individual adverse events, but not the overall proportion of participants in each group experiencing any adverse event. The events included nausea, vomiting, diarrhoea, stomach pain, joint pains and new rash. Number of events were generally low in both groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study reported the proportion of strains of <i>S. aureus</i> that were resistant to the antibiotic used ‐ these were similar between the groups. One other study reported an increase in MRSA until 14 days following treatment but did not give numerical results. A third study reported no resistance to the antibiotic used in either treatment group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72 with higher values indicating greater severity.</p> <p>Follow‐up: 14 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the control group at the end of treatment decreased by<br/> 3.29 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the intervention group decreased by<br/> <b>0.20 less</b> (0.52 less to 0.12 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was also no significant difference in EASI score at 28 days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> <p>Follow‐up: 14‐28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.76</b> </p> <p>(0.46 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>144 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>824 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>626 per 1000</b> </p> <p>(379 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>IDQoL:</b> Infants' Dermatology Quality of Life Index; <b>CDLQI:</b> Children's Dermatology Life Quality Index; <b>EASI:</b> Eczema Area and Severity Index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on the median control group risk across studies </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (attrition bias) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to risk of bias (high risk of attrition bias and baseline imbalance) </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (attrition bias and baseline imbalance), and imprecision of estimate (two levels due to very low number of events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral antibiotic compared with placebo for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003871-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bleach bath compared with placebo or bath emollient for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bleach bath compared with placebo or bath emollient for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with atopic dermatitis </p> <p><b>Settings:</b> secondary care </p> <p><b>Intervention:</b> bleach bath </p> <p><b>Comparison:</b> placebo or bath emollient </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or bath emollient</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bleach bath</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Global outcome (good or excellent improvement in symptoms or signs, or both)</b> </p> <p>Follow‐up: 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.78</b> (0.37 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>One further study assessed this outcome using the mean IGA score and also found no significant difference. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>390 per 1000</b><br/> (185 to 815) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in quality of life</b> </p> <p>CDLQI ranges from 0 to 30 with higher values indicating more impaired quality of life.</p> <p>Follow‐up: 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CDLQI in the control group at the end of treatment decreased by<br/> 1.43 from the baseline value. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean CDLQI in the intervention group decreased by<br/> <b>0.90 less</b> (3.12 less to 1.32 more). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events requiring withdrawal from treatment</b> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rates of adverse events were too low to produce meaningful estimates. One further study reported no adverse events and two other studies also reported very low rates of adverse events requiring withdrawal from treatment but results could not be combined due to differing study designs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Minor adverse events not requiring withdrawal from treatment</b> </p> <p>Follow‐up: 2 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.00</b> (0.35 to 2.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Two further studies reported no adverse events and one other study reported adverse events but results could not be combined due to differing study designs. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000<sup>a</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> </p> <p>(97 to 798)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Emergence of antibiotic‐resistant micro‐organisms</b> </p> <p>Follow‐up: 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study reported no significant difference in antibiotic resistance patterns but no numerical results were presented. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global change in composite ratings scale</b> </p> <p>EASI ranges from 0 to 72 with higher values indicating greater severity.</p> <p>Follow‐up: 1 month</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the control group at the end of treatment was 13.87<sup>f.</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean EASI score in the intervention group was<br/> <b>2.48 lower</b> (7.36 lower to 2.40 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>g</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One further study assessed this outcome using the change from baseline in mean SCORAD and also found no significant difference between the groups. One study additionally followed up EASI score at 2 months and one study reported SCORAD at 3 months; both reported significantly lower scores in the intervention group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No of participants in whom <i>S. aureus</i> was isolated</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported this outcome, although two studies reported no significant difference in <i>S. aureus</i> colony counts. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>IGA:</b> Investigator global assessment; <b>CDLQI:</b> Children's Dermatology Life Quality Index; <b>EASI:</b> Eczema Area and Severity Index; <b>SCORAD:</b> SCORing Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Assumed risk based on control group of the one study reporting this outcome </p> <p><sup>b</sup>Downgraded two levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate </p> <p><sup>c</sup>Downgraded one level due to imprecision of estimate </p> <p><sup>d</sup>Downgraded three levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate (two levels due to very low number of events) </p> <p><sup>e</sup>Downgraded three levels due to imprecision (small study) and study limitations due to selective reporting of results (two levels as numerical data not reported) so we were unable to obtain an estimate of the effect from the available evidence </p> <p><sup>f</sup>Control group mean based on median across the studies reporting this outcome </p> <p><sup>g</sup>Downgraded three levels due to risk of bias (performance bias, baseline imbalance), imprecision of estimate and heterogeneity in control group mean </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Bleach bath compared with placebo or bath emollient for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003871-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Correspondence with authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Information requested</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Response</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0004" title="CanpolatF , ErkocogluM , TezerH , KocabasCN , KandiB . Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age ‐ a randomized double blind pilot trial. European Review for Medical and Pharmacological Sciences2012;16(14):1989‐93. [CENTRAL: CN‐00841489; PUBMED: 23242727] ">Canpolat 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>th</sup> April 2015 </p> <p>Dear Professor Canpolat</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age – a randomized double blind pilot trial’ (Eur Rev Med Pharmacol Sci 2012; 16:1989‐93) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence in the trial?</p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. The abstract indicates that efficacy evaluation was made at ‘day 7 and weeks 2, 4 and 8’ however the results are only reported for ‘day 8’. Could you please clarify and provide any outcome data for additional time points that are available? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0008" title="FluhrJW , BreternitzM , KowatzkiD , BauerA , BossertJ , ElsnerP , et al. Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study. Experimental Dermatology2010;19(8):e9‐15. [CENTRAL: CN‐00768275; PUBMED: 19645851] ">Fluhr 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<sup>th</sup> April 2015 </p> <p>Dear Dr Fluhr</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Silver‐loaded seaweed‐based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single‐blinded exploratory in vivo study’ (Exp Dermatol 2009; 19:e9‐15) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the randomised in vivo study? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was single‐blinded. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes)? </p> <p>4. Could you clarify how and when the outcomes were assessed and who made the assessment?</p> <p>5. Did you record any clinical assessment of the severity of atopic dermatitis or of quality of life? </p> <p>6. Could you provide the values for the mean and standard error of the mean for the S. aureus colonisation changes reported in Figure 2a? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0011" title="GaugerA , FischerS , MempelM , SchaeferT , Foelster‐HolstR , AbeckD , et al. Efficacy and functionality of silver coated textiles in patients with atopic eczema. Journal of the European Academy of Dermatology and Venereology2006;20(5):534‐41. [CENTRAL: CN‐00565215] ">Gauger 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<sup>th</sup> April 2015 </p> <p>Dear Dr Gauger</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Efficacy and functionality of silver‐coated textiles in patients with atopic eczema’ (JEADV 2006; 18:534‐41) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. However, the Results state that ‘Nine of the 11 dropouts were from the placebo group, due to either systemic antibiotics or assignment to the placebo group by the patient.’ This appears to imply that patients in the placebo group were aware of their assignment. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>4. Could you supply the full results for the responses to the questionnaire (Table 2) at 1 week and at the end of the study in terms of the number of participants in each group giving each response? </p> <p>5. Could you supply the standard deviations at each time point for the general SCORAD (fig. 1), eczema extent in the SCORAD (fig. 2), subjective symptoms in SCORAD (fig. 3) and impairment of quality of life (fig. 4)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0020" title="HungSH , LinYT , ChuCY , LeeCC , LiangTC , YangYH , et al. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Annals of Allergy, Asthma &amp; Immunology2007;98(1):51‐6. [CENTRAL: CN‐00574988; MEDLINE: 17225720] ">Hung 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> April 2015 </p> <p>Dear Dr Chiang</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article by Hung et al, ‘Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics’ (Ann Allergy Asthma Immunol 2007; 98:51‐6) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Could you supply the full results for the outcomes reported in Figure 1 and Figure 2 (e.g. means and standard deviations or standard errors at each time point)? </p> <p>4. Could you supply the full results for each group at each time point for the other outcomes not reported in the paper – modified local SCORAD, colonisation density of S. aureus, antibiotic resistance? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0022" title="KollerDY , HalmerbauerG , BockA , EngstlerG . Action of a silk fabric treated with AEGIS in children with atopic dermatitis: a 3‐month trial. Pediatric Allergy and Immunology2007;18(4):335‐8. [CENTRAL: CN‐00636754; PUBMED: 17346297] ">Koller 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> April 2015 </p> <p>Dear Dr Koller</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your article ‘Action of a silk fabric treated with AEGIS<sup>TM</sup> in children with atopic dermatitis: a 3‐month trial’ (Pediatr Allergy Immunol 2009; 18:335‐8) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Did you give any instructions on washing and drying the tubes?</p> <p>4. Did you calculate a total for the modified SCORAD?</p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0024" title="LeinsE , ScullinM . Bleach baths for eczema. Australasian Journal of Dermatology2013;54(Suppl 2):55. ">Leins 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> October 2015 </p> <p>Dear Liz Leins,<br/> We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Our searches identified your trial on Bleach Baths for Eczema as possibly relevant for the Cochrane Systematic Review and we would be very grateful if you could send us further details of the study and any results.<br/> Many thanks for your help.<br/> Kind regards,<br/> Susannah George </p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18<sup>th</sup> October 2015 </p> <p>Hi Susannah,</p> <p>The final results are unpublished so I can’t send you those, however our poster was presented at the Australasian College of Dermatologist’s annual conference and reported pilot data (although our final results are the same). </p> <p>Best,</p> <p>Liz</p> <p>[Conference poster attached]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0025" title="LemboC , PatrunoC , DeLeonibusC , PanarielloL , LemboS , AyalaF . Topical erythromycin in atopic dermatitis [L'eritromicina topica nella terapia della dermatite atopica]. Annali Italiani di Dermatologia Allergologica Clinica e Sperimentale2011;65(3):113‐8. [CENTRAL: CN‐00843852] ">Lembo 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<sup>th</sup> April 2015 </p> <p>Dear Dr Lembo</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘L’eritromicina topica nella terapia della dermatite atopica’ (Ann Ital Dermatol Allergol 2011; 65:3) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. You have indicated that the patients were randomised into the two groups stratified by age and sex. Could you describe the method used to generate the allocation sequence within each stratum? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. Could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<sup>th</sup> April 2015 </p> <p>Dear Dr. George.</p> <p>Sorry for writing you so late but it has been a very busy period. We are happy about your intention to include our paper in your updated review. </p> <p>This is the method we used to generate the two groups stratified for sex and age:</p> <p> <ol id="CD003871-list-0005"> <li> <p>Age and sex of patients were recorded in a word excel sheet in which patients were anonymised </p> </li> <li> <p>Patients were ordered by age</p> </li> <li> <p>Four classes were identified by age range:</p> </li> </ol> </p> <p>I: 0.5 to 3 years</p> <p>II: 4 to 7 years</p> <p>III: 8 to 11 years</p> <p>IV: 12 to 14 years.</p> <p> <ol id="CD003871-list-0006"> <li> <p>Two subclasses were identified by sex in each age class: male and female</p> </li> <li> <p>Each subject in the sex subclass was sequentially enumerated (1…2…3…4…)</p> </li> <li> <p>Pare numbers were assigned to group B and spare numbers were assigned to group A.</p> </li> </ol> </p> <p>Patients and SCORAD evaluator were blind.</p> <p>Best regards</p> <p>Claudio Lembo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0027" title="LeydenJJ , KligmanAM . The case for steroid‐antibiotic combinations. British Journal of Dermatology1977;96(2):179‐87. [CENTRAL: CN‐00569045] ">Leyden 1977</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15<sup>th</sup> February 2017 </p> <p>Dear Professor Leyden</p> <p>I am a consultant dermatologist in the UK and I am currently updating the Cochrane systematic review on antistaphylococcal interventions in atopic dermatitis. Your paper on steroid‐antibiotic combinations from 1977 is included in the review and I am having some difficulty interpreting the detail of the results to include them in the review. </p> <p>For the comparison of Synalar vs Neo‐Synalar, you reported clinical responses of 30% excellent, 40% good and 30% fair for Synalar and 70% excellent, 20% good and 10% fair for Neo‐Synalar. However, these exact percentages do not seem possible based on the reported sample sizes of 21 and 15, respectively. I realise this study was a long time ago, however I wondered if you would be able to clarify whether the percentages reported were based on a smaller subset of patients, or whether they have been approximated/rounded off to multiples of 10%. </p> <p>Many thanks for your help.</p> <p>Kind regards</p> <p>Susannah</p> <p>Dr Susannah George</p> <p>Consultant Dermatologist</p> <p>Brighton and Sussex University Hospitals NHS Trust</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<sup>th</sup> February 2017 </p> <p>I assume the % were rounded off</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0032" title="AraujoCP , GomesJ , VieiraAP , VenturaF , FernandesJC , BritoC . A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis. Cutaneous and Ocular Toxicology2013;32(4):268‐74. [CENTRAL: CN‐00918329; PUBMED: 23485342] ">Portela Araujo 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> October 2015 </p> <p>Dear Dr Araujo</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘A proposal for the use of new silver‐seaweed‐cotton fibers in the treatment of atopic dermatitis’ (Cutan Ocul Toxicol 2013; 32:268‐74) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. Could you describe the reason why one patient in the intervention group did not complete the study? At what point did they drop out? </p> <p>4. In your study, were patients given only one set of clothes to wear continuously for the first seven days? How often were they expected to wash the clothing? Do you have any data as to whether the patients did or did not wear the clothing as instructed? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No response</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003871-bbs2-0041" title="WongSM , NgTG , BabaR . Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia. Journal of Dermatology2013;40(11):874‐80. [CENTRAL: CN‐00915612; PUBMED: 24111816] ">Wong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>th</sup> April 2015 </p> <p>Dear Dr Wong</p> <p>We are currently updating the Cochrane systematic review of Interventions to reduce Staphylococcus aureus in the management of atopic eczema. Your recent article ‘Efficacy and safety of sodium hypochlorite (bleach) baths in patients with moderate to severe atopic dermatitis in Malaysia’ (J Dermatol 2013; 40:874‐80) will be included in the updated review. </p> <p>We would be grateful if you could answer a few questions for clarification:</p> <p>1. Could you describe the method used to generate the allocation sequence for the trial? </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>3. You have indicated that the study was double‐blind. However, previous studies of bleach baths have reported that the intervention was obvious due to the smell of bleach. Did you make any attempt to address this in your study, and did you have any evidence that the participants were genuinely blinded to their treatment allocation? More generally, could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>4. Could you supply the full results for the bacteriological assessments (means and standard deviations in CFU/cm2 at baseline and follow‐up)? </p> <p>5. Could you supply the mean and standard deviation for each group at each time point for EASI (Figure 3), BSA affected (Figure 5) and itch scores (Figure 7)? </p> <p>I look forward to hearing from you.</p> <p>Kind regards</p> <p>Dr Susannah George</p> <p>Specialty Registrar in Dermatology</p> <p>Eastbourne District General Hospital</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<sup>th</sup> April 2015 </p> <p>Dear Dr George,</p> <p>Thank you for your email. I will try and answer all your questions as accurately as possible. </p> <p>1.Could you describe the method used to generate the allocation sequence for the trial?</p> <p>Patients were assigned randomly through computer generated simple randomised numbers to the treatment or placebo study arms. </p> <p>2. Could you describe the method used, if any, to conceal the allocation sequence?</p> <p>I had no access to the allocation sequence. the pharmacist helping in this study, dispensed either bleach or placebo (distilled water) according to the computer generated numbers. So I didn't know which the patient got, and on all the subsequent follow‐up, the patient was assessed by me without knowledge of what treatment they were given. </p> <p>3. You have indicated that the study was double‐blind. However, previous studies of bleach baths have reported that the intervention was obvious due to the smell of bleach. Did you make any attempt to address this in your study, and did you have any evidence that the participants were genuinely blinded to their treatment allocation? More generally, could you clarify who was and was not blinded (the participants, investigators, wider study team, those assessing the outcomes) and how long this was maintained? </p> <p>Both treatment and placebo were placed in identical bottles. yes, the patient may have been able to smell the bleach. but nothing else was done to mask the smell. The investigator (also assessed outcomes) was blinded, pharmacist dispensing the medication was not. This was maintained throughout the study period. </p> <p>4. Could you supply the full results for the bacteriological assessments (means and standard deviations in CFU/cm<sup>2</sup> at baseline and follow‐up)? </p> <p>‐ see excel sheet attached</p> <p>5. Could you supply the mean and standard deviation for each group at each time point for EASI (Figure 3), BSA affected (Figure 5) and itch scores (Figure 7)? </p> <p>‐ see excel sheet attached</p> <p>I hope the above answers your questions. Please do not hesitate to contact me if you need further clarification. </p> <p>Thank you.</p> <p>Regards,</p> <p>Dr Wong S</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Correspondence with authors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/full#CD003871-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral antibiotic vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global outcome (good or excellent) at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change from baseline in IDQoL at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change from baseline in CDLQI at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.28, 7.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change from baseline in POEM at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change from baseline in EASI at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean erythema scores as assessed by a physician at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Number of people with erythema at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Presence of clinically apparent infection at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Number of patients in whom <i>S. aureus</i> was isolated at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.46, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change from baseline in isolation rate of <i>S. aureus</i> at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mean log of <i>S. aureus</i> counts from lesional skin at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Change from baseline in IDQoL at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Change from baseline in CDLQI at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Change from baseline in POEM at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Change from baseline in isolation rate of <i>S. aureus</i> at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Mean erythema scores as assessed by physician 56 days post‐treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral antibiotic vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical steroid plus topical antibiotic vs topical steroid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global outcome (good or excellent) at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global outcome (mean self‐assessment score) at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change from baseline in IDQoL at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change from baseline in CDLQI at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.21, 7.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Minor adverse events not requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.12, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change from baseline in EASI at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change from baseline in POEM at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean value of composite rating scale at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.33, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 No of patients in whom <i>S. aureus</i> was isolated at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.27, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change from baseline in isolation rate of <i>S. aureus</i> at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change from baseline in IDQoL at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Change from baseline in CDLQI at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Change from baseline in POEM at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Change from baseline in isolation rate of <i>S. aureus</i> at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical steroid plus topical antibiotic vs topical steroid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean SCORAD at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 No of patients in whom <i>S. aureus</i> was isolated at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bleach bath vs placebo or bath emollient</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global outcome (good or excellent) at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global outcome (mean IGA score) at 4 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change from baseline in CDLQI at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Minor adverse events not requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean EASI score at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.48 [‐7.36, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change from baseline in objective SCORAD at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean <i>S. aureus</i> counts from lesional skin at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Global outcome (not good or excellent) at 2 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mean value of composite rating scale at 2‐3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.68, ‐0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mean <i>S. aureus</i> counts from lesional skin at 2 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Bleach bath vs placebo or bath emollient</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bleach bath plus antibiotic vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of patients in whom MRSA was isolated at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change from baseline in EASI at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of patients in whom <i>S. aureus</i> was isolated at 1 month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of patients with a reduction in IGA at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of patients in whom MRSA was isolated at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change from baseline in EASI at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Number of patients in whom <i>S. aureus</i> was isolated at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Bleach bath plus antibiotic vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Therapeutic textile vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of patients in complete remission or well under control at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Minor adverse events not requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean SCORAD at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change from baseline in local SCORAD at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean log of <i>S. aureus</i> counts from lesional skin at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean <i>S. aureus</i> counts (thousands) from lesional skin at end of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean DLQI at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean SCORAD at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mean SCORAD at 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 No of patients in whom <i>S. aureus</i> was isolated at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mean log of <i>S. aureus</i> counts at 8 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Therapeutic textile vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003871-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Protease inhibitor vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global outcome (good or excellent) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events not requiring withdrawal from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Protease inhibitor vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003871.pub3/references#CD003871-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003871.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003871-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003871-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003871-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD003871-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD003871-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003871-note-0012">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003871\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003871\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003871\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003871\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003871\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003871.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003871.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003871.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003871.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003871.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729379090"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003871.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729379094"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003871.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918edb6e3d15f4a4',t:'MTc0MDcyOTM3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 